THE UNIVERSITY OF CHICAGO

METAL-ORGANIC FRAMEWORKS FOR BIOMEDICAL APPLICATIONS

A DISSERTATION SUBMITTED TO
THE FACULTY OF THE DIVISION OF THE PHYSICAL SCIENCES
IN CANDIDACY FOR THE DEGREE OF
DOCTOR OF PHILOSOPHY

DEPARTMENT OF CHEMISTRY

BY
KUANGDA LU

CHICAGO, ILLINOIS
AUGUST 2016
# Table of Contents

List of Schemes............................................................................................................................................ vi
List of Tables ................................................................................................................................................ vii
List of Figures ................................................................................................................................................ viii
List of Abbreviations ................................................................................................................................ xii
Abstract ......................................................................................................................................................... xvi
Acknowledgements ...................................................................................................................................... xix

Chapter 1. Introduction .................................................................................................................................. 1

1.1 Metal-organic frameworks .......................................................................................................................... 1
1.2 Nanoscale metal-organic frameworks for drug delivery ............................................................................. 4
1.3 Cancer ....................................................................................................................................................... 6
  1.3.1 Head and neck cancer ....................................................................................................................... 7
  1.3.2 Colorectal cancer ............................................................................................................................ 8
  1.3.3 Ovarian cancer .................................................................................................................................. 9
1.4 Photodynamic therapy ............................................................................................................................... 10
1.5 Checkpoint blockade immunotherapy ....................................................................................................... 14
1.6 RNA interference and small interfering RNA ........................................................................................... 15
1.7 References ................................................................................................................................................. 16

Chapter 2. A Porphyrin-Based Nanoscale Metal-Organic Framework for Photodynamic therapy ................. 29

2.1 Rationale of the nMOF design .................................................................................................................. 29
2.2 Results and Discussion .............................................................................................................................. 30
  2.2.1 Synthesis and characterization of the H₂DBP ligand ........................................................................... 30
  2.2.2 Synthesis and characterization of DBP-Hf........................................................................................ 35
  2.2.3 Photophysics and photochemistry of H₂DBP and DBP-Hf ............................................................... 40
  2.2.4 In vitro and in vivo efficacy .............................................................................................................. 46
2.3 Conclusion ................................................................................................................................................. 52
2.4 Methods .................................................................................................................................................... 52
2.5 References ........................................................................................................................................... 55

Chapter 3. A Chlorin-Based Nanoscale Metal-Organic Framework for Photodynamic therapy. 57
3.1 Rationale of the nMOF design ............................................................................................................. 57
3.2 Results and Discussion ......................................................................................................................... 59
  3.2.1 Synthesis and characterization of the H$_2$DBC ligand ................................................................. 59
  3.2.2 Synthesis and characterization of DBC-Hf ................................................................................... 66
  3.2.3 Photophysics and photochemistry of H$_2$DBC and DBC-Hf ......................................................... 70
  3.2.4 In vitro and in vivo studies ............................................................................................................. 75
3.3 Conclusion ........................................................................................................................................... 83
3.4 Methods .............................................................................................................................................. 84
3.5 References ........................................................................................................................................... 89

4.1 Rationale of the nMOF design ............................................................................................................. 91
4.2 Results .................................................................................................................................................. 93
  4.2.1 Synthesis and characterization of H$_4$TBC ligand and TBC-Hf nMOF ........................................... 93
  4.2.2 Singlet oxygen generation ............................................................................................................. 107
  4.2.3 In vitro PDT efficacy and mechanistic study ............................................................................... 107
  4.2.4 The abscopal effect of IDOi@TBC-Hf ....................................................................................... 114
  4.2.5 Antitumor Immunity ...................................................................................................................... 117
4.3 Discussion .......................................................................................................................................... 123
4.4 Conclusion .......................................................................................................................................... 125
4.5 Methods .............................................................................................................................................. 126
4.6 References .......................................................................................................................................... 132

Chapter 5. A Nanoscale Metal-Organic Framework for the Co-delivery of Chemotherapeutic Agents and Nucleic Acid Drugs ................................................................................................................................. 134
5.1 Rationale of the nMOF design ........................................................................................................... 134
5.2 Results and Discussion ....................................................................................................................... 135
  5.2.1 Synthesis and characterization of the 2’-amino-p-terphenyl-4,4”-dicarboxylate ligand .................. 135
5.2.2 Synthesis of the cisplatin prodrug ................................................................. 138
5.2.3 Synthesis and characterization of nMOF-1 ...................................................... 142
5.2.4 Cisplatin prodrug and siRNA loading ........................................................... 144
5.2.5 In vitro gene silencing study ........................................................................... 150
5.2.6 In vitro anticancer efficacy on resistant tumor models ...................................... 155
5.3 Conclusion ........................................................................................................... 160
5.4 Methods ............................................................................................................. 161
5.5 References .......................................................................................................... 168
Cells .......................................................................................................................... 169
6.1 Rationale of the nMOF design ........................................................................... 169
6.2 Results and Discussion ....................................................................................... 171
  6.2.1 Preparation and Characterization of F-nMOF ............................................... 171
  6.2.2 Response curve calibration .......................................................................... 180
  6.2.3 Live cell pH sensing ..................................................................................... 186
6.3 Conclusion ........................................................................................................... 196
6.4 Methods ............................................................................................................. 196
6.5 References .......................................................................................................... 202
Description of Supplemental Files .......................................................................... 204
List of Schemes

**Scheme 2-1** Synthesis of the 5,15-di(p-benzoato)porphyrin ligand ................................................................. 30

**Scheme 2-2** Synthesis of DBP-Hf and the schematic description of singlet oxygen generation process ................................................................. 36

**Scheme 3-1** Schematic description of the singlet oxygen generation by DBC-Hf photosensitization with LED light ................................................................. 58

**Scheme 3-2** Synthesis of the 5,15-di(p-benzoato)chlorin (H$_2$DBC) ................................................................. 59

**Scheme 4-1** Synthesis of 5,10,15,20-tetra(p-benzoato) chlorin (H$_4$TBC) ................................................................. 93

**Scheme 5-1** MOF synthesis and drug loading ................................................................................................................. 134

**Scheme 5-2** Synthesis of 2’-amino-p-terphenyl-4,4”-dicarboxylic acid (H$_2$L) .................................................. 135

**Scheme 5-3** Synthesis of the cisplatin prodrug ................................................................................................................. 138
List of Tables

Table 2-1 Chemical structure of Zn-DPDBP and crystal structure information of Zn-DPDBP-Zr .................................................................37
Table 2-2 Lifetimes of H₂DBP and DBP-Hf fluorescence in different medium, fitted by software ...........................................................43
Table 2-3 Fitting parameters of singlet oxygen generation rate .........................46
Table 3-1 Fluorescence lifetimes of H₂DBC, DBC-Hf and HfCl₄+H₂DBC control, fitted by software ....................................................72
Table 3-2 Fitting parameters for ¹O₂ generation curves ................................73
Table 3-3 Statistical analysis of tumor weights by t-test shown with P values ........83
Table 4-1 Lifetimes of H₄TBP, H₄TBC, TBP-Hf and TBC-Hf fluorescence in different media, fitted by software ........................................106
Table 4-2 Statistical analysis of the tumor sizes at the end of treatment on CT26 tumor bearing mice ......................................................................115
Table 4-3 Statistical analysis of the tumor sizes at the end of treatment on MC38 tumor bearing mice ..................................................................115
Table 5-1 IC₅₀ (µM) values in A2780 and A2780/CDDP cells.................................158
List of Figures

Figure 1-1 Lattice structures (middle), corresponding SBU (left), and organic linkers (right) of a variety of MOFs ................................................................. 2
Figure 1-2 Structure models of SBU and MOFs ................................................................. 4
Figure 1-3 Different strategies for loading cargo into nMOFs ........................................... 6
Figure 1-4 Ten Leading Cancer Types for the Estimated New Cancer Cases and Deaths by Sex, United States, 2016 ................................................................. 7
Figure 1-5 The mechanism of photodynamic therapy ....................................................... 11
Figure 1-6 The UV-vis absorption spectrum of porphyrin in correspondence to the illustration of Gouterman four-orbital theory ....................................................... 12
Figure 1-7 (a) The UV-vis absorption spectra of protoporphyrin IX (PpIX) and chlorin e6 (Ce6). (b) The effective penetration depth of UV-visible light in human tissue 13
Figure 1-8 T cell proliferation induced by PDT ................................................................. 14
Figure 2-1 1H NMR spectrum of dipyrrylmethane in chloroform-D ............................... 31
Figure 2-2 1H NMR spectrum of 5,15-di(p-methylbenzoato)porphyrin in chloroform-D .... 32
Figure 2-3 13C NMR spectrum of 5,15-di(p-benzoato)porphyrin in DMSO-D6 ................ 33
Figure 2-4 1H NMR spectrum of 5,15-di(p-benzoato)porphyrin in DMSO-D6 ............... 34
Figure 2-5 Mass spectrum of 5,15-di(p-benzoato)porphyrin ......................................... 35
Figure 2-6 Structural confirmation of DBP-Hf ............................................................... 37
Figure 2-7 TEM images of DBP-Hf ............................................................................... 38
Figure 2-8 (a) Nitrogen adsorption isotherm of DBP-Hf at 77K and (b) Thermogravimetric analysis of DBP-Hf ............................................................... 39
Figure 2-9 DLS plot showing the particle size of DBP-Hf ................................................ 40
Figure 2-10 UV-visible spectra of H2DBP and DBP-Hf .................................................... 41
Figure 2-11 Fluorescence of H2DBP and DBP-Hf in PBS ................................................. 42
Figure 2-12 Time-resolved fluorescence decay traces of H2DBP (left) and DBP-Hf (right) in different media .......................................................... 42
Figure 2-13 Singlet oxygen generation by DBP-Hf, H2DBP, and H2DBP+HfCl4 ............... 46
Figure 2-14 Cellular uptake of DBP-Hf after 4 or 12 hour incubation ............................ 47
Figure 2-15 In vitro PDT cytotoxicity of H2DBP, DBP-Hf, and PpIX at different PS concentrations and irradiation doses ................................................. 49
Figure 2-16 In vivo efficacy of PDT on SQ20B tumor bearing mice .................................. 50
Figure 2-17 Histology of tumor slices of mice after PDT treatment ................................. 51
Figure 3-1 ESI-MS of 5,15-di(p-methylbenzoato)chlorin ............................................... 60
Figure 3-2 1H NMR spectra of 5,15-di(p-methylbenzoato)chlorin in chloroform-D ......... 61
Figure 3-3 1H NMR spectrum of 5,15-di(p-benzoato)chlorin in DMSO-D6 ................... 63
Figure 3-4 ESI-MS of 5,15-di(p-benzoato)chlorin ......................................................... 65
Figure 3-5 Structural characterization of DBC-Hf .......................................................... 67
Figure 3-6 DLS plot showing the particle size of DBC-Hf ............................................ 69
Figure 3-7 TEM images of DBC-Hf .............................................................................. 69
Figure 3-8 Photophysical and photochemical properties of H₂DBC and DBC-Hf .......... 71
Figure 3-9 Photostability of DBC-Hf, H₂DBC, DBP-Hf, and Me₂DBB ................................ 74
Figure 3-10 Cellular uptake evaluation of H₂DBC and DBC-Hf in HT29 (a) or CT26 (b) cells 76
Figure 3-11 In vitro PDT efficacies on different cell lines .............................................. 77
Figure 3-12 Annexin V/PI analysis of CT26 cells incubated with DBC-Hf, H₂DBC or PBS with or without irradiation (90 J/cm²) .................................................................................................................. 78
Figure 3-13 Immunogenic cell death detection .................................................................. 79
Figure 3-14 In vivo PDT efficacy on CT26 mouse tumor model ........................................ 81
Figure 3-15 In vivo PDT efficacy on HT29 subcutaneous xenograft mouse model ............ 82
Figure 3-16 Histology of frozen tumor tissue slices after H-E staining ............................. 83
Figure 4-1 Schematic presentation of combined PDT and immunotherapy by IDOi@TBC-Hf. 92
Figure 4-2 ¹H NMR of 5,10,15,20-tetra(p-methylbenzoato)porphyrin ............................... 94
Figure 4-3 ¹H NMR of 5,10,15,20-tetra(p-methylbenzoato)chlorin ................................. 95
Figure 4-4 ESI-MS of 5,10,15,20-tetra(p-methylbenzoato)chlorin .................................. 96
Figure 4-5 ¹H NMR of 5,10,15,20-tetra(p-benzoato)chlorin ........................................... 97
Figure 4-6 ESI-MS of 5,10,15,20-tetra(p-benzoato)chlorin ............................................ 98
Figure 4-7 Structures of TBC-Hf and TBP-Hf .................................................................. 100
Figure 4-8 Nitrogen adsorption isotherms of TBC-Hf (a) and TBP-Hf (b) at 77K ............ 101
Figure 4-9 TEM images showing the morphology of TBP-Hf and TBC-Hf ......................... 102
Figure 4-10 DLS plots showing the particle sizes of TBP-Hf (top) and TBC-Hf (bottom) ...... 103
Figure 4-11 (a) TGA of TBC-Hf before and after IDOi loading. (b) The chemical structure of the IDOi, 4-amino-N-(3-chloro-4-fluoro-phenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide ......................................................... 104
Figure 4-12 Photophysics and photochemistry of the ligands and nMOFs ......................... 105
Figure 4-13 Cellular uptake of TBP-Hf and TBC-Hf in CT26 cells ................................... 108
Figure 4-14 In vitro PDT efficacy on CT26 (a,c), MC38 (b,d) and B16F10 (e) cells .......... 109
Figure 4-15 Annexin V/PI analysis of CT26 (a) and MC38 (b) cells incubated with PBS, TBC-Hf, TBP-Hf, H₄TBC, and H₄TBP with or without irradiation (90 J/cm²) ................. 111
Figure 4-16 CRT exposure on the cell surface .................................................................. 112
Figure 4-17 Immunofluorescence microscopy of CRT expression on the cell surface ...... 113
Figure 4-18 In vivo anticancer efficacy showing abscopal effect ..................................... 116
Figure 4-19 Photos of excised tumors of each group after PDT treatment in the CT26 (a) and MC38 (b) models ................................................................. 117
Figure 4-20 Antigen-specific IFN-γ spot forming cells (SFC) at 14 days after IDOi@TBC-Hf PDT treatment ............................................................................................................. 118
Figure 4-21 Population of leukocytes in the tumor 12 h after IDOi@TBC-Hf PDT treatment 119
Figure 4-22 The MHC-II expression level in the tumor 12 h after IDOi@TBC-Hf PDT treatment .......................................................................................................................... 120
Figure 4-23 Tumor-infiltrating leukocyte profiles in the tumors 12 days after IDOi@TBC-Hf PDT treatment ....................................................................................... 122
Figure 4-24 In vivo T cell blocking experiments .............................................................................. 123
Figure 5-1 ^H NMR spectrum of Me_2L in chloroform-D ............................................................... 136
Figure 5-2 ^H NMR spectrum of H_2L in DMSO-d_6 .................................................................. 137
Figure 5-3 ^C NMR spectrum of H_2L in DMSO-d_6 .................................................................. 137
Figure 5-4 ^H NMR spectrum of Pt(NH_3)Cl_2(OEt)(OCOCH_2CH_2CO_2H) in DMSO-d_6 ................. 138
Figure 5-5 ^H NMR spectra of cis,cis,trans-[Pt(NH_3)Cl_2(OEt)(OCOCH_2CH_2CO_2H)] in DMSO-d_6 .................................................................................................................. 139
Figure 5-6 ^C NMR spectrum of cis,cis,trans-[Pt(NH_3)Cl_2(OEt)(OCOCH_2CH_2CO_2H)] in DMSO-d_6 .................................................................................................................. 141
Figure 5-7 ^{195}Pt NMR spectrum of cis,cis,trans-[Pt(NH_3)Cl_2(OEt)(OCOCH_2CH_2CO_2H)] in DMSO-d_6 .................................................................................................................. 141
Figure 5-8 Structural characterization of the nMOFs before and after drug loading ................. 143
Figure 5-9 Structure models of nMOF-1 .......................................................................................... 143
Figure 5-10 ^H NMR spectrum of Cis@nMOF-1 after digestion .................................................... 145
Figure 5-11 Release profiles of cisplatin prodrug from Cis@nMOF-1 in 5 mM PBS by dialysis method .................................................................................................................. 145
Figure 5-12 ^{195}Pt NMR of the released drug .................................................................................... 146
Figure 5-13 Structure model of the interaction between the siRNA and nMOF surface........ 148
Figure 5-14 DLS plot showing the particle size of nMOF-1 (a), Cis@nMOF-1 (b) and siRNA/Cis@nMOF-1 (c) ................................................................................................................. 149
Figure 5-15 Stabilization effect after loading siRNA to the nMOF ................................................ 150
Figure 5-16 Cellular uptake and endosomal escape of siRNA/Cis@nMOF-1 in SKOV-3 cells ........................................................................................................................................ 152
Figure 5-17 CLSM images showing the time-dependent endosomal escape of siRNA in SKOV-3 cells .................................................................................................................. 153
Figure 5-18 Percent co-localization of siRNA and endosome/lysosome quantified by Image J based on the CLSM images .................................................................................. 154
Figure 5-19 siRNA/Cis@nMOF-1 mediated gene silencing in SKOV-3 cells ......................... 154
Figure 5-20 In vitro cytotoxicity in different cells ........................................................................... 157
Figure 5-21 Annexin V/PI analysis of SKOV-3 cells after the incubation for 24 h ................. 158
Figure 5-22 DNA ladder analysis ................................................................................................. 159
Figure 5-23 CLSM images showing cell apoptosis and siRNA internalization in SKOV-3 cells

Figure 5-24 Immunogenic response of nMOF-1 and pooled siRNAs/Cis@nMOF-1 in SKOV-3 (a) and Raw 264.7 (b) cells

Figure 6-1 Schematic presentation of FITC loading

Figure 6-2 Structures and morphologies of nMOF-1 and F-nMOF

Figure 6-3 DLS measurements of nMOF-1 (a) and F-nMOF (b)

Figure 6-4 $^1$H NMR spectra to confirm covalent attachment

Figure 6-5 Mass spectrum of F-nMOF digest

Figure 6-6 Studies of FITC leaching upon HBSS incubation

Figure 6-7 TEM images of F-nMOF after incubation in HBSS for different time

Figure 6-8 FITC loading quantification

Figure 6-9 Correlation between FITC feed wt.% and FITC loading wt.%

Figure 6-10 Absorption spectra of F-nMOFs at a series of FITC loading amounts

Figure 6-11 Fluorescence efficiency of F-nMOFs with different FITC loadings

Figure 6-12 Calibration curves of r-pH responses

Figure 6-13 Images of F-nMOF dispersed in HBSS with a series of pH acquired by CLSM

Figure 6-14 CLSM images of live cells clamped at various pH

Figure 6-15 pH calibration in live cells by clamping the cells at various pH values

Figure 6-16 Cellular uptake and intracellular distribution of F-nMOF in H460 cells

Figure 6-17 Time relapse pH changes in individual endosomes

Figure 6-18 Orthogonal views of cells incubated with F-nMOF showing that the particle of interest was stuck on the cell membrane over time

Figure 6-19 CLSM images and histograms showing the numbers of endosomes of different pH values
# List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ce6</td>
<td>chlorin e6</td>
</tr>
<tr>
<td>CLSM</td>
<td>confocal laser scanning microscopy</td>
</tr>
<tr>
<td>CRT</td>
<td>calreticulin</td>
</tr>
<tr>
<td>CTLA-4</td>
<td>cytotoxic T-lymphocyte-associated protein 4</td>
</tr>
<tr>
<td>DAPI</td>
<td>4’,6-diamidino-2-phenylindole</td>
</tr>
<tr>
<td>DC</td>
<td>dendritic cell</td>
</tr>
<tr>
<td>DCM</td>
<td>dichloromethane</td>
</tr>
<tr>
<td>DDQ</td>
<td>2,3-dichloro-5,6-dicyano-1,4-benzoquinone</td>
</tr>
<tr>
<td>DEF</td>
<td>N,N-diethylformamide</td>
</tr>
<tr>
<td>DLS</td>
<td>dynamic light scattering</td>
</tr>
<tr>
<td>DMEM</td>
<td>Dulbecco's Modified Eagle's Medium</td>
</tr>
<tr>
<td>DMF</td>
<td>N,N-dimethylformamide</td>
</tr>
<tr>
<td>DMSO</td>
<td>dimethyl sulfoxide</td>
</tr>
<tr>
<td>DPDBP</td>
<td>5,15-di(p-benzoato)-10,20-diphenyl-porphyrin</td>
</tr>
<tr>
<td>ELISPOT</td>
<td>Enzyme-Linked ImmunoSpot</td>
</tr>
<tr>
<td>EPR</td>
<td>enhanced permeability and retention</td>
</tr>
<tr>
<td>FFT</td>
<td>fast Fourier transform</td>
</tr>
<tr>
<td>FITC</td>
<td>fluorescein isothiocyanate</td>
</tr>
<tr>
<td>FOLFIRI</td>
<td>folinic acid, fluorouracil and irinotecan</td>
</tr>
</tbody>
</table>
FOLFOX  Folinic acid, Fluorouracil and Oxaliplatin
HBSS  Hank’s Balanced Saline Solution
H₂DBC  5,15-di(p-benzoato)chlorin
H₂DBP  5,15-di(p-benzoato)porphyrin
HOMO  highest occupied molecular orbital
H₄TBC  5,10,15,20-tetra(p-benzoato)chlorin
H₄TBP  5,10,15,20-tetra(p-benzoato)porphyrin
IACUC  Institutional Animal Care and Use Committee
ICD  immunogenic cell death
ICP-MS  inductively coupled plasma-mass spectrometry
IDO  indoleamine 2,3-dioxygenase
IDOi  indoleamine 2,3-dioxygenase inhibitor
IgG  Immunoglobulin G
IRF  Instrument Response Function
Kyn  kynurenine
LE  loading efficiency
LED  light-emitting diode
LUMO  lowest unoccupied molecular orbital
MDR  multidrug resistance
Me₂DBB  5,15-di(p-methyl-benzoato)bacteriochlorin
Me₂DBC  5,15-di(p-methyl-benzoato)chlorin
Me₂DBP  5,15-di(p-methyl-benzoato)porphyrin
MHC-II  major histocompatibility complex class II
MOF    metal-organic framework
mRNA   messenger RNA
Me₄TBC  5,10,15,20-tetra(p-methyl-benzoato)chlorin
Me₄TBP  5,10,15,20-tetra(p-methyl-benzoato)porphyrin
MTS    (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)
NEt₃   triethylamine
nMOF   nanoscale metal-organic framework
OCT    optimal cutting temperature
PBS    phosphate buffered saline
PCP    porous coordination polymer
PD-1   programmed cell death protein 1
PDI    polydispersity index
PD-L1  programmed death-ligand 1
PDT    photodynamic therapy
P-gp   P-glycoprotein
pHi    intracellular pH
PI     propidium iodide
PpIX   protoporphyrin IX
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>PS</td>
<td>photosensitizer</td>
</tr>
<tr>
<td>PXRD</td>
<td>powder X-ray diffraction</td>
</tr>
<tr>
<td>RNA</td>
<td>ribonucleic acid</td>
</tr>
<tr>
<td>RNAi</td>
<td>RNA interference</td>
</tr>
<tr>
<td>ROI</td>
<td>region of interest</td>
</tr>
<tr>
<td>ROS</td>
<td>reactive oxygen species</td>
</tr>
<tr>
<td>r.t.</td>
<td>room temperature</td>
</tr>
<tr>
<td>SBU</td>
<td>secondary building unit</td>
</tr>
<tr>
<td>SCCHN</td>
<td>squamous cell carcinomas of the head and neck</td>
</tr>
<tr>
<td>SDS</td>
<td>sodium dodecyl sulfate</td>
</tr>
<tr>
<td>SFC</td>
<td>spot forming cells</td>
</tr>
<tr>
<td>siRNA</td>
<td>small interfering RNA</td>
</tr>
<tr>
<td>SOSG</td>
<td>single oxygen sensor green</td>
</tr>
<tr>
<td>TCSPC</td>
<td>Time-Correlated Single Photon Counting</td>
</tr>
<tr>
<td>TEM</td>
<td>transmission electron microscopy</td>
</tr>
<tr>
<td>TFA</td>
<td>trifluoroacetic acid</td>
</tr>
<tr>
<td>THF</td>
<td>tetrahydrofuran</td>
</tr>
<tr>
<td>Trp</td>
<td>tryptophan</td>
</tr>
<tr>
<td>UiO</td>
<td>University of Oslo (Universitetet i Oslo)</td>
</tr>
<tr>
<td>UV-vis</td>
<td>ultraviolet-visible spectroscopy</td>
</tr>
</tbody>
</table>
Abstract

Kuangda Lu: Metal-Organic Framworks for Biomedical Applications

Under Direction of Professor Wenbin Lin

Metal-organic frameworks (MOFs) have emerged as a new class of hybrid molecular materials with potential for a broad range of applications. When scaled down to the nanosize, nanoscale metal-organic frameworks (nMOFs) have been explored for applications in diagnosis, imaging, and biomedicine by virtue of their structural and functional tunability. In this dissertation, we have further demonstrated the use of nMOFs in cancer therapies and pH sensing in live cells.

Chapter 1 briefly introduces the basic concepts of nMOFs and their potential applications. I also provide brief overviews on cancer, photodynamic therapy (PDT), checkpoint blockade immunotherapy, and RNA interference.

Chapter 2 describes the rational design of the first porphyrin-based nMOF, DBP-Hf, for PDT of resistant head and neck cancer. In the nMOF design, porphyrin ligands are incorporated as the strut to maximize the loading of photosensitizers; the porosity and plate morphology of the nMOF facilitate the diffusion of the reactive oxygen species; the coordination of the ligands to Hf centers improve the performance of the photosensitizers. Thus, the nMOF displays greatly enhanced PDT efficacy both in vitro and in vivo, representing a new class of promising PDT agents for resistant cancer treatment.
Chapter 3 reports the design of first chlorin-based nMOF, DBC-Hf, with even more enhanced PDT efficacy. Chlorin is the reduced form of porphyrin and exhibits much improved photophysical properties for PDT application. While inheriting the crystallinity, stability, porosity, and nanoplate morphology of DBP-Hf, the reduction of the DBP ligand to chlorin red-shifts the absorption by 13 nm and increases the extinction coefficient by 11 fold. DBC-Hf thus outperforms DBP-Hf in PDT of two colon cancer mouse models.

Chapter 4 details the design of another chlorin-based nMOF with large 1-D channels for combination of PDT and checkpoint blockade immunotherapy. A small molecular inhibitor of indoleamine 2,3-dioxygenase (IDO) is encapsulated into the MOF channels to alter the tumor microenvironment, which synergizes with the nMOF-mediated PDT to elicit systemic antitumor immune response. The synergistic combination therapy achieves effective local and distant tumor rejection in colorectal cancer models. We also elucidated the underlying immunological mechanisms and revealed compensatory roles of neutrophils and B cells in presenting tumor-associated antigens to T cells in this combination therapy.

Chapter 5 describes the first use of an nMOF as a co-delivery system of chemotherapeutics and small interfering RNAs (siRNAs). A cisplatin prodrug was encapsulated into the pores of the nMOF and pooled siRNAs were loaded onto the nanocrystal surface by coordination to the metal sites. nMOFs protect siRNAs from nuclease degradation, enhance siRNA cellular uptake, and promote siRNA escape from endosomes to silence MDR genes in cisplatin-resistant ovarian cancer cells. Co-delivery of cisplatin and siRNAs with nMOFs led to an order of magnitude enhancement in chemotherapeutic efficacy in vitro.
Chapter 6 illustrates the first use of an nMOFs for intracellular pH sensing in live cells. Fluorescein isothiocyanate (FITC) was covalently conjugated to an nMOF, with exceptionally high FITC loadings, efficient fluorescence, and excellent ratiometric pH-sensing properties. Live cell imaging studies revealed endo and exocytosis of the nMOF and endosome acidification in real time (videos available as supplementary files). Fluorescently labeled nMOFs thus represent a new class of nanosensors for intracellular pH sensing and provide an excellent tool for studying nMOF-cell interactions.
Acknowledgements

It has been a long way of learning before I can write this dissertation. At this moment to finish my graduate study, I would like to acknowledge many people who made this thesis possible.

At the top of the list is my advisor, Professor Wenbin Lin. It is not just for the opportunity he provided for me to study here and work on these challenging but significant projects. I have learned a lot from his passionate but rigorous manner of research. He is always fearless to the unknowns, adventurous on the virgin of knowledge, and restless in discovery. It would be impossible for me to grow from a fledgling to an independent researcher without his guidance.

It is my great luck to meet Dr. Chunbai He, my closest colleague on all the work in this dissertation. She is always reliable as a collaborator and nice as a friend. She deliberated me from the complex biological experiments so that I can focus on the work of my interest. I also gained much experience on management of projects from her.

Special thanks to Dr. Cheng (Wave) Wang, who is profound in knowledge and inspiring in research. He has been and will still be my idol in my career path. I would also thank Dr. Teng Zhang, my old roommate and lab mate, for the inspiring discussion on work and assistance in life.

There are too many people to be acknowledged in the lab: in no particular order — Dr. Demin Liu, Christina Chan, Kaiyuan Ni, Guangxu Lan, Dr. Nathan Thacker, Dr. Ninjing Guo, Youfu Wang, Ruoyu Xu, Zekai Lin, Pengfei Ji, Christopher Poon, Dr. Carter Abney, Dr. Xiaopin Duan, Dr. Takahiro Sawano, Marek Piechowicz, Dan Micheroni, Wenbo Han, Dr. Zhiming Zhang, Dr. Xiangjian Kong, Dr. Xin Zhou, Dr. Kuntal Manna, Irene Hsiao, Dr. Yu Peng, Dr.
Michaël Carboni, Seth Barrett, Dr. Rachel Huxford, Dr. Marcela Wanderly, Dr. Shuang Yao, Dr. Yan Liu, Dr. Stephanie Kramer, Alexei Owen, and anyone I forgot to mention in this list. Thank you all for the experimental help and the discussion and advices on my projects.

I would like to thank my committee members, Prof. Chuan He and Prof. Michael Hopkins, for the advices on my defense and dissertation. I also thank all the faculty and staff members in University of Chicago and University of North Carolina at Chapel Hill for the teaching and help on experiments.

Finally, I would like to thank my family. It is hard to stay away from them for so long time and I am grateful for their supports and love in my whole life.
Chapter 1. Introduction

1.1 Metal-organic frameworks

Metal-organic frameworks (MOFs), also known as porous coordination polymers (PCPs), are a class of crystalline, porous hybrid materials constructed from metal-containing nodes, also known as secondary building units (SBUs), bridged by organic linkers. The archetypal MOF is Prussian blue,\(^1\) a dark blue pigment with a cubic crystal structure constructed from Fe(II)-CN-Fe(III) coordination units. MOFs have been an object of intense study since the 1990s because of their tunability and versatility. Their application to issues as diverse as gas storage/separation,\(^2\)-\(^6\) nonlinear optics,\(^7\),\(^8\) ferroelectricity,\(^9\),\(^10\) conductivity/semiconductivity,\(^11\)-\(^15\) magnetism,\(^16\) luminescence and chemical sensing,\(^17\)-\(^23\) catalysis,\(^24\)-\(^29\) energy conversion,\(^30\)-\(^32\) biomedical imaging,\(^33\)-\(^36\) and drug delivery\(^35\),\(^37\)-\(^43\) have been intensively explored.

The ability to control coordination bond formation between the SBUs and the linkers allows for orthogonal design of the MOF structures (Figure 1-1).\(^44\) By selecting metals with the desired coordination chemistry and ligands with the desired geometry, MOF structures can be designed with significant precision.\(^45\)-\(^48\) Functionalities can thus be intentionally incorporated into MOFs by focusing on its components: the ligand,\(^46\),\(^49\),\(^50\) the SBU sites,\(^26\),\(^44\),\(^49\)-\(^52\) the channels,\(^53\)-\(^56\) and the surface of the material.\(^57\)
Due to lanthanide contraction, hafnium and zirconium are approximately the same size and thus similar in their coordination chemistry. Zr$^{4+}$ and Hf$^{4+}$ are hard acid metal ions that exhibit high affinity to oxygen. As a result, Zr and Hf can form strong bonds with carboxylates to build exceptionally water-stable MOFs. Zr- and Hf-based MOFs are also biocompatible because Zr/Hf...
oxides and phosphates are not very soluble in water so they are not bioavailable to interrupt protein and nucleic acid functions in vivo. For example, zirconium phosphate has extremely low solubility (K_{sp}=10^{-134}), which demonstrates the high affinity of Zr(IV) to phosphate ions. We thus anticipated an accelerated decomposition rate of Zr/Hf-MOFs inside cells, where the phosphate concentration is significantly higher than the extracellular environment.\(^{58,59}\) For these reasons, we believe that Zr/Hf based MOFs should be suitable for biomedical applications.

Several types of Zr-oxo clusters have been previously reported.\(^{48,60-64}\) Of these, \(\text{Zr}_6(\mu_3-O)_4(\mu_3-\text{OH})_4\) is the most common option for highly stable MOFs.\(^{65-69}\) Uio\(^\text{65}\) and MOF-545\(^\text{66}\) are two typical examples. In UiO MOFs, all 12 edges of the Zr\(_6\) octahedron are bridged by carboxylates, and the 8 faces are each capped by \(\mu_3\)-oxo or \(\mu_3\)-hydroxyl. The resultant \(\text{Zr}_6(\mu_3-O)_4(\mu_3-\text{OH})_4\text{(CO}_2\text{)}_{12}\) SBUs are linked by linear dicarboxylate ligands to build a face-centered cubic structure (\(Fm\overline{3}m\), Figure 1-2a,d), with a formula of \(\text{Zr}_6(\mu_3-O)_4(\mu_3-\text{OH})_4\text{L}_6\) (\(\text{L}\) refers to the ligand, similarly hereafter). In the MOF-545 structure, only 8 edges of the Zr\(_6\) octahedron are bridged by carboxylates, and the remaining coordination sites on an equatorial plan are occupied by water or hydroxyl groups (Figure 1-2b). The \(\text{Zr}_6(\mu_3-O)_4(\mu_3-\text{OH})_4(\text{OH})_4(\text{H}_2\text{O})_4\text{(CO}_2\text{)}_8\) SBUs are bridged by tetracarboxylate ligands to construct a hexagonal (\(P6/mmm\)) structure with a formula of \(\text{Zr}_6(\mu_3-O)_4(\mu_3-\text{OH})_4(\text{OH})_4(\text{H}_2\text{O})_4\text{L}_2\) (Figure 1-2 e,f). This structure features a large 1-D channel along the [001] direction with a channel diameter of 3.3 nm. We also discovered a new structure (\(n\text{MOF-1}\)) constructed from linear dicarboxylate ligands and a novel Zr\(_{12}\) SBU, \([\text{Zr}_6(\mu_3-O)_4(\mu_3-\text{OH})_4(\text{CO}_2)_9]_2(\mu_2-\text{OH})_6\), which can be viewed as two Zr\(_6\) clusters bridged by six \(\mu_2\)-OH (Figure 1-2c). Each Zr\(_6\) cluster coordinates to 6 carboxylates from the linear dicarboxylate ligands on the equatorial plane to form a 2-D layer, and the other ligands link
above and below to connect between layers (Figure 1-2 g,h). The Zr$_{12}$ clusters thereby adopt an ABAB packing style along the c axis to form a trigonal structure ($P\overline{3}1c$).

**Figure 1-2** Structure models of SBUs and MOFs. The SBUs of UiO ([Zr$_6$(μ$_3$-O)$_4$(μ$_3$-OH)$_4$(CO$_2$)$_{12}$], a), MOF-545 ([Zr$_6$(μ$_3$-O)$_4$(μ$_3$-OH)$_4$(OH)$_4$(H$_2$O)$_4$(CO$_2$)$_8$], b) and nMOF-1 ([Zr$_6$(μ$_3$-O)$_4$(μ$_3$-OH)$_4$(CO$_2$)$_9$]$_2$(μ$_2$-OH)$_6$, c). Cyan and purple, Zr/Hf; red, O; gray, C. (d) The structure model of UiO MOF: cyan, Zr/Hf; red, O; orange, ligand. The structure models of MOF-545 along [001] (e) and [100] (f) directions: purple, Zr/Hf; red, O; green, ligand. The structure models of nMOF-1 along [001] (g) and [100] (h) directions: cyan, Zr/Hf; red, O; gray, ligand.

1.2 Nanoscale metal-organic frameworks for drug delivery

The past two decades have witnessed the rapid development of nanotechnology for medical applications such as the detection, diagnosis, and treatment of cancer and other diseases.$^{39,70-75}$

Because of their size, which allows them to penetrate the leaky vasculatures of tumors,
nanocarriers are able to accumulate through passive tumor targeting, also known as the enhanced permeability and retention (EPR) effect.\textsuperscript{76,77} More advanced delivery platforms have also been designed that incorporate target moieties for tumor-specific delivery.\textsuperscript{72,78-80}

In contrast to purely inorganic\textsuperscript{81-84} or organic nanomaterials,\textsuperscript{85-88} nanoscale MOFs (nMOFs) are hybrid materials with characteristics that make them excellent candidates for drug delivery\textsuperscript{35,39,40}: (1) structural and compositional tunability for precise material design; (2) high porosity permitting a high cargo payload; and (3) relatively labile coordination bond connections, which make nMOFs intrinsically biodegradable in a biological environment. nMOFs have been successfully applied to the delivery of chemotherapeutic agents,\textsuperscript{37,41,42,89} imaging contrast agents,\textsuperscript{33,34,42,90} photosensitizers,\textsuperscript{91-94} proteins\textsuperscript{95,96} and gene therapy drugs.\textsuperscript{89,97,98}

There are multiple strategies for loading cargo into nMOFs (Figure 1-3): encapsulation into the channels,\textsuperscript{37,89,96} attachment to the ligands\textsuperscript{90,97} or SBUs,\textsuperscript{89} or using them directly as struts\textsuperscript{91,92,99} or nodes.\textsuperscript{33,95} The encapsulation method is the simplest and most frequently used, but premature cargo release can be a concern. Attachment to the linkers or nodes is a better option for postsynthetic functionalization if the attachment strength, feasibility of loading, and the release of cargo can be well balanced. nMOFs directly built from active agents have unique challenges because they require specific alignment of coordination sites, and the functionality of the cargo may be affected after constructing the framework. However, successful cases usually achieve ultra-high payloads, and we have shown that our nMOFs can perform significantly better than the free cargo.
Figure 1-3 Different strategies for loading cargo into nMOFs, (a) Encapsulation in the channels; (b) attachment to the linkers; (c) coordination to the SBUs; (d) used as struts; (e) serving as connection nodes. The red balls represent the cargo.

1.3 Cancer

Cancer is a major public health concern worldwide. It is currently the second leading cause of death in the United States, with ~1.7 million new cases estimated in 2016. However, owing to rapid development of cancer treatment technology, the death rate is decreasing despite the increase in number of new cases every year. Figure 1-4 summarizes the incidence and death rate by sex in the United States. Lung, prostate, colorectal, pancreatic, and liver cancer are the most lethal cancer types for men, and lung, breast, colorectal, pancreatic, and ovarian cancer most fatal for women. Here we will introduce a few types of cancer related to our work.
1.3.1 Head and neck cancer

Head and neck cancer is a group of biologically similar epithelial malignancies that arise in the head or neck region (including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, and larynx). Primary treatment of head and neck cancers include surgery and radiation therapy, with chemotherapy and chemoradiotherapy serving as a secondary treatment. Almost all of
these epithelial malignancies are squamous cell carcinomas of the head and neck (SCCHN), and of those affected, about two-thirds will develop advanced stage disease, commonly involving regional lymph nodes. At least 50% of patients with locally advanced SCCHN relapse, usually within the first 2 years of treatment.

Surgery remains the mainstay treatment of SCCHN but requires wide excision margins and usually causes functional deficits by damaging adjacent structures. Radiotherapy gives good prognosis on early stage tumors but is problematic for recurrent disease due to cumulative toxicity. Chemotherapy develops from a palliative care to a central component of treatment in SCCHN, though systemic toxicity and drug resistance remain a concern. Targeted therapy, such as cetuximab for EGFR inhibition, has emerged as a novel treatment strategy for SCCHN. Since SCCHN is usually superficial, photodynamic therapy (PDT) represents a potential alternative treatment modality. PDT is a localized therapy that can minimize peripheral tissue damage, and the lack of cumulative tissue toxicity enables repeated treatments without excluding the possibility of other treatments. It is as effective as surgery or radiotherapy for small superficial tumors and also works as a last recourse for recurrent head and neck cancer in patients who have failed conventional therapy.

1.3.2 Colorectal cancer

Colorectal cancer is cancer that begins in the colon or rectum. Colorectal cancer ranks third in both incidence and death rate for both sexes. Only 40% of patients with colorectal cancer are diagnosed at a local stage, for which the 5-year survival rate is 90.3%, while for regional and distant metastatic stages the survival drops to 70.4% and 12.5%, respectively.
Chemotherapy has been the mainstay treatment of colorectal cancer.\textsuperscript{110} Cocktails of a few chemotherapeutic drugs, such as FOLFOX (oxaliplatin, fluorouracil and leucovorin)\textsuperscript{111} and FOLFIRI (fluorouracil, folinic acid and irinotecan),\textsuperscript{112} have become gold standards in the first-line treatment of colorectal cancer. Moreover, better understanding of the biology of colorectal cancer promotes the combination of chemotherapy with targeted therapy drugs such as cetuximab, bevacizumab and panitumumab in the clinic.\textsuperscript{113-115}

Despite developments in colorectal cancer treatment, the high probability of metastases remains an issue that cause over one third of death eventually.\textsuperscript{109} The limitations of surgery and adjuvant chemo/radio/targeted therapies to treat metastatic colorectal cancer urge the development of novel approaches.\textsuperscript{116} Immunotherapy is the most welcome candidate, since antitumor immunity generated by stimulation of the host immune system is likely capable of controlling metastatic tumor growth. However, combination with other treatment modalities is necessary to maximize the benefits of immunotherapy and increase the durable response rate. Unlike most of the commonly used cancer therapies, which are immunosuppressive at treatment doses,\textsuperscript{117,118} PDT can stimulate the immune system to recognize and destroy distant metastases during treatment of the primary tumor, owing to a consequent acute inflammatory reaction.\textsuperscript{119} Nevertheless, the studies of PDT on colorectal cancer are still in a preclinical stage.

1.3.3 Ovarian cancer

Ovarian cancer is the deadliest gynecological cancer with a high mortality rate that has remained unchanged over the past four decades.\textsuperscript{120,121} Modern management helps a significant proportion of women attain complete remission in response to treatments, but most of those with
the advanced disease will develop recurrence within 18 months.\textsuperscript{122} Epithelial ovarian cancer is
the most common type, with about 22,000 cases diagnosed each year in the United States.\textsuperscript{123}

Due to the nature of this disease, debulking surgery is only auxiliary to chemotherapy in
advanced ovarian cancer. Platinum drugs (cisplatin or the less toxic carboplatin) in combination
with paclitaxel or docetaxel have been the standard of care for past decades.\textsuperscript{122} Other strategies,
such as targeted therapy and hormone therapy, have been explored, but little improvement in
overall survival has been achieved.\textsuperscript{89,124} The dismal prognosis of ovarian cancer is in large part
due to acquired resistance to chemotherapy.\textsuperscript{125} Though initial epithelial ovarian cancer is
responsive to platinum drug based chemotherapy,\textsuperscript{126} relapses are often refractory to treatment
and ultimately lead to mortality.\textsuperscript{127} New strategies to overcome drug resistance are urgently
needed in order to reduce the mortality rate of ovarian cancer.

Treatment of cancers with chemotherapy drugs often results in multidrug resistance (MDR).
The suggested resistance mechanism includes membrane transportation alteration, genetic
responses, DNA repair enhancement, target molecules alteration, metabolic effects, and growth
factor influence.\textsuperscript{128} Resistance pathways and mutations have been deeply explored both
genetically and epigenetically,\textsuperscript{89,129-131} and a number of inhibitors targeting MDR genes or
proteins have been developed in recent years.\textsuperscript{131-133} However, none of the new agents have
significantly influenced the diagnosis and treatment of ovarian cancer in the clinic.\textsuperscript{134}

1.4 Photodynamic therapy

Photodynamic therapy (PDT) is a phototherapy that combines three nontoxic components—
a photosensitizer (PS), a light source, and oxygen in the tissue—to destroy tumors and other
malignancies. PDT transfers energy from the light-excited PS to oxygen and other molecules in the tissue to generate reactive oxygen species (ROS), particularly, singlet oxygen (\(^1\text{O}_2\)), which induces cellular toxicity (Figure 1-5). PDT can lead to localized destruction of diseased tissues via selective uptake of the PS and/or local exposure to light, providing a minimally invasive cancer therapy.

The mechanism of photodynamic therapy.

The application of PDT to cancer treatment dates back to the 1970s, when hematoporphyrin derivatives were studied for PDT efficacy in vivo. The first PDT agent photofrin\textsuperscript{®} was approved for clinical use in 1993. Most PSs on the market are from the porphyrin family, with a few other dyes emerging in researches in recent years.

For better performance in PDT, the PSs should generate high levels of singlet oxygen. In other words, PSs require strong absorption at the excitation wavelength, high intersystem
crossing efficiency, and low fluorescence and phosphorescence. Porphyrin and its derivatives feature high intersystem crossing quantum yield owing to their strong vibronic spin-orbit coupling.\textsuperscript{139} UV-visible absorptions of porphyrins and their derivatives have been interpreted by Martin Gouterman with a four-orbital model,\textsuperscript{140} in which the transition between two HOMOs and two LUMOs generates two pairs of absorption bands, B bands (Soret bands) and Q bands. For freebase porphyrins, the Q-bands further split to four peaks on the spectrum due to the lowering of molecular symmetry (Figure 1-6).

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{porphyrin_spectrum}
\caption{The UV-vis absorption spectrum of porphyrin in correspondence to the illustration of Gouterman four-orbital theory.}
\end{figure}

Chlorin is the reduced form of porphyrin in which one $\beta-\beta$ double bond of the porphyrin is hydrogenated. The reduced molecular symmetry (from $D_{4h}$ or $D_{2h}$ to $C_{2h}$) and the destabilization of MOs causes red shift of $Q_y$ bands, while the $Q_y$ band intensity increases due to higher oscillator strength of these excited states (Figure 1-7a).\textsuperscript{141} Such changes in absorption vastly improve the performance of chlorins in PDT since near infrared light can penetrate deeper into the tissue (Figure 1-7b). Further reduction of another $\beta-\beta$ double bond on the opposite side of
chlorin affords bacteriochlorin, whose $Q_y$ absorption dramatically red shifts to ~740 nm. Unfortunately, because bacteriochlorins are usually unstable upon light irradiation, no bacteriochlorin PSs are developed for the clinic.\textsuperscript{142}

![Figure 1-7](image_url) (a) The UV-vis absorption spectra of protoporphyrin IX (PpIX) and chlorin e6 (Ce6). (b) The effective penetration depth of UV-visible light in human tissue. Reprinted from Wikipedia: Near-infrared window in biological tissue, created by Zhun310 at English Wikipedia.

Though recognized as a local therapy, PDT is found to be highly immune-active. PDT can induce both apoptosis and necrosis, producing a strong inflammatory response that activates antigen presentation to the lymph nodes (Figure 1-8).\textsuperscript{119} The consequent T cell maturation and proliferation not only enhances local tumor destruction but also potentiates systemic antitumor vaccination. Nevertheless, PDT-induced antitumor immunity has not yet been applied in the clinic.
Figure 1-8 T cell proliferation induced by PDT. Reprinted with permission from Nat. Rev. Cancer 2006, 6, 535-545. Copyright 2006 Nature Publishing Group.

1.5 Checkpoint blockade immunotherapy

Immunotherapy that uses the patient’s own immune system to help fight cancer has recently emerged as a highly effective cancer treatment strategy. It exhibits high overall response rates in multiple cancer types and durable tumor control enjoyed by a small subset of patients. Checkpoint blockade immunotherapy, which uses small molecules or antibodies to stimulate the immunosuppressive microenvironment of tumors by modulating protein expression and/or functions at dysregulated immune checkpoints, is currently a focal point of clinical interest. Multiple checkpoint blockade immunotherapy drugs have been approved by FDA for clinical use recently, including Ipilimumab, which targets CTLA-4, approved in 2011 for treatment of melanoma and Pembrolizumab and Nivolumab, two antibodies against PD-1, approved in 2014.
Indoleamine 2,3-dioxygenase (IDO) is an immunoregulatory enzyme highly expressed in tumors that catalyzes the oxidative catabolism of tryptophan (Trp) to kynurenine (Kyn).\textsuperscript{146-148} The results of this catalytic process leads to depletion of Trp and production of Kyn, thus preventing the clonal expansion of T cells and promoting T cell anergy and apoptosis.\textsuperscript{149,150} Small molecule IDO inhibitors such as 1-methyl-tryptophan,\textsuperscript{149,151} INCB24360,\textsuperscript{152} and NLG919,\textsuperscript{153} can effectively block Trp catabolism but show modest effect as monotherapies, due in part to ineffective antigen presentation and insufficient antitumor immunity.

The combination of immunotherapy with conventional cancer therapies has been under investigation, since cell death caused by other therapies potentiates tumor antigen release that initiates T cell activation.\textsuperscript{145} For example, there are multiple ongoing trials on the combination of radiation therapy with anti-CTLA-4 or anti-PD-1/PD-L1 antibodies,\textsuperscript{154,155} while studies of chemotherapy in combination with immunotherapeutics are also ongoing.\textsuperscript{156}

1.6 RNA interference and small interfering RNA

RNA interference (RNAi) is a biological process that inhibits gene expression by RNA, typically by causing mRNA destruction. The discovery of sequence-specific gene silencing by double-stranded RNA in the nematode worm \textit{Caenorhabditis elegans} won its discoverers, Fire and Mello, the Nobel Prize in Physiology or Medicine in 2006.\textsuperscript{157} Small interfering RNA (siRNA), first detected as a product of RNA degradation in plants as RNA pieces of ~25 nucleotides, induce mRNA degradation and cause post-transcriptional gene silencing.\textsuperscript{158,159} This discovery strongly influenced drug development, since RNA interference provides potential
solutions to dysfunctional gene/protein expression, in addition to expediting the elucidation of a variety of molecular biology mechanisms.160,161

The major challenge of siRNA drug development is delivery. Rapid renal clearance in circulation limits the direct intravenous injection of naked siRNA, which is also complicated by clearance by serum RNase A-type nucleases.162,163 Preventing degradation of nucleic acid drugs is another significant challenge in extracellular and intracellular trafficking control.162,164 Multiple delivery platforms have been evaluated on siRNA delivery, including liposomes and lipid-like materials,165-167 cationic polymers and other polymer nanoparticles,168-171 virus vectors,172,173 and inorganic nanoparticles,174-176 but real clinical success is far ahead. The dilemma lies in the balance between the stealth of the vehicle from reticuloendothelial system clearance and the effective cellular uptake and transfection. Liposomes and some neutral polymeric coating strategies can prolong the blood circulation and increase the tumor uptake of siRNA, but the incapability of endosomal escape leads to degradation of the cargo; the cationic vehicles and virus vectors enhance siRNA transfection, but also invite immune system clearance. In chapter 5, we will introduce the invention of a novel nMOF delivery platform for co-delivery of chemotherapeutics and siRNAs.89

1.7 References


Chapter 2. A Porphyrin-Based Nanoscale Metal-Organic Framework for Photodynamic therapy

2.1 Rationale of the nMOF design

Selective localization of PSs in tumors is critical for effective PDT. However, many PSs are hydrophobic in nature, which not only leads to insufficient tumor localization but also causes PS aggregation to diminish the PDT efficacy. We hypothesized that the incorporation of a porphyrin-derived bridging ligand into a robust and porous UiO nMOF structure with proper morphologies and dimensions would have several advantages over existing nanoparticle PDT agents: first, the PS molecules are well-isolated in the framework to avoid aggregation and self-quenching of the excited states; second, coordination of porphyrin ligands to heavy Hf centers via the carboxylate groups can promote intersystem crossing to enhance ROS generation efficiency; third, the porous nMOF structure provides a pathway for facile diffusion of ROS (such as $^{1}$O$_2$) out of the nMOF interior to exert their cytotoxic effects on cancer cells. In this nMOF design, an unprecedentedly high PS loading can be achieved to enable highly effective PDT of difficult-to-treat cancers.

This chapter reports our efforts on the design of the first porphyrin-based nMOF, DBP-Hf, as an efficient photosensitizer for PDT of resistant head and neck cancer. DBP-Hf efficiently generates $^{1}$O$_2$ owing to site isolation of porphyrin ligands, enhanced intersystem crossing by heavy Hf centers, and facile $^{1}$O$_2$ diffusion through porous DBP-Hf nanoplates. Consequently, DBP-Hf displayed greatly enhanced PDT efficacy both in vitro and in vivo, leading to complete tumor eradication in half of the mice receiving a single DBP-Hf dose and a single light exposure.
2.2 Results and Discussion

2.2.1 Synthesis and characterization of the H_2DBP ligand

The new porphyrin derivative with linearly aligned dicarboxylate groups, 5,15-di(p-benzoato)porphyrin (H_2DBP), was synthesized in 3 steps as shown in Scheme 2-1.


Dipyrrylmethane was synthesized based on a modified literature procedure. To a 1-liter flask 500 mL of distilled pyrrole (7.2 mol) was added. To the flask paraformaldehyde (1.74 g, 58 mmol by formaldehyde) was added and the mixture was degassed for 15 minutes. The mixture was then heated at 60 °C to dissolve most of the solid. After cooling to room temperature, 0.53 mL of trifluoroacetic acid (TFA) was added slowly to the solution. The reaction mixture was stirred for an hour before the addition of 812 mg of sodium hydroxide, then the mixture was stirred for another 45 minutes. Pyrrole was distilled off under vacuum and the remaining solid was extracted with dichloromethane from water and washed with water twice. The crude product was purified by silica gel column chromatography with chloroform as eluent to afford the off-
white product. Yield: 4.94 g, 33.8 mmol (58%). $^1$H-NMR (500 MHz, chloroform-D, ppm, Figure 2-1): $\delta=7.72$ (s, 2H), 6.61 (d, 2H), 6.15 (d, 2H), 6.03 (s, 2H), 3.94 (s, 2H).

![Figure 2-1](image_url)  
**Figure 2-1** $^1$H NMR spectrum of dipyrrylmethane in chloroform-D. Reprinted with permission from *J. Am. Chem. Soc.*, **2014**, *136*, 16712–16715. Copyright 2014 American Chemical Society.

4-(Methoxycarbonyl)benzaldehyde (1.20 g, 7.3 mmol) and dipyrrylmethane (1.07 g, 7.3 mmol) were added to a round bottom flask. To the flask 1 L of anhydrous dichloromethane DCM) was added. Trifluoroacetic acid (0.34 mL, 4.4 mmol) was added dropwise via a syringe. The mixture was stirred at room temperature for 4 hours. To the reaction mixture, 2.49 g 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ, 11.0 mmol) was then added and the mixture was stirred for another hour. Triethylamine was added to neutralize the reaction mixture. The solvent was removed with a rotary evaporator, and the 5,15-di(p-methyl-benzoato)porphyrin (Me₂DBP) product was purified by column chromatography with chloroform as the eluent. Yield: 810 mg, 1.40 mmol (38%). $^1$H-NMR (500 MHz, chloroform-D, ppm, Figure 2-2): $\delta=10.38$ (s, 2H), 9.45 (d, 4H), 9.06 (d, 4H), 8.52 (d, 4H), 8.39 (d, 4H), 4.16 (s, 6H), -3.12 (s, 2H).
The aforementioned Me$_2$DBP (399 mg, 0.69 mmol) was dissolved in a mixture of tetrahydrofuran (THF) and methanol (90 mL, 1:1 vol/vol). A potassium hydroxide aqueous
solution (14 mL, 2 M) was then added. The solution was heated to reflux under nitrogen protection overnight. Half of the solvent was removed with a rotary evaporator before the solution was neutralized to pH=3 with trifluoroacetic acid. The dark purple product was collected by centrifugation and washed with water and ether. The solid residue was dried under vacuum to give the pure H$_2$DBP product in 95% yield (362 mg, 0.66 mmol). $^{13}$C-NMR (125 MHz, DMSO-D$_6$, ppm, Figure 2-3): $\delta$ = 168.05 (a), 145.36 (f), 135.35, 133.46, 131.22, 130.78 (b-e), 128.67 (g, j), 118.19 (k), 106.62 (h, i). $^1$H-NMR (500 MHz, DMSO-D$_6$, ppm, Figure 2-4): $\delta$=13.35 (s, 2H), 10.71 (s, 2H), 9.71 (d, 4H), 9.08 (d, 4H), 8.45 (m, 8H), -3.26 (s, 2H). ESI-MS for [H$_2$DBP+H]$^+:$ 551.1 calc; 551.2 found (Figure 2-5).

Figure 2-3 $^{13}$C NMR spectrum of 5,15-di(p-benzoato)porphyrin in DMSO-D$_6$. Reprinted with permission from J. Am. Chem. Soc., 2014, 136, 16712–16715. Copyright 2014 American Chemical Society.
Figure 2-4 $^1$H NMR spectrum of 5,15-di(p-benzoato)porphyrin in DMSO-D$_6$. The full view (top) and an expanded view of a portion of the spectrum (bottom). Reprinted with permission from J. Am. Chem. Soc., 2014, 136, 16712–16715. Copyright 2014 American Chemical Society.
2.2.2 Synthesis and characterization of DBP-Hf

DBP-Hf was synthesized by a solvothermal reaction between HfCl$_4$ and H$_2$DBP in N, N-dimethylformamide (DMF) at 80 °C (scheme 2-2). The resulting dark purple powder was washed with copious amounts of DMF, 1% triethylamine in ethanol (v/v), and ethanol successively before being dispersed in ethanol as a stock suspension.
The attempts to grow DBP-Hf crystals suitable for single-crystal X-ray diffraction are not successful likely due to the poor solubility of the ligand. Fortunately, the single crystal structure of an analog of DBP-Hf, Zr$_6$(µ$_3$-O)$_4$(µ$_3$-OH)$_4$(Zn-DPDBP)$_6$ (Zn-DPDBP-Zr, where DPDBP is 5,15-di(p-benzoato)-10,20-diphenyl-porphyrin and has the same length as DBP), is determined (Table 2-1 & Figure 2-6) and the powder X-ray diffraction (PXRD) pattern matches that of DBP-Hf (Figure 2-6a). DBP-Hf thus adopts a UiO-type MOF structure that is built from 12-connected Hf$_6$(µ$_3$-O)$_4$(µ$_3$-OH)$_4$(carboxylate)$_{12}$ secondary building units (SBUs) and DBP bridging ligands. DBP-Hf has a very open framework structure with triangular channels of 1.6 nm in dimensions as well as octahedral and tetrahedral cavities of 2.8 nm and 2.0 nm in dimensions, respectively, which facilitates the diffusion of ROS during PDT process.

Table 2-1 Chemical structure of Zn-DPDBP and crystal structure information of Zn-DPDBP-Zr.

<table>
<thead>
<tr>
<th>Formula</th>
<th>Absorption coeff. (mm$^{-1}$)</th>
<th>Zn-DPDBP =</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zr$_6$(O)$_4$(OH)$_4$(Zn-DPDBP)$_6$</td>
<td>0.223</td>
<td>CO$_2$H</td>
</tr>
<tr>
<td>Fw</td>
<td>5263.82</td>
<td>CO$_2$H</td>
</tr>
<tr>
<td>Temperature (K)</td>
<td>293</td>
<td></td>
</tr>
<tr>
<td>Wavelength (Å)</td>
<td>0.41328</td>
<td></td>
</tr>
<tr>
<td>Crystal system</td>
<td>cubic</td>
<td></td>
</tr>
<tr>
<td>Space group</td>
<td>Fm$ar{3}$m</td>
<td></td>
</tr>
<tr>
<td>a, Å</td>
<td>38.758(2)</td>
<td></td>
</tr>
<tr>
<td>b, Å</td>
<td>38.758(2)</td>
<td></td>
</tr>
<tr>
<td>c, Å</td>
<td>38.758(2)</td>
<td></td>
</tr>
<tr>
<td>α, °</td>
<td>90</td>
<td></td>
</tr>
<tr>
<td>β, °</td>
<td>90</td>
<td></td>
</tr>
<tr>
<td>γ, °</td>
<td>90</td>
<td></td>
</tr>
<tr>
<td>V, Å$^3$</td>
<td>58224(5)</td>
<td></td>
</tr>
<tr>
<td>Z</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Density (calcd. g/cm$^3$)</td>
<td>0.600</td>
<td></td>
</tr>
</tbody>
</table>

| F(000)                   | 10640.0                       |            |
| θ range data collection  | 1.01 – 13.00                  |            |
| Limiting indices         | -39<=h<=41, -42<=k<=32, -38<=l<=41 |            |
| Reflection collected     | 81986                         |            |
| Independent reflections  | 1987                          |            |
| R(int)                   | 0.0936                        |            |
| Data/restraints/parameters | 1987/35/59                 |            |
| Goodness-of-fit on $F^2$ | 2.324                         |            |
| Final R indices [I>2σ(I)] | R1 = 0.0896, wR2 = 0.2592 |            |
| R indices (all data)     | R1 = 0.0940, wR2 = 0.2644    |            |

Figure 2-6 Structural confirmation of DBP-Hf. (a) Powder X-ray diffraction patterns of DBP-Hf comparing to Zn-DPDBP-Zr. (b) The structure of Zn-DPDBP-Zr viewed from the [110] direction; (c) the octahedral cavity in the structure. Adapted with permission from J. Am. Chem. Soc., 2014, 136, 16712–16715. Copyright 2014 American Chemical Society.
Transmission electron microscopy (TEM) confirms that DBP-Hf particles display a plate morphology (Figure 2-7). Nitrogen adsorption measurements gave a BET surface area of 558 m$^2$/g for the nMOF (Figure 2-8a). Thermogravimetric analysis (Figure 2-8b) shows a weight loss of 77% from 150-600 °C (calculated 73%). Inductively coupled plasma-mass spectrometry (ICP-MS) confirms a Hf content of 24.3% (calculated 23.7%).
Individual SBUs are clearly visible in high-resolution TEM images of DBP-Hf (Figure 2-7b). The distances between SBUs are measured to be approximately 2.7 nm (Figure 2-7f), which are consistent with the calculated distance of 2.77 nm based on the X-ray structure model. Fast Fourier transform (FFT) of the high-resolution TEM image displays a 3-fold symmetry for the nanoplates (Figure 2-7c), consistent with the symmetry along (111) direction of the cubic structure of DBP-Hf. The dimensions of the nanoplates are measured to be ~100 nm in diameter and ~10 nm in thickness. Such thin plates consist of only 4-5 sets of (111) packing layer (d_{111}=2.2 nm). Dynamic light scattering (DLS) measurements gave an average diameter of 76.3 nm for the particles (Figure 2-9). Notably, the nanoplate morphology is particularly advantageous for generating ROS for PDT. The diffusion length of $^1$O$_2$ is no more than 90-120 nm in aqueous environment$^{4-8}$ and was estimated to be 20-220 nm inside cells.$^9$ Therefore, the nanoplates as thin as 10-nm in thickness are ideally suited for transporting $^1$O$_2$ from the nMOF interior to the cell cytoplasm to exert cytotoxic effects.
DBP-Hf displays high stability in physiological environment. After incubation in RPMI 1640 cell culture medium for 12 h, the DBP-Hf morphology remained unaltered by TEM observation (Figure 2-7d). The remained crystallinity of the nMOFs was also confirmed by the FFT of the TEM images and the unchanged PXRD pattern (Figure 2-7a,e).

![DLS plot showing the particle size of DBP-Hf](image)

**Figure 2-9** DLS plot showing the particle size of DBP-Hf. Reprinted with permission from *J. Am. Chem. Soc.*, 2014, 136, 16712–16715. Copyright 2014 American Chemical Society.

### 2.2.3 Photophysics and photochemistry of H₂DBP and DBP-Hf

The UV-visible absorption spectra of H₂DBP and DBP-Hf in phosphate buffered saline (PBS) buffers (pH=7.4) are compared in Figure 2-10. H₂DBP shows a Soret band at 402 nm and four Q-bands at 505, 540, 566, and 619 nm. The absorption of standard solutions of H₂DBP at concentrations of 0.2, 0.4, 0.6, 0.8, 1, 1.5, 4 and 8 mg/L were acquired and the extinction coefficients of H₂DBP at 402 nm and 619 nm are determined to be 2.2×10⁵ and 1.7×10³ M⁻¹ cm⁻¹, respectively (Figure 2-10b). DBP-Hf shows slight red shifts for all Q-bands, with the peaks appearing at 510, 544, 579, and 634 nm, probably due to the coordination of the carboxylate groups of DBP ligands to Hf centers. The presence of four Q-bands and their red shifts support the presence of free-base porphyrin ligands in DBP-Hf. The Soret band of DBP-Hf is
significantly broadened, presumably due to inequivalent ligand environments in thin nanoplates as well as potential framework distortion in thin MOF structures.

![Figure 2-10](image)

**Figure 2-10** UV-visible spectra of H$_2$DBP and DBP-Hf. Adapted with permission from *J. Am. Chem. Soc.*, 2014, 136, 16712–16715. Copyright 2014 American Chemical Society.

The coordination of the porphyrin ligand to Hf will enhance the intersystem crossing from $^1$DBP excited state to $^3$DBP state,$^{10}$ which decreases the fluorescence emission and increases the singlet oxygen generation quantum yield. The fluorescence spectra of H$_2$DBP ligand and DBP-Hf were taken on a spectrofluorophotometer (RF-5301PC, Shimadzu, Japan, Figure 2-11). The ligand fluorescence appears at 630 nm (strong) and 690 nm (weak) with excitation at 405 nm, while DBP-Hf emission at 640 nm greatly diminished by a factor of 250. The fluorescence lifetimes reduction from 10.9 ns for H$_2$DBP to 0.26 ns for DBP-Hf also confirms such effect (Figure 2-12 and Table 2-2).
**Figure 2-11** Fluorescence of H$_2$DBP and DBP-Hf in PBS (excitation: 405 nm). The expanded view for the DBP-Hf is shown in the inset. Reprinted with permission from *J. Am. Chem. Soc.*, 2014, 136, 16712–16715. Copyright 2014 American Chemical Society.

**Figure 2-12** Time-resolved fluorescence decay traces of H$_2$DBP (left) and DBP-Hf (right) in different media, together with instrument response function (excitation/emission 405/640 nm). Reprinted with permission from *J. Am. Chem. Soc.*, 2014, 136, 16712–16715. Copyright 2014 American Chemical Society.
Table 2-2 Lifetimes of H2DBP and DBP-Hf fluorescence in different medium, fitted by software.

<table>
<thead>
<tr>
<th>sample</th>
<th>( \tau_1 ) (ns)</th>
<th>( \tau_2 ) (ns)</th>
<th>( \bar{\tau} ) (ns)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IRF</td>
<td>0.0074</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>
| \( \text{H}_2\text{DBP\
DMF} \) | 11.3                | N/A                 | N/A                     |
| \( \text{H}_2\text{DBP\
aq} \) | 12.4                | 7.86                | 10.9                    |
| \( \text{DBP-Hf\
DMF} \) | 0.44                | 1.31                | 0.54                    |
| \( \text{DBP-Hf\
aq} \) | 0.21                | 0.70                | 0.26                    |

Singlet oxygen generation efficiencies of \( \text{H}_2\text{DBP} \) and \( \text{DBP-Hf} \) were determined using Singlet Oxygen Sensor Green (SOSG, Life Technologies). After exposure to a LED light source (peak emission at 640 nm, energy irradiance of 100 mW/cm\(^2\)), the produced \(^1\text{O}_2\) react with chemiluminescent reagent SOSG to generate green fluorescence, and the change of fluorescence signal was quantified with a fluorimeter. The fluorescence intensity was plotted against irradiation time (Figure 2-13). The \(^1\text{O}_2\) generation was depicted with an exponential function that corresponded to a pseudo first-order process.

As the light intensity and photosensitizer concentration are fixed, for the photoreaction, we can assume that \([PS^*]\) (the concentration of the excited state of the photosensitizer) is a constant. Therefore, we have singlet oxygen generation rate equation:

\[
\frac{d[\text{\(^1\text{O}_2\)}]}{dt} = -\frac{d[\text{O}_2]}{dt} = k[PS^*][\text{O}_2] = k^*[\text{O}_2]
\]

Where \(k^* = k[PS^*]\). Here we have a coupled reaction of SOSG to consume singlet oxygen:

\[
\frac{d[\text{SOSG}^*]}{dt} = k_2[\text{\(^1\text{O}_2\)}][\text{SOSG}]
\]

Where \([\text{SOSG}^*]\) is the concentration of reacted form of SOSG.
Applying steady state assumption on $[^1O_2]$, we have

$$\frac{d[^1O_2]}{dt} = k[^1O_2] - k_d[^1O_2] - k_2[^1O_2][SOSG] = 0$$

$$[^1O_2] = \frac{k[^1O_2]}{k_d + k_2[SOSG]}$$

Where $k_d$ is the rate constant of singlet oxygen loss (due to relaxation or quenched by other species in the solution). When $k_2[SOSG]<k_d$ and $[^1O_2]$ is high,

$$[^1O_2] \approx \frac{k[^1O_2]}{k_d} = \text{constant}$$

$$\frac{dI_F}{dt} \propto \frac{d[SOSG^*]}{dt} = k_1[SOSG]$$

Where $k_1=k_2k^*[O_2]/k_d$, and the fluorescence intensity is proportional to $[SOSG^*]$:

$$I_F = I_0\varphi_f\varepsilon_S b[SOSG^*]$$

Where $I_0$ is the incident light intensity, $\varphi_f$ is the fluorescence quantum yield of SOSG*, $\varepsilon_S$ is the extinction coefficient of SOSG*, and $b$ is the light path length. We can integrate the equation to obtain the correlation of fluorescence intensity $I_F$ and irradiation time $t$:

$$\ln \frac{[SOSG]}{c_0(SOSG)} = -k_1 t$$

$$I_F = A[1 - e^{-k t}]$$

Where $A$ and $k$ are fitting parameters,

$$A = \varphi_f I_0\varepsilon_S b c_0(SOSG)$$
\[ k = \varphi_\Delta N_{ir}\varepsilon_{PS}bc(PS)k_2/k_d \]

Where \(c_0(SOSG)\) is the initial SOSG concentration; \(\varphi_\Delta\) is the quantum yield of singlet oxygen generation, \(N_{ir}\) is the irradiation light intensity by photons per second, \(\varepsilon_{PS}\) is the extinction coefficient of photosensitizer at LED emission wavelength, \(c(PS)\) is the photosensitizer concentration. Linear approximations are applied in above equations.

Note that for \(\text{H}_2\text{DBP}+\text{HfCl}_4\) sample, singlet oxygen generation rate is very low, SOSG consumption becomes negligible. Then the equation could be simplified to

\[ I_F = Ak t \]

Thus we can compare the linear regression slope to product of \(Ak\) in the other groups.

The fitted equations for \(\text{H}_2\text{DBP}\) and \(\text{DBP-Hf}\) are (Table 2-3):

\[ I_{\text{H}_2\text{DBP}} = 68 \times (1-e^{-0.0015t}) \]

\[ I_{\text{DBP-Hf}} = 88 \times (1-e^{-0.0033t}) \]

The product of \(Ak\) in the equation is proportional to the initial rate of the reaction that indicates the \(^1\text{O}_2\) generation efficiency. \(\text{DBP-Hf}\) is thus at least twice as efficient as \(\text{H}_2\text{DBP}\) in generating \(^1\text{O}_2\).
Figure 2-13 Singlet oxygen generation by DBP-Hf, H\textsubscript{2}DBP, and H\textsubscript{2}DBP+HfCl\textsubscript{4}. The dots are experimental data and the solid lines are fit curves. Reprinted with permission from J. Am. Chem. Soc., 2014, 136, 16712–16715. Copyright 2014 American Chemical Society.

Table 2-3 Fitting parameters of singlet oxygen generation rate.

<table>
<thead>
<tr>
<th></th>
<th>A</th>
<th>k (s\textsuperscript{-1})</th>
<th>r\textsuperscript{2}</th>
<th>Ak</th>
</tr>
</thead>
<tbody>
<tr>
<td>H\textsubscript{2}DBP</td>
<td>68</td>
<td>1.5\times10\textsuperscript{-3}</td>
<td>0.998</td>
<td>0.102</td>
</tr>
<tr>
<td>DBP-Hf</td>
<td>88</td>
<td>3.3\times10\textsuperscript{-3}</td>
<td>0.999</td>
<td>0.290</td>
</tr>
<tr>
<td>H\textsubscript{2}DBP+HfCl\textsubscript{4}</td>
<td></td>
<td>0.97</td>
<td>0.0062</td>
<td></td>
</tr>
</tbody>
</table>

2.2.4 \textit{In vitro} and \textit{in vivo} efficacy

Encouraged by the excellent \textsuperscript{1}O\textsubscript{2} generation efficiency, we tested the PDT efficacy of DBP-Hf on resistant head and neck cancer models. The tumor cell uptake of DBP-Hf was first evaluated by incubating human head and neck cancer cells SQ20B with DBP-Hf (30 \textmu g/mL) for
4 h or 12 h (Figure 2-14). The Hf concentrations in the cells were determined by ICP-MS. No significant difference was observed between the uptake amount after 4 h and 12 h incubation, indicating rapid internalization of DBP-Hf to the cancer cells.

**Figure 2-14** Cellular uptake of DBP-Hf after 4 or 12 hour incubation. Reprinted with permission from *J. Am. Chem. Soc.*, 2014, 136, 16712–16715. Copyright 2014 American Chemical Society.

To further confirm the PDT efficacy of DBP-Hf, SQ20B cancer cells were treated with H₂DBP, DBP-Hf, or PpIX at various concentrations (5, 10, 20, 50 and 100 µM based on ligand concentrations), the cells were irradiated with LED light (640 nm, 100 mW/cm²) for 15 min (total light dose 90 J/cm²) or 30 min (total light dose 180 J/cm²), respectively. Significant PDT efficacy was observed in DBP-Hf treated groups, even for the group receiving 5 µM PS dose and 15 min irradiation (Figure 2-15). H₂DBP-treated groups show moderate PDT efficacy only at 20 µM dose with 30 min light irradiation while no cytotoxicity was observed in dark control or blank control groups. In comparison, PpIX is much less photocytotoxic than DBP-Hf under similar conditions. Cells incubated with PBS after irradiation for 15 min and 30 min did not show appreciable viability changes (95.2±2.2% for 15 min and 96.1±5.2% for 30 min) compared
with cells incubated with PBS and received no irradiation, suggesting that irradiation alone will not induce any cytotoxicity. There was also no cytotoxicity observed in cells treated with H$_2$DBP or DBP-Hf without irradiation. This result indicated that H$_2$DBP and DBP-Hf alone are non-toxic to cells at tested concentrations up to 100 µM.

We carried out proof-of-concept *in vivo* experiments on SQ20B subcutaneous xenograft murine models to evaluate the PDT efficacy of DBP-Hf. The mice were treated with PBS control, DBP-Hf (3.5 mg DBP/kg) or H$_2$DBP (3.5 mg/kg) by intratumoral injection. Twelve hours post injection, each mouse was irradiated at the tumor site with light (180 J/cm$^2$) for 30 min. For comparison from literature, photofrin® is administrated by intraperitoneal injection at 10 mg/kg in tumor bearing mice and with light irradiation of 135 J/cm$^2$. As depicted in Figure 2-16, the tumors of mice treated with DBP-Hf started shrinking 1 day post PDT treatment. Most importantly, among the four tumors in the DBP-Hf group, two tumors were completely eradicated by single nMOF administration and single light irradiation while the sizes of the other two tumors decreased from ~150 mm$^3$ to ~3 mm$^3$. The tumor growth of mice treated with H$_2$DBP was slightly suppressed after PDT, however accelerated after 5 days and exhibited no difference to the control group at the endpoint. After local administration, DBP-Hf could be efficiently internalized by the tumor cells and induce cytotoxicity upon irradiation while the free ligand might be cleared away from the tumor sites before irradiation. No skin/tissue damage was observed after PDT treatment on all mice (Figure 2-16c). The histologies of tumor slices of all three groups were observed after PDT treatment (Figure 2-17). The dominant normal tumor cells are observed in control and ligand treated groups. Prevailing apoptosis/necrosis of tumor cells were observed in tumor slices from nMOF group and massive inflammatory cells indicated the
immunoresponse after PDT. The blood vessels in tumor tissue in nMOF treated group are destroyed after PDT while not disturbed in control and ligand treated groups.

Figure 2-15 *In vitro* PDT cytotoxicity of H$_2$DBP, DBP-Hf, and PpIX at different PS concentrations and irradiation doses. Adapted with permission from *J. Am. Chem. Soc.*, 2014, 136, 16712–16715. Copyright 2014 American Chemical Society.
Figure 2-16 In vivo efficacy of PDT on SQ20B tumor bearing mice. (a) Tumor growth inhibition curve after PDT treatment. Black and red arrow refer to injection and irradiation time point, respectively. (b) Tumor weight after PDT treatment. (c) Photos of the mice on Day 8. (d) Photo of tumors of each group after PDT. Two tumors in the DBP-Hf group were completely eradicated at the endpoint. Adapted with permission from J. Am. Chem. Soc., 2014, 136, 16712–16715. Copyright 2014 American Chemical Society.
Figure 2-17 Histology of tumor slices of mice after PDT treatment. Adapted with permission from *J. Am. Chem. Soc.*, 2014, 136, 16712–16715. Copyright 2014 American Chemical Society.
2.3 Conclusion

In this chapter, we have designed and synthesized a stable and porous DBP-Hf nMOF with an ideal combination of structural regularity and nanoplate morphology for highly effective PDT of resistant head and neck cancer. As a result of site isolation of DBP ligands, enhanced intersystem crossing by Hf clusters, and facile $^1$O$_2$ diffusion out of a porous nanoplate, the nMOF works as an efficient PDT photosensitizer, as demonstrated by both $^1$O$_2$ generation efficiency measurements and in vitro cytotoxicity assays. In vivo PDT efficacy studies with subcutaneous xenograft murine models demonstrated 50 times tumor volume reduction in half of the mice and complete tumor eradication in the other half of mice that were treated with DBP-Hf. In comparison, no therapeutic effect was observed in the mice treated with H$_2$DBP. The facile structural and compositional tunability of nMOFs should allow further tuning of other properties to afford a new generation of highly potent PDT agents for treating resistant cancers in the clinic.

2.4 Methods

**UV-visible absorption:** The UV-vis absorption spectra of H$_2$DBP and DBP-Hf were acquired with a UV-vis spectrophotometer (UV-2401PC, Shimadzu, Japan). The H$_2$DBP solution and DBP-Hf NMOF suspension were prepared in 0.67 mM phosphate buffer saline (PBS). The absorption of standard solutions of H$_2$DBP at concentrations of 0.2, 0.4, 0.6, 0.8, 1, 1.5, 4 and 8 mg/L were acquired and the standard curve was plotted by linear fitting of the absorbance at 402 nm.

**Fluorescence lifetime measurement:** Time-domain lifetimes were measured on a ChronosBH lifetime fluorimeter (ISS, Inc.) using Time-Correlated Single Photon Counting (TCSPC)
The fluorimeter contained Becker-Hickl SPC-130 detection electronics and an HPM-100-40 Hybrid PMT detector. Tunable picosecond pulsed excitation was provided by a Fianium SC400-2 supercontinuum laser source with integrated pulse picker and AOTF. Emission wavelengths were selected with bandpass filters (Semrock and Chroma). The Instrument Response Function (IRF) was measured to be approximately 120ps FWHM in a 1% scattering solution of Ludox LS colloidal silica. Lifetimes were fit via a forward convolution method in the Vinci control and analysis software.

**Singlet Oxygen generation test:** A light-emitting diode (LED) array with peak emission at 640 nm was used as the light source of singlet oxygen generation. The irradiance of LED is 100 mW/cm². Singlet oxygen sensor green (SOSG) reagent (Life Technologies) was employed for the detection of singlet oxygen. H₂DBP and DBP-Hf samples were prepared in 5 μM solutions/suspensions in HBSS buffer (for DBP-Hf samples, the concentration was calculated as ligand equivalents). To 2 mL each of these solutions/suspensions, SOSG stock solution (5 μL at 5 mM) was added (final concentration=12.5 μM) before fluorescence measurement.

For a typical measurement, fluorescence intensity was acquired on a spectrofluorophotometer (RF-5301PC, Shimadzu, Japan) with excitation at 504 nm and emission at 525 nm (slit width 1.5 nm/3 nm for ex/em). Fluorescence was measured after irradiation by LED for 0 (as background), 10 s, 20 s, 30 s, 1 min, 1.5 min, 2 min, 2.5 min, 3 min, 3.5 min, 4 min, 4.5 min, 5 min, 6 min and 7 min.

**Cellular uptake:** SQ20B cells were seeded on 6-well plates at 5×10⁵ cells/well and further incubated for 24 h. The DBP-Hf samples were added to the cells at a concentration of 30 mg/L. After incubating for 4 h and 12 h, the cells were collected and the cell numbers were counted by
hemocytometer. The cells were digested with concentrated nitric acid and subjected to ICP-MS for the determination of the Hf concentration. The cellular uptake amounts were expressed as Hf (ng) per 10^5 of cells.

**In vitro cytotoxicity:** The cytotoxicities of DBP-Hf, H₂DBP, and PpIX were evaluated in human head and neck cancer cells SQ20B which are resistant to cisplatin and conventional radiotherapy. SQ20B cells were seeded on 96-well plates at 2000 cells/well. The cells were treated with DBP-Hf and H₂DBP at various ligand concentrations (5, 10, 20, 50 and 100 µM base on ligand concentrations) after a 24-h incubation. A further incubation of 4 h was allowed, followed by replacing the culture medium with 100 µL of fresh DMEM/F12 medium. The cells were irradiated with LED light (640 nm) at 100 mW/cm² for 15 min (total light dose 90 J/cm²) or 30 min (total light dose 180 J/cm²), respectively. The cells without irradiation treatment served as controls. The cells were further incubated to achieve a total incubation time of 72 h with DBP-Hf, H₂DBP or PpIX. The cell viability was detected by (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) assay (Promega, USA).

**In vivo efficacy:** The PDT efficacy of DBP-Hf was investigated using SQ20B subcutaneous xenograft murine models. Tumor bearing mice were established by subcutaneous inoculation of SQ20B cell suspension (5×10^6 cells per mouse) into the right flank region of 6-week athymic female nude mice. Three groups were included for comparison: PBS as control, H₂DBP, and DBP-Hf. When tumors reached 100 mm³, PBS, H₂DBP, and DBP-Hf were intratumorally injected to animals at a DBP dose of 3.5 mg/kg. At 12 h post-injection, mice were anesthetized with 2% (v/v) isoflurane and tumors were irradiated with a 640 nm LED for 30 min. The light intensity was measured as 100 mW/cm², and the total light dose was 180 J/cm². Both injection and PDT were performed once.
To evaluate the therapeutic efficacy, tumor growth and body weight evolution were monitored. The tumor size was measured with a digital caliper every day. Tumor volumes were calculated as follows: \( \text{width}^2 \times \text{length}/2 \). Finally, all mice were sacrificed on Day 8, and the excised tumors were photographed and weighed. Tumors were fixed with formalin. Paraffin-embedded 5 μm tumor sections were stained with hematoxylin and erisin (H&E) and observed with light microscopy (Pannoramic Scan Whole Slide Scanner, Perkin Elmer, USA).

2.5 References


Chapter 3. A Chlorin-Based Nanoscale Metal-Organic Framework for Photodynamic therapy

3.1 Rationale of the nMOF design

After the first successful attempt to use the porphyrin-based nMOF, DBP-Hf, as a photosensitizer (PS) for PDT, we wish to further optimize the nMOF system. Despite the excellent performance in pilot animal studies, the photophysical properties of DBP-Hf are not optimal. The lowest energy absorption at 634 nm and the relatively small extinction coefficient ($\varepsilon$) of 2200 M$^{-1}$·cm$^{-1}$ indicate a low energy conversion efficiency. In this chapter, we report the design of the first chlorin-based nMOF, DBC-Hf, with much improved photophysical properties and PDT efficacy.

Hematoporphyrin derivatives were developed as the first generation PSs, leading to the clinical application of the first PDT agent photofrin® in 1993. However, the photophysical properties of porphyrins are non-ideal with the absorption peaks typically near the high energy edge of the tissue-penetrating window (600-900 nm) and small $\varepsilon$ values. In molecular PS design, reduction of porphyrins to chlorins has been shown to shift the absorption to a longer wavelength with a concomitant increase in $\varepsilon$. For example, reduction of 5,10,15,20-m-tetra(hydroxyphenyl)porphyrin to its chlorin derivative red-shifts the last Q-band from 644 to 650 nm along with a dramatic enhancement in $\varepsilon$ from 3400 M$^{-1}$·cm$^{-1}$ to 29600 M$^{-1}$·cm$^{-1}$. We hypothesized that a chlorin-based nMOF would have improved photophysical properties over DBP-Hf to lead to more effective cancer treatment by PDT.
3.2 Results and Discussion

3.2.1 Synthesis and characterization of the H$_2$DBC ligand


The synthesis of H$_2$DBC ligand follows the route in scheme 3-2. 5,15-di(p-methylbenzoato)porphyrin (Me$_2$DBP) was synthesized following the protocol in Chapter 2. Me$_2$DBP was reduced to 5,15-di(p-methylbenzoato)chlorin (Me$_2$DBC) following a modified procedure from the literature.$^4$ To a 2-neck round bottom flask were added Me$_2$DBP (239 mg, 0.41 mmol) and anhydrous potassium carbonate (520 mg, 3.76 mmol). Under nitrogen protection 30 mL of anhydrous pyridine was added. The solution was heated to 105 °C before the addition of 3 mL of p-toluenesulfonylhydrazide solution (0.275 M in anhydrous pyridine). The reaction mixture was kept at 105 °C for another 8 hours during which 4 fractions of p-toluenesulfonylhydrazide solutions (0.275 M in anhydrous pyridine, 3 mL for each fraction) were added every 2 h. The reaction mixture was then stirred at 105 °C in the dark for another 12 h. The product was extracted with 2:1 ethyl acetate/water and washed with 2 M HCl, 2 M phosphoric acid (twice), water, and saturated sodium bicarbonate solution. The solution was
treated with 2,3-dichloro-5,6-dicyano-benzoquinone (via slow addition of 1 mg/mL solution in chloroform) until the characteristic absorption of the over-reduced product at 735 nm disappeared. Silica gel chromatography with chloroform as eluent afforded pure Me₂DBC. Yield: 26% (62 mg, 0.11 mmol). ESI-MS for [Me₂DBC+H]⁺: 581.1 calcd; 581.2 found (Figure 3-1).

\(^1\)H-NMR (500 MHz, chloroform-D, ppm, Figure 3-2): \(\delta=9.89\) (s, 1H), 9.14 (dd, 1H), 9.06 (s, 1H), 8.99 (d, 1H), 8.85 (d, 1H), 8.77 (d, 1H), 8.59 (d, 1H), 8.44 (t, 4H), 8.35 (dd, 1H), 8.27 (d, 2H), 8.04 (d, 2H), 4.72 (t, 2H), 4.36 (t, 2H), 4.13 (s, 3H), 4.12 (s, 3H), -1.42 (s, 1H), -1.91 (s, 1H).

**Figure 3-1** ESI-MS of 5,15-di(p-methylbenzoato)chlorin. The sample was prepared in dichloromethane as a 40 mg/L solution and was delivered by dichloromethane. Reprinted with permission from *J. Am. Chem. Soc.*, 2015, 137, 7600–7603. Copyright 2015 American Chemical Society.
Figure 3-2 $^1$H NMR spectra of 5,15-di(p-methylbenzoato)chlorin in chloroform-D. The full spectrum (a) and the expanded view of different portions of the spectrum (b-d) are presented.
Figure 3-2 (Continued) $^1$H NMR spectra of 5,15-di(p-methylbenzoato)chlorin in chloroform-D. The full spectrum (a) and the expanded view of different portions of the spectrum (b-d) are presented. Reprinted with permission from J. Am. Chem. Soc., 2015, 137, 7600–7603. Copyright 2015 American Chemical Society.
Me₂DBC (62 mg, 0.11 mmol) was dissolved in a mixture of tetrahydrofuran (THF) and methanol (24 mL, 1:1 vol/vol). A potassium hydroxide aqueous solution (2.5 mL, 2 mol/L) was then added. The solution was heated to reflux under nitrogen protection overnight. Half of the solvent was removed by a rotary evaporator before the pH was adjusted to pH=3 with the addition of trifluoroacetic acid. The dark brownish product was collected by vacuum filtration, washed with water and ether, and dried under vacuum to afford the desired product in 88% yield (52 mg, 0.094 mmol). \(^1\)H-NMR (500 MHz, DMSO-D\(_6\), ppm, Figure 3-3): \(\delta=13.25\) (s, 2H), 10.11 (s, 1H), 9.40 (d, 1H), 9.28 (s, 1H), 9.08 (m, 2H), 8.79 (d, 1H), 8.48 (d, 1H), 8.35 (m, 5H), 8.27 (d, 2H), 8.12 (d, 2H), 4.70 (t, 2H), 4.32 (t, 2H), -1.50 (s, 1H), -2.03 (s, 1H). ESI-MS for [H₂DBC+H]\(^+\): 553.1 calcd; 553.2 found (Figure 3-4).

**Figure 3-3** \(^1\)H NMR spectrum of 5,15-di(p-benzoato)chlorin in DMSO-D\(_6\). The full spectrum (a) and the expanded view of different portions of the spectrum (b, c) are presented.
Figure 3-3 (Continued) $^1$H NMR spectrum of 5,15-di(p-benzoato)chlorin in DMSO-D$_6$. The full spectrum (a) and the expanded view of different portions of the spectrum (b,c) are presented. Reprinted with permission from J. Am. Chem. Soc., 2015, 137, 7600–7603. Copyright 2015 American Chemical Society.
**Figure 3-4** ESI-MS of 5,15-di(p-benzoato)chlorin. The sample was prepared in DMSO as a 40 mg/L solution and was delivered by methanol. Reprinted with permission from *J. Am. Chem. Soc.*, 2015, 137, 7600–7603. Copyright 2015 American Chemical Society.
3.2.2 Synthesis and characterization of DBC-Hf

A solvothermal reaction between HfCl₄ and H₂DBC in DMF afforded the dark purple powdery product of DBC-Hf. To a 20-mL glass vial was added 3 mL of HfCl₄ solution [2 mg/mL in N,N-dimethylformamide (DMF), 0.018 mmol], 3 mL of the H₂DBC solution (3.5 mg/mL in DMF, 0.018 mmol), and 0.36 mL of acetic acid (6.3 mmol). The reaction mixture was kept in an 80 °C oven for 3 days. The nMOF product was collected by centrifugation and washed with copious amounts of DMF, 1% triethylamine (NEt₃) in ethanol (v/v), and ethanol successively and stored as a stock suspension in ethanol.

Powder X-ray diffraction (PXRD) indicated that DBC-Hf adopts the same UiO-type structure as DBP-Hf, due to the geometric similarity between the DBC and DBP ligands (Figure 3-5a). The Hf₆(µ₃-O)₄(µ₃-OH)₄ secondary building units (SBUs) in DBC-Hf are bridged by DBC ligands to construct a UiO framework of Hf₆(µ₃-O)₄(µ₃-OH)₄(DBC)₆. The Hf content was determined by inductively coupled plasma-mass spectrometry (ICP-MS, Agilent 7700x, USA) to be 24.0% (23.8% calculated) whereas a DBC weight loss of 64% (72% calculated) was observed in thermogravimetric analysis (Figure 3-5b). The discrepancy of organic weight loss by TGA is presumably a result of the termination of Hf₆(µ₃-O)₄(µ₃-OH)₄ SBUs by acetate groups in the ultrathin DBC-Hf nMOF.
Figure 3-5 Structural characterization of DBC-Hf. (a) PXRD pattern of DBP-Hf and DBC-Hf before and after incubation in cell culture medium. (b) Thermogravimetric analysis of DBC-Hf.
**Figure 3-5 (Continued)** (c) TEM images of DBC-Hf at different resolutions showing nanoplate morphology and the thickness of the nanoplates lying perpendicular to the grid (left), along with the zoomed-in view of two parts of the image showing the particles constructed from two (top right) or three (bottom right) packing layers. (d) TEM image showing a tilt particle (left) and the zoomed-in view of the particle (top right) and its FFT showing 4-fold symmetry (bottom right). Adapted with permission from *J. Am. Chem. Soc.*, 2015, 137, 7600–7603. Copyright 2015 American Chemical Society.

Transmission electron microscopy (TEM) confirms that DBC-Hf adopts a nanoplate morphology similar to that of DBP-Hf (Figure 3-5c). The plate diameters are 100~200 nm, while the thickness varies from 3.3 to 7.5 nm by direct observation of the particles lying perpendicular to the TEM grid (Figure 3-5c,d). Notably, since the calculated distances between neighboring (111) packing layers (d_{111}) of the UiO-type structure are 2.2 nm, the ultra-thin plates consist of only 2-4 sets of (111) packing layers. Such plates are even thinner than DBP-Hf of ~10 nm in thickness, further facilitating the ROS diffusion during PDT. Dynamic light scattering (DLS) measurements of DBC-Hf gave an average diameter of 128.5 nm with a polydispersity index of 0.17 and a ζ potential of -10.2 mV in phosphate buffer saline (PBS) (Figure 3-6).

The stability of DBC-Hf in biological media was confirmed by culturing the nMOF in RPMI 1640 cell culture medium for 12 h. The morphology of nMOFs did not change by TEM (Figure 3-7 a,b), while high resolution TEM images along with their fast-Fourier transform (FFT) patterns indicate the retention of nMOF crystallinity (Figure 3-7 c-f). The PXRD pattern of DBC-Hf did not change after incubation in RPMI 1640 cell medium, further proving the framework stability of DBC-Hf in physiological environments (Figure 1a). (Figure 3-5a).
Figure 3-6 DLS plot showing the particle size of DBC-Hf. Adapted with permission from *J. Am. Chem. Soc.*, **2015**, *137*, 7600–7603. Copyright 2015 American Chemical Society.

**Figure 3-7** TEM images of DBC-Hf at different resolutions before (a-c) and after (d-f) incubation in cell culture medium, along with the corresponding FFT patterns. Adapted with permission from *J. Am. Chem. Soc.*, **2015**, *137*, 7600–7603. Copyright 2015 American Chemical Society.
3.2.3 Photophysics and photochemistry of H$_2$DBC and DBC-Hf

UV-visible absorption spectroscopy confirmed the improved photophysical properties of chlorin-based PSs (Figure 3-8a). H$_2$DBC has a split Soret band at $\lambda_{\max}=408$ nm and four Q-bands at 504, 534, 591, and 643 nm. DBC-Hf shows slight red-shifts for all Q-bands compared to H$_2$DBC, with the peaks at 508, 545, 592, and 646 nm. The lowest energy Q-band of DBC-Hf has thus red-shifted by 13 nm from DBP-Hf, with an $\varepsilon$ value of 24600 M$^{-1}$·cm$^{-1}$ that is 11-fold greater than that of DBP-Hf. H$_2$DBC has an $\varepsilon$ value of 21800 M$^{-1}$·cm$^{-1}$ for the lowest energy Q-band, which is 13-fold greater than that of H$_2$DBP (1700 M$^{-1}$·cm$^{-1}$).

The fluorescence peak of H$_2$DBC shows up majorly at ~641 nm, with a weak peak at ~700 nm (Figure 3-8b). The DBC-Hf fluorescence was ~200 fold weaker than H$_2$DBC, similar to the case of DBP-Hf and H$_2$DBP, due to an enhanced intersystem crossing upon coordination of DBC ligands to Hf$^{4+}$ ions via the carboxylate groups. Consistent with this, DBC-Hf has a slightly shorter fluorescence lifetime of 7.88 ns compared to H$_2$DBC (8.15 ns) by Time-Correlated Single Photon Counting measurements (Figure 3-8c and Table 3-1).
Figure 3-8 Photophysical and photochemical properties of H₂DBC and DBC-Hf. (a) UV-vis absorption spectra of H₂DBC, DBC-Hf, H₂DBP and DBP-Hf in DMF or 0.67 mM PBS. (b) Steady-state fluorescence of 1 µM H₂DBC and DBC-Hf in aqueous solutions. (c) Time-resolved fluorescence decay traces of H₂DBC, DBC-Hf and a mixture solution of HfCl₄ and H₂DBC as a control in HBSS, together with instrument response function (excitation/emission 408/640 nm). (d) ^1O₂ generation of DBC-Hf, H₂DBC, DBP-Hf, H₂DBP and PpIX at an irradiance of 0.1 W/cm². DBC-Hf and H₂DBC are irradiated with a 650 nm LED, while the others are irradiated with a 640 nm LED. The dots are experimental data and the solid lines are fitted curves. Adapted with permission from J. Am. Chem. Soc., 2015, 137, 7600–7603. Copyright 2015 American Chemical Society.
Table 3-1 Fluorescence lifetimes of H₂DBC, DBC-Hf and HfCl₄+H₂DBC control, fitted by software.

<table>
<thead>
<tr>
<th>sample</th>
<th>τ₁ (ns)</th>
<th>τ₂ (ns)</th>
<th>τ₃ (ns)</th>
<th>̅τ  (ns)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IRF</td>
<td>0.0086</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>H₂DBC</td>
<td>5.80</td>
<td>8.77</td>
<td>N/A</td>
<td>8.15</td>
</tr>
<tr>
<td>DBC-Hf</td>
<td>3.27</td>
<td>8.26</td>
<td>0.14</td>
<td>7.88*</td>
</tr>
<tr>
<td>HfCl₄+DBC</td>
<td>6.12</td>
<td>8.78</td>
<td>N/A</td>
<td>8.13</td>
</tr>
</tbody>
</table>

* The average lifetimes are fitted with only τ₁ and τ₂, since the τ₃ of this set is likely from scattering.

Singlet Oxygen Sensor Green (SOSG) was employed to determine \(^1\)O₂ generation efficiencies of H₂DBC and DBC-Hf. The fluorescence of SOSG response to \(^1\)O₂ (λ<sub>ex</sub> = 504 nm, λ<sub>em</sub> = 525 nm) was quantified with a fluorimeter. For comparison, \(^1\)O₂ generation efficiency of H₂DBP, DBP-Hf and protoporphyrin IX (PpIX) were also determined. The fluorescence plotted against irradiation time was fitted with an exponential function (Eq 1), indicating a pseudo first-order \(^1\)O₂ generation process (Figure 3-8d). For detailed discussion on the fitting model see chapter 2.

\[
I_F = A(1-e^{-kt}) 
\]  
(Eq 1)

Where \(I_F\) is fluorescence intensity and \(t\) is irradiation time while \(A\) and \(k\) are fitting parameters (Table 3-2). The total \(^1\)O₂ generation yield was normalized based on that of PpIX to compare the overall photosensitization efficiency. DBC-Hf is ~3 times as efficient as DBP-Hf in generating \(^1\)O₂.
Table 3-2 Fitting parameters for $^{1}$O$_{2}$ generation curves.

<table>
<thead>
<tr>
<th></th>
<th>A</th>
<th>k (min$^{-1}$)</th>
<th>Normalized yield</th>
</tr>
</thead>
<tbody>
<tr>
<td>H$_2$DBC</td>
<td>102</td>
<td>0.25</td>
<td>4.3</td>
</tr>
<tr>
<td>DBC-Hf</td>
<td>195</td>
<td>0.18</td>
<td>7.3</td>
</tr>
<tr>
<td>H$_2$DBP</td>
<td>101</td>
<td>0.06</td>
<td>1.8</td>
</tr>
<tr>
<td>DBP-Hf</td>
<td>55.9</td>
<td>0.24</td>
<td>2.4</td>
</tr>
<tr>
<td>PpIX</td>
<td>26.6</td>
<td>0.19</td>
<td>1</td>
</tr>
</tbody>
</table>

One of the drawbacks of chlorins comparing to porphyrins is the faster photodegradation.$^5$ The photobleaching of DBC-Hf and H$_2$DBC were monitored under LED irradiation (100 mW/cm$^2$, 650 nm, Figure 3-9). Solutions of 7.5 µM ligand or DBP-Hf (based on ligand concentration) were irradiated for 0, 0.5, 1, 2, 3, 5, 7 and 9 minutes and the concentrations were calculated from the characteristic absorption of chlorin species at ~650 nm (Figure 3-9a,b). DBC-Hf degraded much slower than the ligand: 87% of DBC-Hf absorption was preserved after 9 min irradiation (54 J/cm$^2$ total light dose), comparing to 76% for H$_2$DBC (Figure 3-9c) under the same conditions. The improved photostability of DBC-Hf is attributed to the rigidification and isolation of the PSs in the nMOF structure. In comparison, DBP-Hf is even less sensitive to light: after 10 min irradiation at 640 nm (60 J/cm$^2$ light dose) over 98% of Soret band absorption was retained (Figure 3-9d).

During synthesis of the H$_2$DBC ligand, we also acquired the bacteriochlorin byproduct, 5,15-di(p-methylbenzoato)bacteriochlorin (Me$_2$DBB). Bacteriochlorins have strong Q-band absorption at ~735 nm, which should be perfect for light penetration for PDT application. Unfortunately, the rapid photobleaching of bacteriochlorins hinders the practical PDT applications that no bacteriochlorin products have been developed to the clinic.$^5$ After isolating Me$_2$DBB by column chromatography, we prepared it into dichloromethane solution and monitored the absorbance at 735 nm upon LED irradiation (100 mW/cm$^2$, 740 nm, Figure 3-9e).
With only 2 minute irradiation (12 J/cm² light dose) over 90% of Me₂DBB degraded (Figure 3-9f). Due to the unstable nature of the bacteriochlorin upon light irradiation, we abandoned the efforts to grow DBB-based nMOFs.

**Figure 3-9** Photostability of DBC-Hf, H₂DBC, DBP-Hf, and Me₂DBB. The photobleaching of DBC-Hf (a) and H₂DBC (b) upon LED irradiation. (c) The dependence of the chlorin concentration of both DBC-Hf and H₂DBC on the irradiation time.
**Figure 3-9 (Continued)** (d) The photobleaching of DBP-Hf upon 640 nm LED irradiation. (e) The photobleaching of Me₂DBB upon 740 nm LED irradiation. (f) The dependence of the bacteriochlorin concentration of Me₂DBB on the irradiation time. Adapted with permission from *J. Am. Chem. Soc.*, **2015**, *137*, 7600–7603. Copyright 2015 American Chemical Society.

### 3.2.4 *In vitro and in vivo* studies

PDT is used in the clinic to treat colon cancer by delivering light through endoscope.⁶,⁷ It is also known that PDT treatment of primary colon tumors can elicit immunogenic response on metastatic tumors.⁸-¹⁰ Encouraged by the improved photophysical properties and increased \(^1\text{O}_2\) generation efficiency of DBC-Hf, we further tested its PDT efficacy against murine and human colorectal cancers in mouse models.

The tumor cell uptake of nMOFs was evaluated by incubating CT26 cells with DBP-Hf or DBC-Hf for 4 h (equivalent Hf concentrations of 50 μM). The Hf contents in CT26 cells were determined to be (3.44±0.13) and (2.35±0.08) nmol/10⁵ cells for DBP-Hf and DBC-Hf, respectively, by ICP-MS. We also compared the cellular uptake of DBC-Hf and H₂DBC in terms of ligand concentrations by UV-vis analysis in CT26 and HT29 (Figure 3-10). The cellular uptake amounts of DBC-Hf and H₂DBC in terms of ligand concentrations were (13.7±0.8) and (20.2±1.7) nmol/10⁶ cells in HT29 cells (Figure 3-10a) and (4.9±0.4) and (0.6±0.1) nmol/10⁶ cells in CT26 cells (Figure 3-10b).
The *in vitro* PDT efficacy of DBC-Hf against colon cancer cells were investigated and compared with DBP-Hf and their corresponding free ligands. The nMOFs or free ligands were incubated with CT26 or HT29 cells at various concentrations, and the cells were irradiated with LED light at a total light dose of 90 J/cm². DBC-Hf outperformed DBP-Hf by effectively killing both cancer cell lines at low nMOF and light doses (Figure 3-11). Free ligand treated groups also showed moderate PDT efficacy, while no cytotoxicity was observed in dark control or PBS control groups. The IC₅₀ values of DBC-Hf, H₂DBC, DBP-Hf, and H₂DBP in CT26 cells with irradiation were calculated to be 5.1±0.2, 8.5±0.1, 10.4±0.5, and 20.0±3.1 µM (by ligand concentrations), respectively. The IC₅₀ values of DBC-Hf, H₂DBC, DBP-Hf, and H₂DBP in HT29 cells with irradiation were calculated to be 6.0±1.5, 7.5±2.3, 13.1±2.2, and 17.0±4.0 µM, respectively. These results confirm that DBC-Hf is a more potent PS than DBP-Hf in PDT owing to the enhanced photophysical properties. DBC-Hf showed efficient PDT cytotoxicity in murine...
macrophage Raw264.7 cells, but higher ligand concentration (> 20 µM) was required to achieve 50% cell killing (Figure 3-11c).

**Figure 3-11** _In vitro_ PDT efficacies on different cell lines. PDT cytotoxicity of DBC-Hf, H₂DBC, DBP-Hf, and H₂DBP at different PS concentrations in CT26 cells (a) and HT29 cells (b). (c) _In vitro_ PDT cytotoxicity of DBC-Hf and H₂DBC at different PS concentrations in murine macrophage Raw 264.7 cells. Adapted with permission from _J. Am. Chem. Soc._, 2015, 137, 7600–7603. Copyright 2015 American Chemical Society.

We further studied the mechanism of PDT cytotoxicity of the DBC-Hf nMOF and the ligand. CT26 cells were incubated with 5 µM DBC-Hf or H₂DBC followed by light irradiation at 0.1 W/cm² for 15 min (90 J/cm²). The apoptosis induced by PDT treatment was determined with the Alexa Fluor 488 Annexin V/dead cell apoptosis kit by flow cytometry. No apoptosis or necrosis was observed for cells treated with DBC-Hf or H₂DBC in the dark while significant amounts of cells underwent apoptosis when treated with DBC-Hf or H₂DBC upon light irradiation (Figure 3-12). Calreticulin (CRT) is a distinct biomarker exposed on the surface of cells undergoing immunogenic cell death (ICD). The CRT expression was determined by flow cytometry and immunofluorescence to assess the ICD induced by PDT with DBC-Hf (Figure 3-13). Cells treated with DBC-Hf or H₂DBC without light irradiation showed no surface CRT expression
while significant amounts of CRT were detected on the surface of cells upon irradiation. Both apoptosis and ICD therefore contribute to the superior \textit{in vitro} PDT efficacy of DBC-Hf.

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{annexin_v_pi_analysis.png}
\caption{Annexin V/PI analysis of CT26 cells incubated with DBC-Hf, \textit{H}_2\text{DBC} or PBS with or without irradiation (90 J/cm\textsuperscript{2}). The quadrants from lower left to upper left (counter clockwise) represent healthy, early apoptotic, late apoptotic, and necrotic cells, respectively. The percentage of cells in each quadrant was shown on the graphs. (+) and (-) refer to with and without irradiation, respectively. Adapted with permission from \textit{J. Am. Chem. Soc.}, \textbf{2015}, \textit{137}, 7600–7603. Copyright 2015 American Chemical Society.}
\end{figure}
Figure 3-13 Immunogenic cell death detection. (a) CRT exposure on the cell surface of CT26 cells was assessed after incubation with DBC-Hf, H$_2$DBC or PBS with or without light irradiation (90 J/cm$^2$) by flow cytometry analysis. The fluorescence intensity was gated on PI-negative cells.
We carried out in vivo anticancer efficacy experiments on subcutaneous flank tumor mouse models of CT26 and HT29. The mice were intratumorally injected with (1) PBS control, (2) DBC-Hf, (3) DBP-Hf, (4) H$_2$DBC, or (5) H$_2$DBP at a ligand dose of 1 mg/kg or (6) DBC-Hf at a ligand dose of 3.5 mg/kg. As depicted in Figure 3-14 and 3-15, the tumor growth of mice treated with DBC-Hf (1 mg/kg DBC dose) was effectively inhibited in both models. DBP-Hf and the two PS ligands failed to suppress the tumor growth in either model, due to low PS and light doses. Higher doses of DBC-Hf and light irradiation led to effective tumor regression in HT29 with single treatment and in CT26 with two treatments (Figure 3-14a and 3-15a). The weights and sizes of tumors treated with DBC-Hf at the endpoint were also significantly smaller than the other groups (Figure 3-14 b,d and 3-15 b,d). Histology of frozen tumor slices further confirmed that only DBC-Hf treatment caused apoptosis/necrosis of tumors but not in DBP-Hf or the two PS ligands (Figure 3-16). Along with the in vitro PDT results, the superior anticancer efficacies achieved by DBC-Hf in both colorectal cancer models indicate that DBC-Hf is a more efficient photosensitizer than DBP-Hf.

The statistical analysis of tumor weights was run by two-way T-test. For CT26 model, the $P$ values of DBC-Hf, DBC-Hf (higher dose), DBP-Hf, H$_2$DBC, and H$_2$DBP vs. PBS are $1 \times 10^{-5}$, $4 \times 10^{-6}$, 0.20656, 0.06635, and 0.43296, respectively. For HT29 model, the $P$ values of DBC-Hf, DBC-Hf (higher dose), DBP-Hf, H$_2$DBC, and H$_2$DBP vs. PBS are $5 \times 10^{-7}$, $8 \times 10^{-9}$, 0.43374, 0.07042, and 0.15008, respectively. Significant difference of tumor weights was only observed
between DBC-Hf and PBS control group. DBC-Hf with higher doses of nMOF and light irradiation led to successful tumor regression in both models.

**Figure 3-14** *In vivo* PDT efficacy on CT26 mouse tumor model. (a) Tumor growth inhibition curves after PDT treatment. Red arrows refer to treatment time points. (b) Tumor weights after PDT treatment. (c) Body weight evolution of CT26 tumor bearing BALB/c mice treated with nMOFs or ligands (*n*=6). (d) Photos of excised tumors of each group after PDT treatment. Adapted with permission from *J. Am. Chem. Soc.*, 2015, 137, 7600–7603. Copyright 2015 American Chemical Society.
Figure 3-15 *In vivo* PDT efficacy on HT29 subcutaneous xenograft mouse model. (a) Tumor growth inhibition curves after PDT treatment. Red arrows refer to treatment time points. (b) Tumor weights after PDT treatment. (c) Body weight evolution of HT29 tumor bearing nude mice treated with nMOFs or ligands (n=6). (d) Photos of excised tumors of each group after PDT treatment. Adapted with permission from *J. Am. Chem. Soc.*, 2015, 137, 7600–7603. Copyright 2015 American Chemical Society.
Figure 3-16 Histology of frozen tumor tissue slices after H-E staining. Bar=100 µm. Adapted with permission from J. Am. Chem. Soc., 2015, 137, 7600–7603. Copyright 2015 American Chemical Society.

Table 3-3 Statistical analysis of tumor weights by t-test shown with P values.

<table>
<thead>
<tr>
<th></th>
<th>CT26 tumor model</th>
<th>HT29 tumor model</th>
</tr>
</thead>
<tbody>
<tr>
<td>DBC-Hf vs. PBS</td>
<td>0.00001</td>
<td>0.000005</td>
</tr>
<tr>
<td>DBP-Hf vs. PBS</td>
<td>0.20656</td>
<td>0.43374</td>
</tr>
<tr>
<td>H₂DBC vs. PBS</td>
<td>0.06635</td>
<td>0.07042</td>
</tr>
<tr>
<td>H₂DBP vs. PBS</td>
<td>0.43296</td>
<td>0.15008</td>
</tr>
<tr>
<td>DBC-Hf (higher dose) vs.</td>
<td>0.000004</td>
<td>0.000000008</td>
</tr>
<tr>
<td>DBC-Hf vs. DBC-Hf (higher</td>
<td>0.000441</td>
<td>0.000000054</td>
</tr>
<tr>
<td>dose)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

3.3 Conclusion

In this chapter, we have rationally designed the first chlorin-based nMOF, DBC-Hf, with an exceptionally high PS loading, crystallinity, framework stability, porosity, nanoplate morphology, and enhanced intersystem crossing. Importantly, DBC-Hf exhibits a 13 nm red-shift and an 11-fold extinction coefficient increase in the lowest energy Q-band when compared to the previously generation DBP-Hf. As a result, DBC-Hf is three times as efficient as DBP-Hf in generating ¹O₂ and exhibits much higher PDT cytotoxicity in two colon cancer cell lines. The
superior anticancer efficacy of DBC-Hf compared to DBP-Hf was also demonstrated in two colorectal adenocarcinoma mouse models. We further elucidated that both apoptosis and immunogenic cell death contribute to the anticancer efficacy induced by DBC-Hf based PDT. nMOFs thus provide an excellent platform for achieving highly efficient PDT via both apoptosis and immunogenic cell death, and represent a novel class of nanomedicine with significant potential for clinical translation.\textsuperscript{12,13}

3.4 Methods

**Digestion for ICP-MS:** The nMOF sample was dried on vacuum overnight before being digested by a mixture of concentrate nitric acid and hydrofluoric acid (63% HF/69% HNO\textsubscript{3} 1/100 v/v). The sample was diluted with 2% nitric acid to a total MOF concentration of 80 ppb.

**Thermalgravimetric analysis:** Thermogravimetric analysis on DBC-Hf nMOF was carried out on Shimadzu TGA-50 thermogravimetric analyzer. The nMOF was collected by centrifugation and dried on the vacuum overnight. The sample was then transferred to a platinum plate and heated at 3 °C/min to 650 °C in air. The weight percentage was plotted against temperature and was normalized to the weight at 100 °C to eliminate the influence of absorbed moisture.

**Fluorescence measurement:** The fluorescence spectra of H\textsubscript{2}DBC ligand and DBC-Hf were taken on a spectrofluorophotometer (Fluorolog-3, Horiba, Japan). H\textsubscript{2}DBC was prepared into 1 µM solution in phosphate buffer saline and DBC-Hf was suspended in water to 1 µM by equivalent ligand concentration for the measurement.
**Fluorescence lifetime measurement:** Time-domain lifetimes were measured on a ChronosBH lifetime fluorometer (ISS, Inc.) using Time-Correlated Single Photon Counting (TCSPC) methods. The fluorometer contained Becker-Hickl SPC-130 detection electronics and an HPM-100-40 Hybrid PMT detector. Excitation was provided by a 403 nm picosecond pulsed laser source (Hamamatsu PLP-10). Emission wavelengths were selected with interference filters (Semrock). The Instrument Response Function (IRF) was measured to be approximately 0.009 ns FWHM in a 1% scattering solution of Ludox LS colloidal silica. Multi-component exponential decay lifetimes were fit via a forward convolution method in the Vinci control and analysis software. DBC-Hf, H$_2$DBC and a control mixture of HfCl$_4$ and H$_2$DBC were prepared into solution/suspensions in Hank’s Balanced Saline Solution (HBSS) for the measurement.

**Singlet Oxygen generation test:** A light-emitting diode (LED) array with peak emission at 650 nm was used as the light source of singlet oxygen generation test for H$_2$DBC and DBC-Hf while a 640 nm LED was used on H$_2$DBP, DBP-Hf and protoporphyrin IX (PpIX) samples. The irradiance of LEDs are 100 mW/cm$^2$. Singlet Oxygen Sensor Green (SOSG) reagent (Life Technologies) was employed for the detection of singlet oxygen. H$_2$DBC, DBC-Hf, H$_2$DBP, DBP-Hf and PpIX samples were prepared in 1 µM solutions/suspensions in diluted HBSS buffer (for DBC-Hf and DBP-Hf, the concentration was calculated as ligand equivalents). To 2 mL each of these solutions/suspensions, SOSG stock solution (5 µL at 5 mM) was added (final concentration=12.5 µM) before fluorescence measurement.

For a typical measurement, fluorescence intensity was acquired on a spectrofluorophotometer (RF-5301PC, Shimadzu, Japan) with excitation at 504 nm and emission at 525 nm (slit width 1.5 nm/3 nm for ex/em). Fluorescence was measured after irradiation by LED for 0 (as background), 15 s, 30 s, 45 s, 1 min, 1.5 min, 2 min, 3 min, 4 min, 5 min and 7 min.
**Cellular uptake evaluation:** DBP-Hf or DBC-Hf was incubated with CT26 cells at a Hf concentration of 50 μM for 4 h. The cells were collected, counted with a hemocytometer, and digested by concentrated nitric acid. The cellular uptake amounts of Hf were determined by ICP-MS and normalized with cell numbers.

H₂DBC or DBC-Hf was incubated with CT26 cells or HT29 cells at a ligand concentration of 5 μM for 4 h. The cells were collected, counted with a hemocytometer, redispersed in saturated K₃PO₄ aqueous solution, and homogenized with an ultrasound probe. The ligand was further extracted by DMSO followed by centrifugation. The upper phase (organic) was isolated and diluted before UV-vis determination of the ligand concentrations.

**In vitro cytotoxicity:** The cytotoxicity of DBC-Hf, H₂DBC, DBP-Hf, and H₂DBP was evaluated in murine colorectal cancer cell CT26 and human colorectal cancer cell HT29 cells, respectively. CT26 cells and HT29 cells were seeded on 96-well plates at 1000 cells/well and 2500 cells/well, respectively. The cells were treated with DBC-Hf, H₂DBC, DBP-Hf, and H₂DBP at various ligand concentrations (2, 5, 10, and 20 μM base on ligand concentrations). A further incubation of 4 h was allowed followed by replacing the culture medium with 100 μL of fresh RPMI 1640 medium. The cells were irradiated with LED light (650 nm for DBC-Hf and H₂DBC; 640 nm for DBP-Hf and H₂DBP) at 100 mW/cm² for 15 min (total light dose 90 J/cm²) or kept in dark, respectively. The cells were further incubated to achieve a total incubation time of 72 h. The cell viability was detected by (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) assay (Promega, USA).

In vitro cytotoxicity was also carried out in a murine macrophage Raw 264.7 cell line. Raw 264.7 cells were seeded on 96-well plates at 1000 cells/well. The cells were treated with DBC-Hf
and H₂DBC at various ligand concentrations (2, 5, 10, 20, and 50 μM base on ligand concentrations). A further incubation of 4 h was allowed, followed by replacing the culture medium with 100 μL of fresh RPMI 1640 medium. The cells were irradiated with LED light (650 nm) at 100 mW/cm² for 15 min (total light dose 90 J/cm²) or kept in dark, respectively. The cells were further incubated to achieve a total incubation time of 72 h. The cell viability was detected by MTS assay.

**Apoptosis and necrosis detection:** The apoptosis and necrosis induced by PDT of DBC-Hf and H₂DBC were evaluated by flow cytometry. CT26 cells were seeded at 1×10⁶ cells per well in 6-well plates and further cultured for 24 h. The culture media were replaced by 2 mL of fresh culture media containing 10% FBS. DBC-Hf and H₂DBC were added to the cells, respectively, at an equivalent ligand concentration of 5 μM. Cells incubated with PBS served as control. After 24-h incubation, the cells were irradiated with LED light (650 nm) at 100 mW/cm² for 15 min (90 J/cm²). Following further incubation of 24 h, the floating and adherent cells were collected and stained with Alexa Fluor 488 Annexin V/dead cell apoptosis kit (Invitrogen, USA) according to manufacturer’s instructions. The apoptosis and necrosis was examined on a flow cytometer (LSRII Orange, BD, USA).

**Immunogenic cell death detection:** The immunogenic cell death by PDT of DBC-Hf and H₂DBC were evaluated by immunofluorescence and flow cytometry. For immunofluorescence analysis, CT26 cells were seeded at 5×10⁵ cells per well in 6-well plates and further cultured for 24 h. The culture media were replaced by 2 mL of fresh culture media containing 10% FBS. DBC-Hf and H₂DBC were added to the cells, respectively, at an equivalent ligand concentration of 5 μM. Cells incubated with PBS served as control. After 24-h incubation, the cells were irradiated with LED light (650 nm) at 100 mW/cm² for 15 min (90 J/cm²). Following further
incubation of 4 h, the cells were washed with PBS three times, fixed with 4% paraformaldehyde, incubated with AlexaFluor 488-calreticulin (CRT) antibody for 2 h, stained with DAPI, and observed under CLSM using 405 nm and 488 nm lasers for visualizing nuclei and CRT expression on the cell membrane, respectively.

For flow cytometry analysis, CT26 cells were seeded at 1×10^6 cells per well in 6-well plates and further cultured for 24 h. The culture media were replaced by 2 mL of fresh culture media containing 10% FBS. DBC-Hf and H₂DBC were added to the cells, respectively, at an equivalent ligand concentration of 5 µM. Cells incubated with PBS served as control. After 24-h incubation, the cells were irradiated with LED light (650 nm) at 100 mW/cm² for 15 min (90 J/cm²). Following further incubation of 4 h, the cells were collected, incubated with AlexaFluor 488-CRT antibody for 2 h, and stained with propidium iodide (PI). The samples were analyzed by flow cytometer (LSRII Orange, BD, USA) to identify cell surface CRT. The fluorescence intensity of stained cells was gated on PI-negative cells.

**In vivo efficacy:** The PDT efficacy of DBC-Hf was investigated using a flank CT26 mouse tumor model and HT29 subcutaneous xenograft mouse model. Tumor bearing mice were established by subcutaneous inoculation of HT29 cell suspension (2×10^6 cells per mouse) or CT26 cell suspension (1×10^6 cells per mouse) into the right flank region of 6-week athymic male nude mice or 6-week BALB/c male mice, respectively. Six groups were included for comparison: (1) PBS control, (2) DBC-Hf, (3) DBP-Hf, (4) H₂DBC, or (5) H₂DBP at a ligand dose of 1 mg/kg or (6) DBC-Hf at a ligand dose of 3.5 mg/kg. Twelve hours post injection, each mouse in group (1)-(5) was irradiated at the tumor site with light (0.1 W/cm²) for 15 min (90 J/cm²) and the mice in group (6) received light irradiation (0.1 W/cm²) for 30 min (180 J/cm²). For (1) to (5) groups on the CT26 model, mice are treated again 4 days after first treatment, while for (1) to (5)
groups on HT29 model, mice are treated every 4 days for total 4 treatments. When tumors reached 100 mm$^3$, PBS, DBC-Hf, DBP-Hf, H$_2$DBC, or H$_2$DBP were intratumorally injected to animals. At 12 h post-injection, mice were anesthetized with 2% (v/v) isoflurane and tumors were irradiated with a 640 nm LED for DBP-Hf/H$_2$DBP or a 650 nm LED for DBC-Hf/H$_2$DBC. The light intensity was measured as 100 mW/cm$^2$.

To evaluate the therapeutic efficacy, tumor growth and body weight evolution were monitored. The tumor size was measured with a digital caliper every day. Tumor volumes were calculated as follows: (width$^2$ × length)/2. Finally, all mice were sacrificed when the tumor size of control group exceeded 2 cm$^3$, and the excised tumors were photographed and weighed. The tumors were embedded in optimal cutting temperature (OCT) medium, sectioned at 5-µm thickness, and subjected to hematoxylin and eosin (H&E) stain for histopathological analysis.

3.5 References


Chapter 4. A Chlorin-based Nanoscale Metal-Organic Framework
Systemically Rejects Colorectal Cancers via Synergistic Photodynamic Therapy and Checkpoint Blockade Immunotherapy

4.1 Rationale of the nMOF design

In Chapters 2 and 3, we demonstrated examples of nMOFs to exert highly efficient photodynamic therapy (PDT).\(^1,2\) Moreover, we showed in Chapter 3 that nMOF-mediated PDT causes immunogenic cell death (ICD) in tumors. We believe that an immunotherapeutic agent that alters the tumor microenvironment can potentiate the immune activation by PDT and lead to systemic cancer vaccination.

We herein designed a new nMOF, TBC-Hf, constructed from a chlorin derivative, 5,10,15,20-tetra(p-benzoato)chlorin (H\(_4\)TBC) and Hf-based SBUs. We took advantage of the highly porous structure of the nMOF to load an IDO inhibitor (IDOi) into TBC-Hf to afford IDOi@TBC-Hf. The IDOi@TBC-Hf system enables a novel cancer treatment strategy by combining nMOF-enabled PDT and IDOi-based immunotherapy (Figure 4-1). Unlike the combination of chemotherapy/radiotherapy with immunotherapy that the treatment dose on major tumor is compromised, the new treatment enjoys the local tumor destruction potency by PDT while eliciting systemic antitumor immune response. Hence, the synergistic combination therapy achieved effective local and distant tumor rejection in colorectal cancer models.
Figure 4-1 Schematic presentation of combined PDT and immunotherapy by IDOi@TBC-Hf. Local injection of IDOi@TBC-Hf and light irradiation generate reactive oxygen species (ROS), causing immunogenic cell death (ICD), and releasing tumor-associated antigens that are presented to T-cells. Meanwhile, the IDO inhibitor released from IDOi@TBC-Hf modulates tryptophan/kynurenine catabolism to activate the immunosuppressive tumor microenvironment. The combination of antigen presentation from PDT and checkpoint blockade by IDO inhibition causes T-cell proliferation and infiltration, leading to not only eradication of local, treated tumors but also rejection of distant, untreated tumors.
4.2 Results

4.2.1 Synthesis and characterization of $\text{H}_4\text{TBC}$ ligand and TBC-Hf nMOF

The new chlorin derivative $5,10,15,20$-tetra(p-benzoato)chlorin ($\text{H}_4\text{TBC}$) was synthesized in 3 steps as depicted in scheme 4-1.

Scheme 4-1 Synthesis of 5,10,15,20-tetra(p-benzoato)chlorin ($\text{H}_4\text{TBC}$).

Synthesis of 5,10,15,20-tetra(p-methylbenzoato)porphyrin ($\text{Me}_4\text{TBP}$)

A mixture of 6.83 g of methylterephthalaldehyde (41.6 mmol) and 2.80 mL of pyrrole (40.4 mmol) was dissolved in 100 mL of propionic acid. The solution was heated to reflux (150 °C) in dark overnight. The purple product was collected by vacuum filtration and was washed with water, methanol and ethyl ether in sequence. Yield: 24.3%. $^1\text{H}$ NMR (500 MHz, CDCl$_3$, ppm, Figure 4-2): $\delta=8.84$ (s, 8H), 8.47 (d, 8H), 8.32 (d, 8H), 4.14 (s, 12H), -2.79 (s, 2H).

Synthesis of 5,10,15,20-tetra(p-methylbenzoato)chlorin ($\text{Me}_4\text{TBC}$)

$\text{Me}_4\text{TBP}$ (500 mg, 0.59 mmol) and anhydrous potassium carbonate (750 mg, 5.4 mmol) were added to a 2-neck round bottom flask. 40 mL of anhydrous pyridine was added under nitrogen. The solution was heated to 105 °C before the addition of 4.0 mL of p-toluenesulfonhydrazide solution (0.30 M in anhydrous pyridine). The reaction mixture was kept
at 105 °C for 4 hours during which another 2 fractions of p-toluenesulfonylhydrazide solutions (0.30 M in anhydrous pyridine, 4.0 mL for each fraction) were added every 2 h. The reaction mixture was then stirred at 105 °C in the dark for another 12 h. The product was extracted with 2:1 ethyl acetate/water and washed with 2 M HCl, 2 M phosphoric acid, water, and saturated sodium bicarbonate solution. The solution was treated with 2,3-dichloro-5,6-dicyano-benzoquinone (via slow addition of 1 mg/mL solution in chloroform) until the characteristic absorption of the over-reduced product at ~735 nm disappeared. The product was purified by aluminum oxide column chromatography with dichloromethane as the eluent. Yield: 16%. $^1$H NMR (500 MHz, CDCl$_3$, ppm, Figure 4-3): $\delta$=8.57 (d, 2H), 8.40 (m, 10H), 8.20 (m, 6H), 7.99 (d, 4H), 4.18 (s, 4H), 4.11 (s, 6H), 4.09 (s, 6H), -1.45 (s, 2H). ESI-MS for [Me$_4$TBC+H]$^+$: 849.3 calcd, 849.4 found (Figure 4-4).

Figure 4-2 $^1$H NMR of 5,10,15,20-tetra(p-methylbenzoato)porphyrin.
Figure 4-3 $^1$H NMR of 5,10,15,20-tetra(p-methylbenzoato)chlorin. (a) The full spectrum and (b) the expanded view of a portion of the spectrum.
Synthesis of 5,10,15,20-tetra(p-benzoato)chlorin ($H_4$TBC)

The hydrolysis of Me$_4$TBC was conducted in 1:1 THF/methanol under N$_2$. An aqueous NaOH solution (2 mol/L, 40 equiv.) was added to a solution of Me$_4$TBC after degas with N$_2$. The solution was heated at 74 °C (reflux) overnight. After removing most of the organic volatile by a rotary evaporator, the solution was diluted with water and neutralized with HCl (1 M) to pH=3. The product was collected by vacuum filtration and washed with water and methanol before drying on the vacuum. Yield: 78%. $^1$H NMR (500 MHz, CDCl$_3$, ppm, Figure 4-5): $\delta=8.60$ (d,
2H), 8.31 (m, 10H), 8.19 (m, 6H), 8.01 (d, 4H), 4.10 (s, 4H), -1.56 (s, 2H). ESI-MS for [H4TBC+H]+: 793.2 calcd, 793.3 found (Figure 4-6).

**Figure 4-5** $^1$H NMR of 5,10,15,20-tetra(p-benzoato)chlorin. (a) The full spectrum and (b) the expanded view of a portion of the spectrum.
Synthesis and characterization of TBC-Hf

A solvothermal reaction between HfCl₄ and H₄TBC in N,N-dimethylformamide (DMF) at 80 °C led to the purple powder of TBC-Hf in 87% yield. TBC-Hf was washed with copious amounts of DMF, 1% triethylamine (NEt₃) in ethanol (v/v), and ethanol successively and stored in ethanol as a stock suspension. As a control, TBP-Hf with the corresponding porphyrin ligand
5,10,15,20-tetra(p-benzoato)porphyrin (H₄TBP) was synthesized by a solvothermal reaction between HfCl₄ and H₄TBP in N,N-diethylformamide (DEF) at 120 °C and washed in the same fashion as for TBC-Hf.

TBC-Hf and TBP-Hf adopt the same structure as the previously reported TBP-Zr analog (MOF-545), based on powder X-ray diffraction (PXRD) (Figure 4-7a).³ The carboxylate moieties from the TBC ligands bridge 8 out of 12 edges of octahedral Hf₆(µ₃-O)₄(µ₃-OH)₄ SBU's. The remaining coordination sites on the SBUs are occupied by 4 water and 4 terminal hydroxy groups on the equatorial plane to afford a hexagonal framework of Hf₆(µ₃-O)₄(µ₃-OH)₄(OH)₄(H₂O)₄(TBC)₂ (Figure 4-7b). The nMOFs therefore feature large one-dimensional channels with diameters of 3.5 nm along the c axis, along with smaller channels with diameters of 1.0 nm along the c axis and 1.1 nm × 0.9 nm windows perpendicular to the c axis (Figure 4-7 c,d). TBC-Hf and TBP-Hf exhibit BET surface area of 1077 and 1462 m²/g, respectively (Figure 4-8). During the course of this study, a few reports of TBP-based nMOFs with a cubic structure for PDT have appeared.⁴,⁵ However, we expect that our highly porous TBP-Hf control will outperform the cubic TBP-based nMOFs due to the enhanced ¹O₂ diffusion through the nMOF channels. In TBC-Hf and TBP-Hf, the porphyrin and chlorin rings are highly rigid in the nMOF structures to minimize energy transfer and self-quenching.
Figure 4-7 Structures of TBC-Hf and TBP-Hf. (a) PXRD patterns of TBP-Hf and TBC-Hf in comparison with MOF-545. (b) The secondary building unit (SBU) of TBC-Hf (Violet, Hf; red, O; gray, C). (c-d) The view of TBC-Hf structure along [001] (c) and [100] (d) direction.
Figure 4-8 Nitrogen adsorption isotherms of TBC-Hf (a) and TBP-Hf (b) at 77K.

Transmission electron microscopy (TEM) revealed nanorod/nanorice morphologies for TBP-Hf and TBC-Hf (Figure 4-9 a,d). The rods are typically 50-100 nm long and 30-60 nm wide for TBC-Hf, and 50-100 nm long and 20-30 nm wide for TBP-Hf. High resolution TEM images show the lattice fringes with the distances matching d$_{200}$ and d$_{001}$ spacings of the crystal structure (Figure 4-9 b,c,e). The average diameter of TBC-Hf and TBP-Hf are 83.2 nm and 72.7 nm, respectively, by dynamic light scattering (DLS) measurements. (Figure 4-10). The nMOFs are stable in biological environments, as evidenced by the lack of significant changes in PXRD pattern or morphology after incubation in Hank’s balanced salt solution for 24 h (Figure 4-9f).

The Hf content was determined by inductively coupled plasma-mass spectrometry (ICP-MS) to be 30.4% (36.6% calculated). The TBC weight loss of 61.7% (56.8% calculated) determined by thermogravimetric analysis further confirms the framework formula (Figure 4-11). We encapsulated an INCB24360 analogue IDOi,$^6$ 4-amino-N-(3-chloro-4-fluoro-phenoxy)-N’-hydroxy-1,2,5-oxadiazole-3-carboximidamide (Figure 4-11b), into the TBC-Hf channels to afford IDOi@TBC-Hf for the co-delivery of IDOi with PSs. The IDOi weight percentage after loading is determined to be 4.7% by TGA.
**Figure 4-9** TEM images showing the morphology of TBP-Hf and TBC-Hf. (a) TEM images of TBP-Hf. (b-c) High resolution TEM showing the lattice fringes of TBP-Hf in different directions. (d) TEM images of TBC-Hf. (e) High resolution TEM showing the lattice fringes of TBC-Hf. (f) TBC-Hf after incubation in Hank’s balanced salt solution for 24 h.
Figure 4-10 DLS plots showing the particle sizes of TBP-Hf (top) and TBC-Hf (bottom).
Figure 4-11 (a) TGA of TBC-Hf before and after IDOi loading. (b) The chemical structure of the IDOi, 4-amino-N-(3-chloro-4-fluoro-phenyl)-N’-hydroxy-1,2,5-oxadiazole-3-carboximidamide.

UV-visible absorption spectroscopy indicates that TBC-Hf more effectively absorbs red light compared to TBP-Hf (Figure 4-12a). H₄TBC has a major Soret peak at $\lambda_{\text{max}}=420$ nm and four Q-bands at 518, 546, 600, and 652 nm. The Soret absorption of TBC-Hf almost overlaps with that of the free ligand ($\lambda_{\text{max}}=421$ nm) while the Q-bands slightly red-shift to 520, 548, 600, and 653 nm. In comparison, the Soret peaks of H₄TBP and TBP-Hf are at $\lambda_{\text{max}}=420$ nm and 418 nm, respectively, and the Q-bands are at 516, 549, 592 and 646 nm for H₄TBP and 517, 550, 593 and 647 nm for TBP-Hf. The lowest energy Q-band of the chlorin therefore red-shifts by 6 nm after reduction from the porphyrin counterpart (652 nm compared to 646 nm). The extinction coefficient of H₄TBC at the lowest energy absorption ($\varepsilon=44700$ M$^{-1}$·cm$^{-1}$) is ~9 fold greater than that of H₄TBP ($\varepsilon=4800$ M$^{-1}$·cm$^{-1}$) while the lowest energy absorption of TBC-Hf ($\varepsilon=38500$ M$^{-1}$·cm$^{-1}$) is 6-fold greater than that of TBP-Hf ($\varepsilon=6400$ M$^{-1}$·cm$^{-1}$). Notably, the lowest energy absorption of TBC-Hf (653 nm) is at a wavelength of 7-nm longer than that of our previously reported DBC-Hf and the $\varepsilon$ of TBC-Hf is ~1.6 fold higher than that of DBC-Hf.
Figure 4-12 Photophysics and photochemistry of the ligands and nMOFs. (a) UV-visible absorption spectra of $H_4$TBP, $H_4$TBC, TBP-Hf, and TBC-Hf. Inset shows expanded views of the Q-band regions. The fluorescence spectra of $H_4$TBP and TBP-Hf (b), $H_4$TBC and TBC-Hf (c) with excitation at 420 nm. Time-resolved fluorescence decay traces of $H_4$TBP and TBP-Hf (d), $H_4$TBC and TBC-Hf (e) along with instrument response function (IRF). (f) Singlet oxygen generation by $H_4$TBP, $H_4$TBC, TBP-Hf, and TBC-Hf with a 650 nm LED irradiation at 20 mW/cm$^2$, detected by Singlet Oxygen Sensor Green.
H₄TBC exhibits two fluorescence emissions at 655 nm and 715 nm with an intensity ratio of ~6.8 when excited at 420 nm (Figure 4-12c). H₄TBP fluorescence emissions are close to those of H₄TBC, though the 651 nm/713 nm peak intensity ratio is ~2 (Figure 4-12b). After forming nMOFs, the fluorescence intensities drop significantly, consistent with other nMOF systems.¹,² For TBC-Hf, the fluorescence peaks slightly blue-shift to 650 nm and 712 nm and the intensities decrease by 5.3-fold and 4.7-fold, respectively; for TBP-Hf, the fluorescence peaks blue-shift to 648 nm and 704 nm and the fluorescence intensities drop by 9.0-fold and 6.5-fold, respectively. The decrease in fluorescence intensity results from the enhanced intersystem crossing after coordination of the chlorin/porphyrin ligands to Hf on the SBUs. Time-Correlated Single Photon Counting measurement results also supported this interpretation: the fluorescence lifetime at 650 nm dropped from 9.56 ns for H₄TBC to 8.25 ns for TBC-Hf and from 9.25 ns for H₄TBP to 8.38 ns for TBP-Hf (Figure 4-12 d, e and Table 4-1).

<table>
<thead>
<tr>
<th>Sample</th>
<th>τ (ns)</th>
<th>χ²</th>
</tr>
</thead>
<tbody>
<tr>
<td>H₄TBP_PBS</td>
<td>9.25±0.05</td>
<td>1.05</td>
</tr>
<tr>
<td>TBP-Hf_water</td>
<td>8.38±0.04</td>
<td>1.65</td>
</tr>
<tr>
<td>H₄TBC_PBS</td>
<td>9.56±0.01</td>
<td>2.22</td>
</tr>
<tr>
<td>TBC-Hf_water</td>
<td>8.25±0.01</td>
<td>1.08</td>
</tr>
</tbody>
</table>

Table 4-1 Lifetimes of H₄TBP, H₄TBC, TBP-Hf and TBC-Hf fluorescence in different media, fitted by software.
4.2.2 Singlet oxygen generation

The $^1$O$_2$ generation efficiencies of H$_4$TBC, TBC-Hf, H$_4$TBP, and TBP-Hf were determined by Singlet Oxygen Sensor Green (SOSG) assay. The nMOF samples and ligand controls were irradiated with a LED ($\lambda_{\text{max}}$=650 nm, 20 mW/cm$^2$) and the fluorescence enhancement upon reaction of SOSG with $^1$O$_2$ was measured by a fluorimeter (excitation/emission at 504/525 nm). The fluorescence intensity plotted against irradiation time fit exponential decay equations, as we had previously observed in other nMOF systems, indicating a pseudo first-order $^1$O$_2$ generation process (Figure 4-12f). TBC-Hf outperforms both TBP-Hf and H$_4$TBC in terms of $^1$O$_2$ generation efficiency.

4.2.3 *In vitro* PDT efficacy and mechanistic study

We first confirmed efficient cellular uptake of TBC-Hf and TBP-Hf by cancer cells. TBC-Hf and TBP-Hf were incubated with colorectal cancer CT26 cells at a ligand concentration of 25 $\mu$M for 24 h. The Hf contents inside cells were determined to be (2.07±0.26) and (1.79±0.17) nmol/10$^4$ cells, respectively, by ICP-MS analysis (Figure 4-13). The *in vitro* PDT efficacy of TBP-Hf, TBC-Hf, and both ligands against CT26 cells was next investigated. TBC-Hf outperformed TBP-Hf under 90 J/cm$^2$ light irradiation. Both nMOFs and ligands outperformed protoporphyrin IX (PpIX) upon irradiation, a commonly used PS, while no cytotoxicity was observed in dark control groups (Figure 4-14). The IC$_{50}$ values of TBC-Hf, TBP-Hf, H$_4$TBC, H$_4$TBP and PpIX for CT26 cells were 4.82±0.50, 7.09±0.39, 10.04±1.22, 12.83±1.59 and 23.72±0.60 $\mu$M, respectively, at an irradiation dose of 90 J/cm$^2$ (Figure 4-14c). These results were confirmed by a second colorectal cancer MC38 cell with IC50 values of 2.57±0.85 and
17.9±5.0 μM for TBC-Hf and H₄TBC, respectively. The IC₅₀ values exceeded 50 μM for TBP-Hf, H₄TBP, and PpIX for MC38 cells (Figure 4-14d). To demonstrate the versatility of our nMOF system, an unrelated B16F10 melanoma cell were employed to confirm the PDT efficacy, yielding IC₅₀ values of 5.48±0.70, 9.72±0.78, 11.03±1.57, 20.10±4.28 and 16.48±0.77 μM for TBC-Hf, TBP-Hf, H₄TBC, H₄TBP, and PpIX, respectively (Figure 4-14e).

**Figure 4-13** Cellular uptake of TBP-Hf and TBC-Hf in CT26 cells.
Figure 4-14 *In vitro* PDT efficacy on CT26 (a,c), MC38 (b,d) and B16F10 (e) cells.
Unlike most conventional cytotoxic agents, PDT is known to induce ICD via apoptosis and necrosis, thereby mediating antitumor immune response. We confirmed that both apoptosis and necrosis occur upon treatment with PDT by flow cytometry of Alexa Fluor 488 Annexin V-labeled dead cells. MC38 cells were incubated with TBC-Hf, TBP-Hf, H₄TBC, and H₄TBP at 1 µM (ligand concentration of 2 µM) followed by light irradiation at 90 J/cm² (650 nm, 100 mW/cm²). Significant amounts of cells underwent apoptosis/necrosis when treated with PDT of TBC-Hf, TBP-Hf, H₄TBC, and H₄TBP with only 30.0%, 32.7%, 55.5%, and 57.6% healthy cells, respectively, compared to 80-90% healthy cells in dark control or PBS-treated cells with irradiation (Figure 4-15a). These results were further confirmed in CT26 cells under the same conditions (Figure 4-15b). These results indicate the chlorin-based TBC-Hf is a more efficient PS than the porphyrin-based TBP-Hf at equivalent nMOF and light doses.

We also investigated the ability of PDT treatment to induce ICD by determining cell-surface expression of calreticulin (CRT). MC38 cells were incubated with TBC-Hf, TBP-Hf, H₄TBC, and H₄TBP at 1 µM (ligand concentration of 2 µM) followed by light irradiation at 90 J/cm². For flow cytometry analysis, cells were collected and stained with Alexa Fluor 488-CRT antibody and propidium iodide (PI, Figure 4-16). The fluorescence intensity of stained cells was gated on PI-negative cells. For immunostaining analysis, the cells were stained with AlexaFluor 488-CRT and DAPI, and observed under confocal laser scanning microscopy (CLSM, Figure 4-17). In both instances, cells treated with nMOF or ligand showed significant CRT expression on the cell-surface upon irradiation but none with PBS control or without irradiation. Due to the higher \(^1\)O₂ generation efficiency and in vitro PDT efficacy of TBC-Hf, we focus our subsequent in vivo studies on TBC-Hf and use TBP-Hf as a control wherever appropriate.
Figure 4-15 Annexin V/PI analysis of CT26 (a) and MC38 (b) cells incubated with PBS, TBC-Hf, TBP-Hf, H₄TBC, and H₄TBP with or without irradiation (90 J/cm²). The quadrants from lower left to upper left (counter clockwise) represent healthy, early apoptotic, late apoptotic, and necrotic cells, respectively. The percentage of cells in each quadrant was shown on the graphs. (+) and (-) refer to with and without irradiation, respectively.
Figure 4-16 CRT exposure on the cell surface. Expression in CT26 (a) and MC38 (b) was assessed after incubation with PBS, TBC-Hf, TBP-Hf, H$_4$TBC, and H$_4$TBP, with (+) or without (-) light irradiation (90 J/cm$^2$) by flow cytometry analysis. The fluorescence intensity was gated on PI-negative cells.
Figure 4-17 Immunofluorescence microscopy of CRT expression on the cell surface. Expression in CT26 (a) and MC38 (b) treated with PBS, TBC-Hf, TBP-Hf, H₄TBC, and H₄TBP with (+) or without (-) irradiation (90 J/cm²). The fluorescence intensity was gated on PI-negative cells. Scale bar = 50 µM.
4.2.4 The abscopal effect of IDOi@TBC-Hf

The immunoregulatory enzyme IDO is often overexpressed in the tumor microenvironment, where it facilitates the survival and growth of tumor cells by suppressing antitumor immune responses. The small-molecule IDO inhibitor (IDOi) INCB24360, developed by Incyte, can reverse immunosuppression and inhibits tumor growth upon oral administration. We propose that by encapsulation of IDOi into the nMOF channels, IDOi@TBC-Hf can release IDOi both into the local tumor environment and enter blood circulation for systemic IDO inhibition. The effects of IDOi will alter the suppressive tumor microenvironment of both the treated and untreated tumors. We hypothesize that synergizing local PDT of IDOi@TBC-Hf with checkpoint blockade therapy can promote an efficient abscopal effect, regression of an untreated tumor at a distant site following the local treatment of another tumor in the same organism.

We evaluated the abscopal effect of IDOi@TBC-Hf and light irradiation in two immunocompetent mouse models using bilateral tumor models of colorectal cancers CT26 and MC38 in the flank regions of BALB/c mice and C57BL/6 mice, respectively. When the primary tumors reached ~100 mm³, mice received a single injection of H₄TBC, H₄TBC plus IDOi, TBC-Hf, or IDOi@TBC-Hf into the primary tumors at a ligand dose of 20 µmol/kg or a corresponding IDOi dose of 1.5 mg/kg. Twelve hours after injection, the primary tumors were irradiated at a light dose of 90 J/cm² (650 nm, 100 mW/cm²). Mice treated with IDOi@TBC-Hf without light irradiation served as dark controls. As depicted in Figure 4-18 and 4-19, local nMOF injection with light irradiation led to near elimination of the treated primary tumors. At the endpoint, CT26 tumor-bearing mice treated with IDOi@TBC-Hf or TBC-Hf and PDT therapy had tumors only (1.1±0.2)% and (0.7±0.4)% the size of PBS treated tumors, respectively. Similarly, MC38 tumor-bearing mice had tumors only (0.8±0.3)% and (0.9±0.4)% of the size of PBS treated
tumors, respectively. H₄TBC with light irradiation and IDOi@TBC-Hf dark group failed to inhibit the tumor growth while H₄TBC plus IDOi with light irradiation slightly inhibits the tumor growth (Table 4-2). Moreover, only PDT treatment of IDOi@TBC-Hf successfully reduced the sizes of the untreated distant tumors. Tumors began shrinking on Day 6 and 5 after treatment in the CT26 and MC38 models, respectively, suggesting the treatment evoked systemic antitumor immunity in mice (Table 4-2 and 4-3). TBC-Hf with light irradiation and IDOi@TBC-Hf dark control slightly inhibited the distant tumor growth, showing ineffectiveness of monotherapies.

**Table 4-2** Statistical analysis of the tumor sizes at the end of treatment on CT26 tumor bearing mice.

<table>
<thead>
<tr>
<th></th>
<th>Treated tumor</th>
<th>Untreated tumor</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBS vs H₄TBC</td>
<td>0.0098</td>
<td>0.0011</td>
</tr>
<tr>
<td>PBS vs H₄TBC+IDOi</td>
<td>&lt; 0.0001</td>
<td>0.0002</td>
</tr>
<tr>
<td>PBS vs TBC-Hf</td>
<td>&lt; 0.0001</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>PBS vs IDOi@TBC-Hf (-)</td>
<td>0.34</td>
<td>0.0005</td>
</tr>
<tr>
<td>PBS vs IDOi@TBC-Hf</td>
<td>&lt; 0.0001</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>TBC-Hf vs IDOi@TBC-Hf</td>
<td>0.17</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>IDOi@TBC-Hf (-) vs (+)</td>
<td>&lt; 0.0001</td>
<td>&lt; 0.0001</td>
</tr>
</tbody>
</table>

**Table 4-3** Statistical analysis of the tumor sizes at the end of treatment on MC38 tumor bearing mice.

<table>
<thead>
<tr>
<th></th>
<th>Treated tumor</th>
<th>Untreated tumor</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBS vs TBC-Hf</td>
<td>&lt; 0.0001</td>
<td>0.0005</td>
</tr>
<tr>
<td>PBS vs IDOi@TBC-Hf (-)</td>
<td>0.19</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>PBS vs IDOi@TBC-Hf</td>
<td>&lt; 0.0001</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>TBC-Hf vs IDOi@TBC-Hf</td>
<td>0.81</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>IDOi@TBC-Hf (-) vs (+)</td>
<td>&lt; 0.0001</td>
<td>&lt; 0.0001</td>
</tr>
</tbody>
</table>
Figure 4-18 In vivo anticancer efficacy showing abscopal effect. Growth curves for treated (a and c) and untreated (b and d) tumors of CT26 (a and b) or MC38 (c and d) tumor-bearing mice after PDT treatment. Black and red arrows refer to the time of injection and irradiation, respectively. Tumor weights after PDT treatment on CT26 (e) and MC38 (f) models, collected after euthanizing the mice at day 10.
4.2.5 Antitumor Immunity

We have shown that PDT of IDOi@TBC-Hf caused effective tumor regression of both primary, treated tumors and distant, untreated tumors in two syngeneic mouse models of colorectal cancer. We further investigated the underlying immunological mechanisms in the MC38 model by Enzyme-Linked ImmunoSpot (ELISPOT) and flow cytometry. We first performed an ELISPOT assay to detect the presence of tumor antigen-specific T cells 14 days after treatment. As shown in Figure 4-20, the number of antigen-specific IFN-γ producing T cells
increased to 799 per million splenocytes in mice treated with IDOi@TBC-Hf (vs. 128 per million splenocytes in PBS group, P=0.0879), indicating that PDT of IDOi@TBC-Hf induced in situ tumor vaccination to effectively generate tumor-specific T cell response.

Figure 4-20 Antigen-specific IFN-γ spot forming cells (SFC) at 14 days after IDOi@TBC-Hf PDT treatment.

Further analysis of the immune response was carried out by investigating the tumor-infiltrating leukocyte profiles in each tumor by flow cytometry. Previous research has shown that PDT can evoke acute inflammation, so we first evaluated the population of leukocytes responsible for innate immune response (neutrophils, B cells, dendritic cells, and macrophages) in both primary and distant tumors 12 hours after PDT treatment. As shown in Figure 4-21, IDOi@TBC-Hf administration and light irradiation led to significant increase in the percentage of tumor-infiltrating neutrophils and B cells with respect to the total number of cells in the tumor compared to PBS (neutrophils: P=0.0369 vs. PBS; B cells: P=0.0215 vs. PBS). To our surprise,
the percentage of infiltrating dendritic cells (DC) appeared to decrease compared to PBS control in the primary tumor (Figure 4-21c), although the difference is not of statistical significance.

![Graphs showing population of leukocytes in the tumor 12 h after IDOi@TBC-Hf PDT treatment.](image)

**Figure 4-21** Population of leukocytes in the tumor 12 h after IDOi@TBC-Hf PDT treatment. The percentage of tumor-infiltrating neutrophils (a), B cells (b), DCs (c) and macrophages (d), with respect to the total number of cells in the tumor compared to PBS.

To better understand the roles these types of cells played in the antigen presentation after PDT, we further detected the major histocompatibility complex class II (MHC-II) expression on these cells 12 hours after PDT treatment. MHC-II mediates establishment of specific immunity by interacting with CD4 molecules on the surface of helper T cells. We found a significant decrease in MHC-II expression levels on DCs, macrophages, and neutrophils in the primary treated tumors (DC: P<0.0001 vs. PBS; macrophages: P=0.0004 vs. PBS; neutrophils: P=0.006
vs. PBS, Figure 4-22). These results imply that TBC-Hf mediated PDT may have an impact on the mode of antigen presentation, which is typically the role of DCs.

![Figure 4-22](image)

**Figure 4-22** The MHC-II expression level in the tumor 12 h after IDOi@TBC-Hf PDT treatment. (a) DCs, (b) macrophages, (c) B cells, and (d) neutrophils.

We also determined the tumor-infiltrating leukocyte profiles 12 days post PDT treatment. As shown in Figure 4-23 a-c, IDOi@TBC-Hf significantly increased the proportion of infiltrating CD8⁺ T cells relative to the total number of cells in the distant tumor (P=0.0012 vs. PBS), an essential step to mounting an antitumor immune response to induce the abscopal effect. In both primary and distant tumors, the percentages of infiltrating CD45⁺ leukocytes and CD4⁺ T cells with respect to the total number of cells in the tumors were significantly increased in mice treated with PDT of IDOi@TBC-Hf (Treated tumor, CD45⁺: P=0.0061 vs. PBS; CD4⁺ T cells:
P=0.0206 vs. PBS. Untreated tumor, CD45\(^+\): P=0.0001 vs. PBS; CD4\(^+\) T cells: P=0.0388 vs. PBS). Interestingly, IDOi@TBP-Hf administration and PDT also led to a significant increase in the percentages of tumor-infiltrating B cells and a decrease in the percentages of tumor infiltrating DCs with respect to the total number of cells in the primary tumors 12 days post the treatment (B cells, P=0.0017 vs. PBS; DCs: P=0.0041 vs. PBS, Figure 4-23 d, e).

We also performed T cell blocking experiments to confirm the involvement of T cells in the efficient abscopal response on bilateral subcutaneous MC38 mouse model. MC38 tumor-bearing mice were treated with IDOi@TBC-Hf and light irradiation as described before and received intraperitoneal injection of Mouse IgG, anti-CD4, or anti-CD8 antibody at a dose of 200 µg/mouse/injection on Day 0 and Day 5 post the PDT treatment. While mice treated with Mouse IgG showed regression of both primary and distant tumors, no abscopal effect was observed on mice with blocking of CD4\(^+\) or CD8\(^+\) T cells (Figure 4-24). Furthermore, blocking of CD4\(^+\) and CD8\(^+\) T cells also diminished the effect of IDOi@TBC-Hf in regressing the primary tumors. These results indicated that CD4\(^+\) and CD8\(^+\) T cells were essential not only to abscopal effect but also to primary tumor rejection.
Figure 4-23 Tumor-infiltrating leukocyte profiles in the tumors 12 days after IDOi@TBC-Hf PDT treatment. (a) CD45+ T cells, (b) CD8+ T cells, (c) CD4+ T cells, (d) B cells and (e) DCs, percentages with respect to the total number of cells in the tumors.
4.3 Discussion

In this chapter, we present a new treatment strategy that combines local PDT of a new nMOF, TBC-Hf, in combination with IDO inhibition with nMOF-delivered small molecules to achieve effective and consistent abscopal responses in mouse models of colorectal cancers. We have shown that IDOi released from locally injected IDOi@TBC-Hf reversed the suppressive tumor microenvironment in both treated and untreated tumors, which further synergized with TBC-Hf mediated PDT to stimulate the immune system for activating both acute innate and prolonged adaptive immune response to achieve efficient local tumor regression and a consistent abscopal response. Our treatment method maximizes the benefits of local treatment with systemic immune response for the rejection of both primary and distant tumors while minimizing side effects, potentially affording an effective systemic therapy for metastatic colorectal cancers.
Owing to the outstanding photophysical properties of the chlorin-based TBC ligand, TBC-Hf shows potent PDT efficacy and outperforms its porphyrin counterpart TBP-Hf. The tetracarboxylate ligand constructs a robust framework with very large channels for small molecular inhibitor loading and ROS diffusion, and the coordination to Hf$_6$ SBUs enhances intersystem crossing of TBC to enhance $^1$O$_2$ generation. As we$^{10-13}$ and others$^{14-16}$ have demonstrated the synthetic tunability and potential biomedical applications of nMOFs in the past decade, we believe that the nMOF compositions and structures can be further optimized in order to enhance light absorption and $^1$O$_2$ generation/diffusion. We thus expect nMOF-based synergistic PDT and immunotherapy have the potential for future clinical translation for the treatment of metastatic cancers.

We propose that IDOi@TBC-Hf administration and light irradiation causes highly efficient tumor regression of both primary treated tumors and distant untreated tumors owing to two factors. First, TBC-Hf based PDT causes ICD of cancer cells in the primary tumors, which activates innate immune system and promotes antigen presentation (Figure 4-1). The massive stressed and dying necrotic tumor cells in the PDT-treated primary tumor sites are engulfed by the innate immune effector cells followed by presenting tumor-derived antigenic peptides to T cells, thus stimulating a tumor-specific T cell response. Second, the IDOi is released from intratumorally injected IDOi@TBC-Hf to systemically inhibit IDO activity to reverse the immunosuppressive tumor environments. The two treatment modalities, PDT and IDOi checkpoint blockade therapy, synergize with each other to kill cancer cells locally and create an immunogenic tumor microenvironment systemically, leading to durable and consistent abscopal effects.
Dendritic cells are one of the most important antigen-presenting cells and prevalently believed to play a key role in antitumor immune response.\textsuperscript{17} However, we observed a slight decrease of DC population percentage along with a significant decrease of MHC-II expression level on DCs after PDT treatment with IDOi@TBC-Hf, indicating an altered role for DCs after PDT treatment. Meanwhile, the increase of both neutrophils and B cell population percentages implies a compensating effect of other antigen presenting cells to present tumor-associated antigens and initiate the antitumor immune response. Previous studies also suggested that neutrophils, rather than DCs, directly affect T cell proliferation upon PDT treatment.\textsuperscript{18} Our future efforts will be directed toward elucidating the roles of neutrophils and B cells in initiating antitumor immune response after the PDT of IDOi@TBC-Hf.

4.4 Conclusion

In this work, we have rationally designed a chlorin-based nMOF with large channels for highly efficient PDT, while simultaneously loaded an IDO inhibitor into its channels to achieve combination therapies of PDT and checkpoint blockade immunotherapy. We consistently observed an abscopal effect in mice receiving treatment with PDT of IDOi@TBC-Hf. The \textit{in situ} vaccination induced by PDT treatment and IDOi immunotherapy synergize with each other and effectively generate systemic antitumor immunity. We believe the present strategy has the potential to significantly increase the durable response rates of checkpoint blockade cancer immunotherapy and lead to clinical benefits for the treatment of metastatic colorectal cancers and other difficult-to-treat cancers.
4.5 Methods

Materials, cell lines, and animals: All of the starting materials were purchased from Sigma-Aldrich and Fisher (USA), unless otherwise noted, and used without further purification.

Murine colon adenocarcinoma cells CT26 and MC38 and murine melanoma cells B16F10 were purchased from the American Type Culture Collection (Rockville, MD, USA) and cultured in Dulbecco’s Modified Eagle's Medium (DME) medium (Gibco, Grand Island, NY, USA) supplemented with 10% FBS.

C57BL/6 female mice (6 weeks, 20-22 g) and BALB/c female mice (6 weeks, 20-22 g) were provided by Harlan Laboratories, Inc (USA). The study protocol was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Chicago.

Synthesis of TBC-Hf: To a 2-dram glass vial was added 1 mL of HfCl₄ solution [2 mg/mL in N,N-dimethylformamide (DMF), 6.2 µmol], 1 mL of the H₄TBC solution (1.9 mg/mL in DMF, 2.4 µmol), and 60 µL of 88% formic acid (1.4 mmol). The reaction mixture was kept in an 80 °C oven for 2 days. The purple powder was collected by centrifugation and washed with DMF, 1% triethylamine in ethanol (v/v) and ethanol.

Synthesis of TBP-Hf: To a 2-dram glass vial was added 1 mL of HfCl₄ solution [2 mg/mL in N,N-diethylformamide (DEF), 6.2 µmol], 1 mL of the H₄TBP solution (1.9 mg/mL in DEF, 2.4 µmol), and 60 mg of benzoic acid (0.49 mmol). The reaction mixture was kept in a 120 °C oven for 2 days. The violet powder was collected by centrifugation and washed with DMF, 1% triethylamine in ethanol (v/v), and ethanol.
**Powder X-ray diffraction:** TBC-Hf or TBP-Hf sample was prepared by centrifugation in a capillary tube with one end sealed. The powder X-ray diffraction pattern was acquired on Bruker D8 VENTURE single crystal dual-source diffractometer (Bruker, Germany) and integrated by software.

**BET surface area measurement:** Nitrogen adsorption of TBC-Hf and TBP-Hf was tested on 3Flex-Surface Characterization Analyzer (Micromeritics, USA) at 77K. The BET surface areas were calculated by software to be 1077 and 1462 m²/g.

**Digestion for ICP-MS:** The nMOF samples was dried under vacuum overnight before being digested by a mixture of concentrate nitric acid and hydrofluoric acid (63% HF/69% HNO₃ 1/100 v/v). The sample was diluted 35 times and filtered by a PES syringe filter unit before instrument analysis.

**Thermogravimetric analysis:** Thermogravimetric analysis on TBC-Hf was carried out on a Shimadzu TGA-50 thermogravimetric analyzer. The nMOF was collected by centrifugation and dried under vacuum overnight. The sample was then transferred to a platinum plate and heated at 3 °C/min to 650 °C in air. The weight percentage was plotted against temperature and was normalized to the weight at 150 °C to eliminate the influence of absorbed moisture. The IDOi loading was calculated following the equation below:

\[
loading \text{ wt\%} = \left(1 - \frac{\text{remaining wt\% after loading}}{\text{remaining wt\% before loading}}\right) \times 100\%
\]
**Fluorescence measurement:** The fluorescence spectra were taken on a spectrofluorophotometer (Fluorolog-3, Horiba, Japan). Samples were prepared as 1 μM solutions in phosphate buffer saline or water by equivalent ligand concentration for the measurements.

**Fluorescence lifetime measurement:** Time-domain lifetimes were measured on a ChronosBH lifetime fluorometer (ISS, Inc.) using Time-Correlated Single Photon Counting (TCSPC) methods. The fluorometer contained Becker-Hickl SPC-130 detection electronics and an HPM-100-40 Hybrid PMT detector. Excitation was provided by a 403 nm picosecond pulsed laser source (Hamamatsu PLP-10). Emission wavelengths were selected with interference filters (Semrock). The Instrument Response Function (IRF) was measured to be approximately 0.009 ns FWHM in a 1% scattering solution of Ludox LS colloidal silica. Multi-component exponential decay lifetimes were fit via a forward convolution method in the Vinci control and analysis software. Samples were prepared into solution/suspensions in water for the measurement.

**Singlet Oxygen Generation:** A light-emitting diode (LED) array with peak emission at 650 nm was used as the light source of singlet oxygen generation test. The irradiance of LED is 20 mW/cm². Singlet oxygen sensor green (SOSG) reagent (Life Technologies) was employed for the detection of singlet oxygen. H₄TBP, H₄TBC, TBP-Hf and TBC-Hf samples were prepared in 1 μM solutions/suspensions in water (for the nMOFs, the concentration was calculated as ligand equivalents). To 2 mL each of these solutions/suspensions, SOSG stock solution (5 μL at 5 mM) was added (final concentration=12.5 μM) before fluorescence measurement. For a typical measurement, fluorescence intensity was acquired on a spectrofluorophotometer (RF-5301PC, Shimadzu, Japan) with excitation at 504 nm and emission at 525 nm (slit width 1.5 nm/3 nm for ex/em). Fluorescence was measured after irradiation by LED for 0 (as background), 0.5, 1, 1.5, 2, 3, 4, 5, 7 and 10 min.
**Cellular uptake evaluation:** TBP-Hf or TBC-Hf was incubated with CT26 cells at a Hf concentration of 150 µM for 24 h. The cells were collected, counted with a hemocytometer, and digested by concentrated nitric acid. The cellular uptake amounts of Hf were determined by ICP-MS and normalized with cell numbers.

**IDOi encapsulation:** To a suspension of TBC-Hf in ethanol (2.5 mg/mL, 3.0 mL), 3.3 mg of IDOi was added. The mixture was sonicated for 1 minute and 3.0 mL of water was added. The solution was stirred at room temperature in dark for 12 h to afford IDOi@TBC-Hf. IDOi@TBC-Hf was collected by centrifugation and washed with 50% ethanol/water.

**In vitro PDT efficacy:** The cytotoxicity of TBC-Hf and H₄TBC was evaluated in murine colorectal cancer cell CT26 and murine melanoma cell B16F10, respectively. CT26 cells or B16F10 cells were seeded on 96-well plates at 1000 cells/well. The cells were treated with TBC-Hf and H₄TBC at various ligand concentrations (2, 4, 10, 15, 20, and 50 µM base on ligand concentrations). A further incubation of 4 h was allowed followed by replacing the culture medium with 100 µL of fresh medium. The cells were irradiated with LED light (650 nm) at 100 mW/cm² for 15 min (total light dose 90 J/cm²) or kept in dark, respectively. The cells were further incubated to achieve a total incubation time of 72 h. The cell viability was detected by (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) assay (Promega, USA).

**Abscopal Effect:** The PDT efficacy of IDOi@TBC-Hf was investigated using a bilateral CT26 mouse colorectal cancer model and a bilateral MC38 mouse colorectal cancer model. Tumor bearing mice were established by subcutaneous inoculation of CT26 or MC38 cell suspension (1×10⁶ cells per mouse on the right flank and 2×10⁵ cells per mouse on the left flank) into 6-
week female BALB/c or 6-week female C57BL/6 mice, respectively. When the right tumors reached 100 mm³, the CT26 tumor bearing mice received intratumoral injection only into the right tumors of PBS, H₄TBC, H₄TBC+IDOi, TBC-Hf, or IDOi@TBC-Hf at a ligand dose of 20 µmol/kg and IDOi dose of 1.5 mg/kg. Twelve hours post injection, CT26 tumor bearing mice were anesthetized with 2% (v/v) isoflurane and right flank tumors were irradiated with a 650 nm LED at 0.1 W/cm² for 15 min (90 J/cm²). IDOi@TBC-Hf without light irradiation served as a dark control. The nMOF injection and light irradiations were performed every three days for a total two injections and irradiations. For MC38 tumor model, mice received intratumoral injection only into the right tumors of PBS, TBC-Hf, or IDOi@TBC-Hf at a ligand dose of 20 µmol/kg and IDOi dose of 1.5 mg/kg. Twelve hours post injection, MC38 tumor bearing mice were anesthetized with 2% (v/v) isoflurane and right flank tumors were irradiated with a 650 nm LED at 0.1 W/cm² for 15 min (90 J/cm²). IDOi@TBC-Hf without light irradiation served as a dark control. The nMOF injection and light irradiations were performed only once on MC38 tumor bearing mice. For both CT26 and MC38 models, no NMOF injection or light irradiation was performed on the left tumors.

To evaluate the therapeutic efficacy, the tumor size was measured with a digital caliper every day. Tumor volumes were calculated as follows: (width² × length)/2. Finally, all mice were sacrificed when the tumor size of control group exceeded 2 cm³, and the excised tumors were photographed and weighed.

**T cell blocking:** The abscopal effect of IDOi@TBC-Hf was evaluated on bilateral subcutaneous MC38 model on C57BL/6 mice with CD4⁺ T cell or CD8⁺ T cell depletion. When the right tumors reached ~100 mm³, IDOi@TBC-Hf was intratumorally injected to the mice at a dose of 20 µmol/kg. Anti-CD4 (for CD4⁺ T cell depletion), anti-CD8 (for CD8⁺ T cell depletion), or
mouse IgG (control) were intraperitoneally injected to the mice (200 µg/mouse/injection) on Day 0 and Day 5 post the first treatment. Twelve hours post injection, mice were anesthetized with 2% (v/v) isoflurane and the right tumors were irradiated with LED light irradiation (100 mW/cm², 90 J/cm², 650 nm). Single IDOi@TBC-Hf injections followed by single light irradiations were carried out. To evaluate the therapeutic efficacy, the tumor size was measured with a digital caliper every other day. Tumor volumes were calculated as follows: (width² × length)/2.

**ELISPOT assay:** Tumor-specific immune responses to IFN-γ was measured *in vitro* by ELISPOT assay (Mouse IFN gamma ELISPOT Ready-SET-Go!®; Cat. No. 88-7384-88; eBioscience). A Millipore Multiscreen HTS-IP plate was coated overnight at 4°C with anti-Mouse IFN-γ capture antibody. Single-cell suspensions of splenocytes were obtained from MC38 tumor-carrying mice and seeded onto the antibody-coated plate at a concentration of 2×10⁵ cells/well. Cells were incubated with or without KSPWFTTL (KSP) stimulation (10 µg/mL; in purity > 95%; PEPTIDE 2.0) for 48 h at 37 °C and then discarded. The plate was then incubated with biotin-conjugated anti-IFN-γ detection antibody at room temperature (r.t.) for 2 h, followed by incubation with Avidin-HRP for 2 h at r.t. AEC substrate solution (Sigma, Cat. AEC101) was added for cytokine spot detection.

**Flow Cytometry:** Tumors were harvested, treated with 1 mg/mL collagenase I (Gibco™, USA) for 1 h, and ground by the rubber end of a syringe. Cells were filtered through nylon mesh filters and washed with PBS. The single-cell suspension was incubated with anti-CD16/32 (clone 93; eBiosciences) to reduce nonspecific binding to FcRs. Cells were further stained with the following fluorochrome-conjugated antibodies: CD45 (30-F11), CD3e (145-2C11), CD4 (GK1.5), CD8 (53-6.7), Foxp3 (FJK-16s), CD11b (M1/70), Ly6C (HK1.4), Ly6G (RB6-8C5),
F4/80 (BM8), B220 (RA3-6B2) and PI staining solution (all from eBioscience). LSR FORTESSA (BD Biosciences) was used for cell acquisition, and data analysis was carried out using FlowJo software (TreeStar, Ashland, OR).

**MHC-II expression:** Tumors were harvested 12 hours after LED irradiation, treated with 1 mg/mL collagenase I, and ground by the rubber end of a syringe. Cells were filtered through nylon mesh filters and washed with PBS. The single cell suspension was incubated with anti-CD16/32 (clone 93; eBiosciences) for 10 minutes and then stained with CD45, CD3e, CD11b, Ly6G, B220, F4/80, CD11c and MHC-II. The expression levels of MHC-II on CD11b+Ly-6G+, CD3e-B220+, CD3e-CD11c+ and CD3e-CD11c-F4/80 populations were determined respectively.

4.6 References


Chapter 5. A Nanoscale Metal-Organic Framework for the Co-delivery of Chemotherapeutic Agents and Nucleic Acid Drugs

5.1 Rationale of the nMOF design

Nanoscale metal-organic frameworks display multifunctionality as a nanocarrier platform for drug delivery, by virtue of their high porosity and structural tunability. In Chapters 2, 3, and 4, we showed examples that directly construct nMOFs with cargo molecules as the struts. In this chapter, we will introduce another work on drug delivery where we employed the large pores of the MOF structure as well as the surface metal coordinate sites for the co-delivery of therapeutic agents to treat resistant cancer.

We surmise that nMOFs can realize the co-delivery of chemotherapeutics and small interfering RNAs (siRNAs) with the following strategy: the large pores of nMOFs can be used to load chemotherapeutics while the metal ions on the nMOF surfaces can be used to bind siRNAs. The simultaneous and efficient delivery of cisplatin and pooled siRNAs to ovarian cancer cells can allow for enhanced anticancer efficacy by blocking multiple drug resistance pathways.

5.2 Results and Discussion

5.2.1 Synthesis and characterization of the 2’-amino-p-terphenyl-4,4’’-dicarboxylate ligand


2’-amino-p-terphenyl-4,4’’-dicarboxylic acid (H$_2$L) was synthesized by the route described in Scheme 5-2 as reported previously.$^1$ In an 100 mL round-bottom flask 2,5-dibromoaniline (2.00 g, 8.0 mmol), 4-(methoxycarbonyl)-phenylboronic acid (4.40 g, 24.5 mmol) and CsF (5.82 g, 38 mmol) were suspended in 50 mL of anhydrous tetrahydrofuran (THF) under nitrogen protection, followed by addition of palladium acetate (0.60 g, 2.7 mmol) and PPh$_3$ (1.61 g, 6.1 mmol). The mixture was heated at 50 °C for 48 h. The methyl ester product (Me$_2$L) was extracted with water/dichloromethane (DCM) and purified by silica gel column chromatography (DCM: ethyl ether = 50:1 with 0.2% - 0.5% triethylamine). Yield: 58%.$^1$H NMR (Chloroform-D, Figure 5-1): δ=8.10 (m, 4H), 7.65 (d, 2H), 7.57 (d, 2H), 7.22 (d, 1H), 7.09 (d, 1H), 7.01 (s, 1H), 3.93 (two overlapping singlets, 6H), 3.88 (s, 2H).
The Me₂L (1.68 g, 4.65 mmol) was suspended in 200 mL of THF and heated to 40 °C. To the suspension 100 mL of 5.5 M KOH methanol solution was added and the resulting mixture was stirred at 40 °C for 18 hours. A white solid was collected by centrifugation, and then treated with 12 mL of trifluoroacetic acid in 100 mL of THF at room temperature for 2 h. The yellow solid product (H₂L) was isolated by vacuum filtration and washed with THF, methanol and ether.

Yield: 80%. ¹H NMR (DMSO-d6, Figure 5-2): δ=12.97 (br, 2H), 8.03 (m, 4H), 7.74 (d, 2H), 7.61 (d, 2H), 7.16 (d, 2H), 7.02 (dd, 1H), 5.12 (br, 2H). ¹³C NMR (DMSO-d6, Figure 5-3): δ=167.66, 167.63 (COOH), 146.24 (C1’), 145.00 (C1”), 144.25 (C1), 139.96 (C4’), 131.31 (C6’), 130.40, 130.28 (C3”, C3), 129.98, 129.54 (C4”, C4), 129.19 (C2”), 126.97 (C2), 125.04 (C2’), 115.96 (C5’), 114.26 (C3’).

**Figure 5-1** ¹H NMR spectrum of Me₂L in chloroform-D. Reprinted with permission from *J. Am. Chem. Soc.*, 2014, 136, 5181–5184. Copyright 2014 American Chemical Society.
Figure 5-2 $^1$H NMR spectrum of H$_2$L in DMSO-d$_6$. Reprinted with permission from J. Am. Chem. Soc., 2014, 136, 5181–5184. Copyright 2014 American Chemical Society.

Figure 5-3 $^{13}$C NMR spectrum of H$_2$L in DMSO-d$_6$. Reprinted with permission from J. Am. Chem. Soc., 2014, 136, 5181–5184. Copyright 2014 American Chemical Society.
5.2.2 Synthesis of the cisplatin prodrug


A modified procedure from a previous report was employed to synthesize the cisplatin prodrug cis,cis,trans-\([\text{Pt(NH}_3)_2\text{Cl}_2\text{(OEt)(OCOCH}_2\text{CH}_2\text{CO}_2\text{H})}\] (Scheme 5-3).\(^2\) To an ethanolic suspension of cisplatin (445 mg in 240 mL, 1.48 mmol) 1.00 mL of 30% hydrogen peroxide solution was added. The reaction mixture was heated at 70 °C in the dark for 6 h. A yellow product of cis,cis,trans-\([\text{Pt(NH}_3)_2\text{Cl}_2\text{(OH)(OEt)}]\) was obtained in 76% yield after removal of the solvent in vacuo. \(^1\)H NMR (DMSO-\(d_6\), Figure 5-4): \(\delta=5.55\) (m, 6H), 3.50 (teta, 2H), 1.05 (t, 3H).

![Figure 5-4](image-url) \(^1\)H NMR spectrum of Pt(NH\(_3\))\(_2\)Cl\(_2\)(OH)(OEt) in DMSO-\(d_6\). Reprinted with permission from *J. Am. Chem. Soc.*, 2014, 136, 5181–5184. Copyright 2014 American Chemical Society.
Succinic anhydride (298 mg, 2.98 mmol) and Pt(NH$_3$)$_2$Cl$_2$(OH)(OEt) (107 mg, 0.30 mmol) were dissolved in 3 mL of anhydrous DMSO after drying in vacuo. The mixture was stirred in the dark at 65 °C overnight. Solution volume was reduced under vacuum and the product was crushed out by DCM and was recrystallized in acetone and ethyl ether. Yield: 53%. $^1$H NMR (DMSO-d$_6$, Figure 5-5): $\delta=12.04$ (br, 1H), 5.86 (m, 6H), 3.40 (tetra, 2H), 2.41 (m, 2H), 2.37 (m, 2H), 1.05 (t, 3H). $^{13}$C NMR (DMSO-d$_6$, Figure 5-6): $\delta=180.49$, 174.56 (carboxylate), 67.04 (OCH$_2$), 32.05, 30.67 (-CH$_2$CH$_2$-), 17.17 (CH$_3$). $^{195}$Pt NMR (DMSO-d$_6$, Figure 5-7): $\delta= 1001.7$ (quintet).

**Figure 5-5** $^1$H NMR spectra of cis,cis,trans-[Pt(NH$_3$)$_2$Cl$_2$(OEt)(OCOCH$_2$CH$_2$CO$_2$H)] in DMSO-d$_6$, the full spectrum (a) and expanded view of portions of the spectrum (b,c).
Figure 5-5 (Continued) $^1$H NMR spectra of cis,cis,trans-[$\text{Pt(NH}_3\text{)}_2\text{Cl}_2(\text{OEt})\text{-}(\text{OCOCH}_2\text{CH}_2\text{CO}_2\text{H})]$ in DMSO-$d_6$, the full spectrum (a) and expanded view of portions of the spectrum (b,c). Reprinted with permission from J. Am. Chem. Soc., 2014, 136, 5181–5184. Copyright 2014 American Chemical Society.
Figure 5-6 $^{13}$C NMR spectrum of cis,cis,trans-$[\text{Pt(NH}_3)_2\text{Cl}_2(\text{OEt})-(\text{OCOCH}_2\text{CH}_2\text{CO}_2\text{H})]$ in DMSO-$d_6$. Reprinted with permission from J. Am. Chem. Soc., 2014, 136, 5181–5184. Copyright 2014 American Chemical Society.

Figure 5-7 $^{195}$Pt NMR spectrum of cis,cis,trans-$[\text{Pt(NH}_3)_2\text{Cl}_2(\text{OEt})-(\text{OCOCH}_2\text{CH}_2\text{CO}_2\text{H})]$ in DMSO-$d_6$. The coupling to two equivalent $^{14}$N nuclei splits the peak to quintet, coupling constant $^{1}J(^{195}\text{Pt}^{14}\text{N})=197.0$. Reprinted with permission from J. Am. Chem. Soc., 2014, 136, 5181–5184. Copyright 2014 American Chemical Society.
5.2.3 Synthesis and characterization of nMOF-1

**nMOF-1** was synthesized by heating a N,N-dimethylformamide (DMF) solution of ZrCl₄ and H₂L at 80 °C for 5 days with acetic acid as modulator, which is different from the other reports (Scheme 5-1).³ To our surprise, the as-synthesized **nMOF-1** did not adopt a UiO type structure as predicted, implied by its powder X-ray diffraction (PXRD, Figure 5-8a) from that for a UiO MOF and the hexagonal plate-like morphology by TEM (Tecnai F30, FEI, USA, Figure 5-8b). Instead, a new type of SBU with a formula of \([\text{Zr}_6(\mu_3-O)_4(\mu_3-OH)_4]_2(\mu_2-OH)_6\) was formed in which two \(\text{Zr}_6(\mu_3-O)_4(\mu_3-OH)_4\) SBUs are bridged by 6 \(\mu_2\)-hydroxyl groups to construct a new structure as modeled in Figure 5-9. The new structure adopts \(P\overline{3}1c\) symmetry and the pore sizes are the same to the UiO type structures with the same ligand. TEM micrographs give the dimensions of the nMOFs to be ~100 nm in diameter of plates and ~30 nm in thickness (Figure 5-8 b,e). High resolution TEM images confirm that the distances between the lattice fringes are 1.83 nm (Figure 5-8e), corresponding to the predicted \(d_{101}\) value of 1.87 nm. The fast Fourier transform pattern (FFT) proved a 6-fold symmetry along the observation direction, consistent to the hexagonal symmetry of the structure (Figure 5-8e, inset).
Figure 5-8 Structural characterization of the nMOFs before and after drug loading. (a) PXRD patterns of UiO-68 (black), nMOF-1 (red), and Cis@nMOF-1 (blue). TEM images of nMOF-1 (b), Cis@nMOF-1 (c), and siRNA/Cis@nMOF-1 (d). Bars: 200 nm. High resolution TEM image of nMOF-1 (e), Cis@nMOF-1 (f), and siRNA/Cis@nMOF-1 (g). Bar: 20 nm. The inset of (e) is the fast Fourier transform pattern of the high-res TEM image showing the 3-fold symmetry. Adapted with permission from J. Am. Chem. Soc., 2014, 136, 5181–5184. Copyright 2014 American Chemical Society.

Figure 5-9 Structure models of nMOF-1, observed along c axis (a) and a axis (b).
5.2.4 Cisplatin prodrug and siRNA loading

The cisplatin prodrug, cis,cis,trans-[Pt(NH$_3$)$_2$Cl$_2$(OEt)(OCOCH$_2$CH$_2$CO$_2$H)], was loaded into the pores of nMOF-1 via encapsulation to form Cis@nMOF-1 (Scheme 5-1). NMR spectroscopy supported the non-covalent encapsulation loading process, as the spectrum appears identical to that was obtained by adding the prodrug to the digested suspension of nMOF-1 (Figure 5-10). The TEM images of Cis@nMOF-1 are identical to nMOF-1 (Figure 5-8c). Interestingly, we observed “standing” particles that align perpendicular to the TEM grid (a) as well as a “leaning” particle stacking on another plate (b) in the high-resolution TEM graph (Figure 5-8f). The cisplatin loading in Cis@nMOF-1 was determined to be 12.3±1.2 wt% by inductively coupled plasma mass spectrometry (ICP-MS).

The release of the prodrug from Cis@nMOF-1 is monitored by ICP-MS following dialysis in PBS. The prodrug released slower after encapsulation into nMOF-1 with a total release of 34% up to 24 h (Figure 5-11). The significantly decreased release rate indicates successful encapsulation of the prodrug and can be attributed to the collapse of nMOF structure in 5 mM PBS to retard the drug release. The cisplatin prodrug was released even much more slowly from Cis@nMOF-1 in water, with less than 15% release in 24 h. The study shows that negligible amount of cisplatin prodrug was released from Cis@nMOF-1 during the siRNA loading, which was done in water in 30 min. The released drug was confirmed to be intact cisplatin prodrug by $^{195}$Pt NMR (DMSO-d$_6$, Figure 5-12): $\delta$= 998.8.
Figure 5-10 $^1$H NMR spectrum of Cis@nMOF-1 after digestion. Reprinted with permission from J. Am. Chem. Soc., 2014, 136, 5181–5184. Copyright 2014 American Chemical Society.

Figure 5-11 Release profiles of cisplatin prodrug from Cis@nMOF-1 in 5 mM PBS by dialysis method. The full plot (a) and the zoomed-in view of the first 3 h (b) are presented. Adapted with permission from J. Am. Chem. Soc., 2014, 136, 5181–5184. Copyright 2014 American Chemical Society.
Drug resistance often involves multiple and dynamically acquired multidrug resistance (MDR) mechanisms. Among them, P-glycoprotein (P-gp) is over-expressed in the malignant tissues and is responsible for decreased drug accumulation in cells. Bcl-2 is responsible for the activation of cellular anti-apoptotic defense. Survivin has a functional role in both cell division and apoptosis control, and is often found to be upregulated in cancers. Simultaneously blockade of these MDR-relevant molecular signaling pathways can potentially overcome drug resistance in cancer cells. siRNA was loaded onto Cis@nMOF-1 by simply mixing Cis@nMOF-1 and siRNA in water at a cisplatin : siRNA mass ratio of 4.5:1 to afford siRNA/Cis@nMOF-1 (Scheme 5-1). siRNA is believed to bind to nMOF-1 surface via multiple coordination bonds between phosphate residues on the siRNA backbone and vacant Zr sites on the nMOF surface.
The siRNA loading did not change the morphology of nMOFs as shown by TEM (Figure 5-8 d,g). Dynamic light scattering (DLS, Nano-ZS, Malvern, UK) measurements gave average diameters of 98±11 nm (PDI=0.070), 103±17 nm (PDI=0.124), and 128±3 nm (PDI=0.116) for nMOF-1, Cis@nMOF-1 and siRNA/Cis@nMOF-1, respectively (Figure 5-14). The increase in the DLS diameter for siRNA/Cis@nMOF-1 evidences the presence of siRNA on the nMOF-1 surface. The siRNA binding capabilities of nMOFs were confirmed by gel electrophoresis, which showed that nMOFs could efficiently “capture” siRNA on the surface as evidenced by the complete retardation of siRNA band migration for siRNA/Cis@nMOF-1 (Figure 5-15a). The siRNA loading efficiency (LE) was also quantitatively examined by fluorimetry. Fluorescently labeled siRNA (TAMRA-siRNA) was used to form siRNA/Cis@nMOF-1, and the LE was determined to be as high as 81.6±0.6 %. As a result of steric hindrance on surfaces, nMOFs protected siRNA from RNase degradation: a siRNA band was clearly visible upon incubating siRNA/Cis@nMOF-1 in serum for up to 4 h while the naked siRNA was completely degraded under the same condition (Figure 5-15b). Interestingly, siRNA “coating” on the NMOF surface significantly retarded protein adsorption, suggesting possible stabilization of NMOFs via siRNA binding (Figure 5-15c).
Figure 5-13 Structure model of the interaction between the siRNA and nMOF surface. Gray, C; red, O; cyan, Zr; blue, N; magenta, P.
Figure 5-14 DLS plot showing the particle size of nMOF-1 (a), Cis@nMOF-1 (b) and siRNA/Cis@nMOF-1 (c). Reprinted with permission from J. Am. Chem. Soc., 2014, 136, 5181–5184. Copyright 2014 American Chemical Society.
5.2.5 In vitro gene silencing study

High siRNA uptake levels and successful endosomal escape are two prerequisites for efficient siRNA-mediated gene silencing.\(^7\)-\(^9\) Compared to the naked siRNA solution, cellular uptake of siRNA/Cis@nMOF-1 were significantly enhanced by more than 11 folds (Figure 5-16a), indicating that the nMOF facilitates the siRNA internalization via endocytosis pathways. The siRNA uptake was also directly observed by confocal laser scanning microscopy (CLSM). As illustrated in Figure 5-16c, large amounts of siRNA (red fluorescence) were located in the cytoplasms of SKOV-3 cells. In addition, zirconium phosphate has extremely low solubility (\(K_{sp}=10^{-134}\)), which demonstrates a high affinity of Zr(IV) to phosphate ions. As illustrated in Figure 5-16b, phosphate buffer saline (PBS) containing relatively high phosphate group concentration (2 mM) significantly promoted siRNA release compared to water. It is reasonable
to expect that siRNA could dissociate from Cis@nMOF-1 by decomposition of nMOF after internalization and entrapment in endosomes due to the presence of much higher concentrations of endogenous phosphate ions in endosomes than in extracellular environments.\textsuperscript{10,11} The dissociated Zr ions can bind to the negatively charged and phosphate-group-enriched endosome membrane to disrupt the endosome structure and facilitate the release of entrapped siRNAs. This hypothesis was supported by CLSM studies and time-dependent endosome/siRNA co-localization studies (Figure 5-17 and 5-18). After 2-hour incubation, siRNA in the siRNA/Cis@nMOF-1 was able to escape from the endo/lysosome entrapment, as demonstrated by the separation of red (siRNA) and green (Lysotracker Green stained lysosome) fluorescence in the cytoplasm (Figure 5-16d).

We further evaluated the transfection efficiency mediated by siRNA/Cis@nMOF-1 in SKOV-3 cells. As shown in Figure 5-19, siRNA/Cis@nMOF-1 evoked potent gene silencing in SKOV-3 cells at 0.4 µg/mL (30 nM) of siRNA as determined by ELISA. Interestingly, by using one-third of the siRNA dose for the pooled siRNAs/Cis@nMOF-1 compared to single siRNA/Cis@nMOF-1, equivalent gene silencing efficiencies were achieved, suggesting the synergistic silencing effects of pooled siRNAs. In comparison, none of the free siRNA solution, Cis@nMOF-1, and nMOF-1 was able to down-regulate the gene expression.
Figure 5-16 Cellular uptake and endosomal escape of siRNA/Cis@nMOF-1 in SKOV-3 cells. (a) Cellular uptake of siRNA/Cis@nMOF-1 in SKOV-3 cells (n = 3). (b) siRNA release from nMOFs, dramatically promoted in 2 mM PBS compared to water. (c) CLSM image showing the internalization of siRNA (TAMRA-labeled) into the cytoplasm of SKOV-3 cells. Nuclei were stained with DAPI. Bar represents 20 µm. (d) siRNA (TAMRA-labeled, red) successfully escaped from endosomes as evidenced by the separation of green and red fluorescence (white arrows). Endo-some/lysosome and nuclei were stained with Lysotracker Green and DAPI, respectively. Bar represents 5 µm. Adapted with permission from J. Am. Chem. Soc., 2014, 136, 5181–5184. Copyright 2014 American Chemical Society.
Figure 5-17 CLSM images showing the time-dependent endosomal escape of siRNA in SKOV-3 cells. Endosome/lysosome and nuclei were stained with Lysotracker Green and DAPI, respectively. Bar represented 10 µm. Reprinted with permission from *J. Am. Chem. Soc.*, 2014, *136*, 5181–5184. Copyright 2014 American Chemical Society.

Figure 5-19 siRNA/Cis@nMOF-1 mediated gene silencing in SKOV-3 cells. Silencing efficiency was expressed as percentage values of control group treated with PBS. Adapted with permission from J. Am. Chem. Soc., 2014, 136, 5181–5184. Copyright 2014 American Chemical Society.
5.2.6 *In vitro* anticancer efficacy on resistant tumor models

To examine whether the efficient and simultaneous knockdown of three MDR-relevant genes including survivin, Bcl-2, and P-gp could effectively reverse the cisplatin resistance in ovarian cancer cells, the cytotoxicity of free cisplatin, Cis@nMOF-1, and siRNA/Cis@nMOF-1 was assessed by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay (Figure 5-20a) and by flow cytometry (Figure 5-21). The cisplatin IC$_{50}$ values of free cisplatin, Cis@nMOF-1, pooled siRNAs/Cis@nMOF-1, free cisplatin plus free pooled siRNAs, and free cisplatin plus pooled siRNAs/nMOF-1 were calculated to be 53.9±4.7, 53.2±4.4, 4.7±1.8, 45.1±7.0, and 6.6±0.3 µM, respectively. No cytotoxicity (cell viability of 96.2±3.4%) was observed in SKOV-3 cells when treated with siRNA/nMOF-1 at 12 times higher siRNA dose. By co-delivering pooled siRNAs and cisplatin utilizing nMOFs, the IC$_{50}$ value dramatically decreased (by more than 11 fold) compared to free cisplatin and Cis@nMOF-1. In control experiments, pooled siRNAs/Cis@nMOF-1 and Cis@nMOF-1 exhibited a similar level of cytotoxicity in cisplatin-sensitive cancer cell lines including A2780, PC-3, MCF-7, and H460 cells but significantly lower IC$_{50}$ values in cisplatin-resistant A2780/CDDP cells (4.2±0.6 vs. 21.4±1.4 µM for pooled siRNAs/Cis@nMOF-1 and Cis@nMOF-1, respectively; Figure 5-20 b-f and Table 5-1). This result suggested that the cisplatin-resistant ovarian cancer cells could be re-sensitized after being transfected with siRNA/Cis@nMOF-1, and the synergistic effects of siRNA and cisplatin significantly enhanced the *in vitro* chemotherapeutic efficacy. At 50 times higher nMOF-1 dose, cell viability was determined to be 98.1±5.4%, indicating a lack of toxicity for nMOF-1. We carried out DNA ladder and Annexin V conjugate staining assays in order to demonstrate that the enhanced cytotoxicity of siRNA/Cis@nMOF-1 was caused by cell apoptosis rather than necrosis. As indicated in Figure
5-22, no DNA fragmentation was detectable in the control, Cis@nMOF-1, and free cisplatin groups. Cells treated with siRNA/Cis@nMOF-1 displayed characteristic DNA fragmentation or laddering, demonstrating that the cytotoxicity induced by siRNA/Cis@nMOF-1 was associated with apoptosis. Annexin V conjugate staining provided further evidence to the apoptosis induced by siRNA/Cis@nMOF-1 (Figure 5-23). siRNA (red fluorescence) loaded in the nMOFs were efficiently internalized into the cytoplasm after a 24-h incubation to trigger MDR-relevant gene silencing. Annexin V conjugate (green fluorescence) was clearly visible in cells treated with siRNA/Cis@nMOF-1 but not in cells treated with siRNA/nMOF-1 (pooled siRNAs alone) or Cis@nMOF-1 (cisplatin alone). This result indicates that co-delivery of cisplatin and pooled siRNAs would induce cell apoptosis in cisplatin-resistant cells by combining the synergistic effects of down-regulating the expressions of MDR-relevant genes and chemotherapeutics. Importantly, nMOF-1 and pooled siRNAs/Cis@nMOF-1 evoked no immunogenic response in Raw 264.7 macrophage and SKOV-3 cells (Figure 5-24).
Figure 5.20 In vitro cytotoxicity in different cells. (a) SKOV-3 cells; (b) PC-3 cells; (c) MCF-7 cells; (d) H460 cells; (e) A2780 cells; (f) A2780/CDDP cells. Adapted with permission from J. Am. Chem. Soc., 2014, 136, 5181–5184. Copyright 2014 American Chemical Society.
Figure 5-21 Annexin V/PI analysis of SKOV-3 cells after the incubation for 24 h. The Q1-Q4 quadrants represent necrosis, late apoptotic, healthy, and early apoptotic cells, respectively. The percent of cells in each quadrant was shown on the graphs. Adapted with permission from *J. Am. Chem. Soc.*, 2014, 136, 5181–5184. Copyright 2014 American Chemical Society.

Table 5-1 IC$_{50}$ (µM) values in A2780 and A2780/CDDP cells. The cells are incubated for 72 h with free cisplatin solution, Cis@nMOF-1, pooled siRNAs/Cis@nMOF-1, free cisplatin solution plus free pooled siRNA solution (weight ratio of cisplatin to siRNA = 4.5:1), free cisplatin solution plus pooled siRNAs/nMOF-1 (weight ratio of cisplatin to siRNA = 4.5:1).

<table>
<thead>
<tr>
<th>Treatment</th>
<th>A2780</th>
<th>A2780/CDDP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Free cisplatin</td>
<td>4.16±0.21</td>
<td>23.20±0.60</td>
</tr>
<tr>
<td>Cis@nMOF-1</td>
<td>4.06±0.20</td>
<td>21.4±1.38</td>
</tr>
<tr>
<td>Pooled siRNAs/Cis@nMOF-1</td>
<td>4.49±0.68</td>
<td>4.20±0.61</td>
</tr>
<tr>
<td>Free cisplatin+pooled siRNAs</td>
<td>4.18±0.33</td>
<td>22.85±2.30</td>
</tr>
<tr>
<td>Free cisplatin+pooled siRNAs/nMOF-1</td>
<td>4.18±0.17</td>
<td>4.87±0.63</td>
</tr>
</tbody>
</table>
**Figure 5-22** DNA ladder analysis. Lane 1-5: DNA marker, control, Cis@nMOF-1, siRNA/Cis@nMOF-1, and free cisplatin. Reprinted with permission from *J. Am. Chem. Soc.*, 2014, 136, 5181–5184. Copyright 2014 American Chemical Society.

**Figure 5-23** CLSM images showing cell apoptosis and siRNA internalization in SKOV-3 cells. The cells are incubated with Cis@nMOF-1 (a), siRNA/nMOF-1 (b), and siRNA/Cis@nMOF-1 (c) for 24 h. The apoptotic cells were stained with Alexa Fluor 488 Annexin V conjugate, and the nuclei were stained with DAPI. Upper left: DAPI stained nuclei; upper right: Alexa Fluor 488 Annexin V conjugate stained apoptotic cells; lower left: TAMRA-labeled siRNA; lower middle: overlay of upper left, upper right, and lower left; lower right: DIC. Bar represented 20 µm. Reprinted with permission from *J. Am. Chem. Soc.*, 2014, 136, 5181–5184. Copyright 2014 American Chemical Society.
Figure 5-24 Immunogenic response of nMOF-1 and pooled siRNAs/Cis@nMOF-1 in SKOV-3 (a) and Raw 264.7 (b) cells. The cells were incubated with nMOF-1 or pooled siRNAs/Cis@nMOF-1 for 72 h followed by the determination of TNF-α, IL-6, and IFN-γ by ELISA. Adapted with permission from J. Am. Chem. Soc., 2014, 136, 5181–5184. Copyright 2014 American Chemical Society.

5.3 Conclusion

In this chapter, we have shown that nMOF-1 with high porosity and surface binding sites represent a unique nanocarrier platform for the co-delivery of chemotherapeutic agents and pooled MDR gene silencing siRNAs to drug-resistant ovarian cancer cells. Cisplatin prodrug was efficiently encapsulated into nMOF-1 whereas siRNA were loaded by coordinating to metal sites on the nMOF surfaces. nMOF-1 protects siRNAs from nuclease degradation, enhances siRNA cellular uptake, and promotes siRNA escape from endosomes to silence MDR genes, leading to an order-of-magnitude enhancement in chemotherapeutic efficacy of cisplatin. The simplicity of the present approach makes it amenable to co-delivery of chemotherapeutics and other nucleic acid drugs such as siRNA, microRNA, plasmid DNA by nMOFs. We believe that
this unique nMOF platform holds great promise in the treatment of difficult-to-cure cancers by co-delivering therapeutic cargoes of disparate characteristics and functions.

5.4 Methods

**nMOF-1 synthesis:** DMF solutions of ZrCl$_4$ (3 mL, 1.4 mg/mL, 18 µmol) and H$_2$L (3 mL, 2 mg/mL, 18 µmol) were added to a 20 mL glass vial. The mixture was diluted to 10 mL, followed by addition of 750 µL of acetic acid. The mixture was kept in an 80 °C oven for 5 days. The light yellow product was collected by centrifugation and washed with DMF, 5% triethylamine ethanolic solution and ethanol in sequence, and preserved in ethanol as a stock suspension. (Yield: ~20%).

**Encapsulation of the cisplatin prodrug:** Cis,cis,trans-[Pt(NH$_3$)$_2$Cl$_2$(OEt)(OCOCH$_2$CH$_2$CO$_2$H)] (5.0 mg, 0.011 mmol) were dissolved in 2 mL of DMF. To this solution 10.7 mg of nMOF-1 was suspended. The resulting mixture was stirred at room temperature for 36 hours. The prodrug-loaded nMOF-1 (Cis@nMOF-1) was collected by centrifugation and washed with copious amounts of DMF and ethanol in sequence, and was suspended in ethanol.

**nMOF digestion for NMR:** Cis@nMOF-1 (2-3 mg) is collected by centrifugation and dried on vacuum overnight. The yellow powder is then digested in sodium phosphate (tribasic) saturated D$_2$O by sonication for 10 min and vortex for 2 min. The organic components were extracted by DMSO-d$_6$ for $^1$H NMR analysis.

**Cisplatin prodrug release profile:** The release of the cisplatin prodrug from Cis@nMOF-1 was evaluated. Cis@nMOF-1 was dialyzed in 5 mM phosphate buffer saline (PBS) in a dialysis bag
(MWCO 7000) with stirring (150 rpm) at 37 °C in a beaker. Free cisplatin prodrug solution served as control. Samples were taken at 2 min, 5 min, 10 min, 15 min, 30 min, 45 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, and 24 h to determine the release percentage of cisplatin by ICP-MS.

**Loading of siRNA onto Cis@nMOF-1:** Survivin siRNA, Bcl-2 siRNA, and P-gp siRNA were dissolved in DEPC-treated water at weight ratio of 1: 1: 1 to achieve a 2 mg/mL pooled siRNA solution. Cis@nMOF (1 mg/mL) dispersed in DECP-treated water was mixed with siRNA solution (2 mg/mL) at weight ratio of cisplatin : siRNA = 15 : 4, and the mixture was stirred (800 rpm) at room temperature for 30 min to afford siRNA/Cis@nMOF-1. After siRNA loading, the nMOFs were centrifuged at 13000 rpm for 15 min. The supernatant was discarded to remove the free siRNA and the precipitate of nMOFs was collected and re-suspended in aqueous solution for subsequent evaluations.

**siRNA protection and release assay:** siRNA/Cis@nMOF-1 containing 1 μg of siRNA was mixed with an equal volume of FBS. After incubation for a determined period of time at 37 °C, 100 mM PBS was added to the mixture to disrupt the nMOF structure, and thus the siRNA was dissociated from nMOFs. The mixture was heated to 80 °C to inactivate the nucleases. The siRNA integrity was subsequently evaluated on 4% (w/v) agarose gel electrophoresis. Naked siRNA solution containing 1 μg of siRNA served as control.

As for the evaluation of siRNA release profiles from nMOFs, siRNA/Cis@nMOF-1 containing 1 μg of TAMRA-siRNA were incubated with 1 mL of 2 mM PBS or DEPC-treated water at 37 °C under shaking. At predetermined time intervals (0.5, 1, 2, 4, 6, and 8 h), the suspension was centrifuged at 13,000 rpm for 10 min and 0.5 mL of the supernatant was
quantified for TAMRA-siRNA content by fluorimetry. An equal volume of the release medium was added, and the precipitate was re-suspended before further incubation.

**Protein binding assay:** Five hundred microliters of siRNA/Cis@nMOF-1 (1 mg/mL) and Cis@nMOF-1 (1 mg/mL) were incubated with 100, 250, 400, 750, and 1500 µg/mL of bovine serum albumin (BSA) at 37 °C for 1 h, respectively. The nMOFs were centrifuged at 13000 rpm for 10 min, and the BSA concentrations in the supernatant were determined by Pierce BCA Protein Assay Kit (Promega, USA) according to the manufacture instructions. The protein binding was expressed as the amount of protein (µg) associated to per µg nMOFs.

**siRNA loading efficiency:** We quantitatively determined the loading efficiency (LE) of siRNA onto Cis@nMOF-1 by fluorimetry. TAMRA-labeled siRNA was loaded onto Cis@nMOF-1 and the nMOF suspension was centrifuged at 13,000 rpm for 30 min. The amount of free TAMRA-siRNA in the supernatant was determined with fluorimetry based on the standard curve (TAMRA, λ_ex = 565 nm, λ_em = 580 nm). LE was calculated from the following equation:

\[
\text{LE} (\%) = \frac{W_0 - W_1}{W_0} \times 100
\]

Where \( W_0 \) and \( W_1 \) stand for the content of total siRNA and free siRNA in the supernatant, respectively.

**siRNA cellular uptake:** SKOV-3 cells were seeded on a 24-well plate at 1×10^5 cells per well and cultured for 24 h. TAMRA-siRNA-containing nMOFs and naked TAMRA-siRNA solution (2 mg/mL) were added (0.4 µg siRNA/well). Following a 4-h incubation, cells were washed with PBS three times and then lysed with 0.5% (w/v) sodium dodecyl sulfate (SDS, pH 8.0). The

163
lysate was quantified for TAMRA-siRNA by fluorimetry and protein content by the BCA kit. Uptake level was expressed as the amount of TAMRA-siRNA associated with 1 mg of cellular protein.

The internalization of TAMRA-siRNA/Cis@nMOF-1 was also directly visualized using confocal laser scanning microscopy (CLSM, Olympus FV1000). SKOV-3 cells were incubated with TAMRA-siRNA/Cis@nMOF-1 for 4 h at 37 °C. The cells were washed with PBS three times, fixed with 4% paraformaldehyde for 20 min at 4 °C, and stained with 4',6-diamidino-2-phenylindole (DAPI) (10 μg/mL) for 20 min at room temperature before observation on the microscopy.

**Endosomal escape observation:** To visualize the co-localization of internalized siRNA/Cis@nMOF-1 with endosomal/lysosomal compartments, cells were incubated with nMOF containing TAMRA-siRNA for 2 h at 37 °C. The cells were washed with PBS three times, fixed with 4% paraformaldehyde for 20 min at 4 °C, and sequentially stained with Lysotracker Green (100 nM) for 2 h at room temperature and DAPI (10 μg/mL) for 20 min at room temperature before observation on CLSM.

A time dependent study of endosomal escape was performed by incubation siRNA/Cis@nMOF-1 with SKOV-3 cells for 10, 30, 60, 90, and 120 min followed by Lysotracker Green and DAPI staining. The time-dependent co-localization of siRNA/Cis@nMOF-1 and endosome/lysosome was observed under CLSM, and the co-localization efficiency was quantitatively determined using Image J (co-localization threshold) based on the CLSM images.

**In vitro transfection efficiency of siRNA/Cis@nMOF-1:** SKOV-3 cells were seeded at 2×10^5 cells per well in 24-well plates and further cultured for 24 h. The culture media were replaced by
1 mL of pre-warmed and fresh culture media containing 10% FBS prior to the experiment. siRNA/Cis@nMOF-1 containing pooled siRNAs and single siRNA, pooled siRNAs/nMOF-1, free siRNA solution, and Cis@nMOF-1 were added to the cells at a siRNA dose of 0.4 μg (30 nM) per well, corresponding to the cisplatin dose of 1.5 μg per well. Following incubation for 4 h, the culture media were replaced by pre-warmed and fresh culture media containing 10% FBS, and a further 20-h incubation was allowed. The supernatant of the culture media was collected for the determination of extracellular survivin and P-gp production by ELISA (R&D Systems, USA; MyBiosource, USA) following manufacture instructions. The cells were lysed, and the Bcl-2 amount in the lysate was quantified by ELISA (R&D Systems, USA).

**In vitro cytotoxicity:** SKOV-3 cells were seeded at 5000 cells per well in 96-well plates and further cultured for 24 h. The culture media were replaced by 100 μL of fresh culture media containing 10% FBS. Free cisplatin solution, Cis@nMOF-1, pooled siRNA/Cis@nMOF-1, free cisplatin solution plus free pooled siRNA solution (weight ratio of cisplatin to siRNA = 4.5:1), free cisplatin solution plus pooled siRNAs/nMOF-1 (weight ratio of cisplatin to siRNA = 4.5:1), and pooled siRNAs/nMOF-1 at different siRNA or cisplatin doses are applied. Following incubation for 72 h, the cell viability was determined by (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) assay (Promega, USA) according to manufacture instructions. The concentrations of cisplatin required to inhibit cell growth by 50% (IC$_{50}$ values) were calculated.

The cytotoxicity of pooled siRNAs/Cis@nMOF-1 was evaluated on cisplatin-sensitive cancer cell lines. PC-3, MCF-7, and H460 cells were seeded at 1500, 5000, and 2500 cells per well in 96-well plates and further cultured for 24 h. The culture media were replaced by 100 μL of fresh culture media containing 10% FBS. Free cisplatin solution, Cis@nMOF-1, pooled
siRNA/Cis@nMOF-1 were added at different cisplatin doses. Following incubation for 72 h, the cell viability was determined by MTS assay. IC\textsubscript{50} values were calculated accordingly.

The enhanced \textit{in vitro} anticancer efficacy of pooled siRNAs/Cis@nMOF-1 was further confirmed by carrying out cytotoxicity analysis on cisplatin sensitive and resistant A2780 and A2780/CDDP cells. A2780 and A2780/CDDP cells were seeded at 2500 cells per well in 96-well plates and further cultured for 24 h. The culture media were replaced by 100 µL of RPMI 1640 containing 10% FBS. Free cisplatin solution, Cis@nMOF-1, pooled siRNA/Cis@nMOF-1, free cisplatin solution plus free pooled siRNA solution (weight ratio of cisplatin to siRNA = 4.5:1), free cisplatin solution plus pooled siRNAs/nMOF-1 (weight ratio of cisplatin to siRNA = 4.5:1), and pooled siRNAs/nMOF-1 were added at different cisplatin doses and equivalent siRNA doses. Following incubation for 72 h, the cell viability was determined by MTS assay. IC\textsubscript{50} values were calculated accordingly.

\textbf{DNA ladder:} SKOV-3 cells were seeded at 1×10\textsuperscript{6} cells per well in 6-well plates and further cultured for 24 h. The culture media were replaced by 2 mL of fresh culture media containing 10\% FBS. Free cisplatin solution, Cis@nMOF-1 or siRNA/Cis@nMOF-1 was added to the cells, respectively, at cisplatin concentration of 10 µM. Following incubation for 24 h, total DNA of cancer cells was extracted using DNA ladder isolation kit (Sigma-Aldrich, USA) according to the manufacture instructions and examined for DNA fragmentation on a 2\% (w/v) agarose gel electrophoresis at 35 V for 3 h.

\textbf{Cell apoptosis by Annexin V staining:} Coverslips putting in the 6-well plates were seeded with SKOV-3 cells at the density of 1×10\textsuperscript{6} cells per well. The cells were incubated at 37°C and 5\% CO\textsubscript{2} for 24 h prior to nanoparticle treatment. siRNA/Cis@nMOF-1, siRNA/nMOF-1 solution,
and Cis@nMOF-1 were incubated with cells at 37°C and 5% CO₂ for 24 h. Then, the cells were washed with PBS, stained with Alexa Fluor 488 conjugated Annexin V (Invitrogen, USA) according to the manufacture instructions for 15 min at room temperature, fixed with iced 4% paraformaldehyde for 20 min at 4 °C, and stained with 10 µg/mL of DAPI. The cells were observed using CLSM at excitation wavelength of 405 nm, 488 nm, and 546 nm to visualize nuclei (blue fluorescence), cell apoptosis (green fluorescence) and nanoparticle internalization (red fluorescence), respectively.

**Flow cytometry analysis:** SKOV-3 cells were seeded at 1×10⁶ cells per well in 6-well plates and further cultured for 24 h. The culture media were replaced by 2 mL of fresh culture media containing 10% FBS. Free cisplatin solution, nMOF-1, Cis@nMOF-1, and pooled siRNAs/Cis@nMOF-1 were added to the cells, respectively, at cisplatin concentration of 5 µM or equivalent nMOF-1 concentration of 10 µg/mL. Cells incubated with saline served as control. Following incubating for 24 h, the floating and adherent cells were collected by cell scraper and stained with Alexa Fluor 488 annexin V/dead cell apoptosis kit with Alexa Fluor 488 annexin V and PI (Invitrogen, USA) according to the manufacture instructions. The apoptosis was examined on a flow cytometer (LSRII Blue, BD, USA).

**Immunogenic response assay:** SKOV-3 cells and Raw 264.7 cells were seeded at 2×10⁵ cells per well in 24-well plates and further cultured for 24 h. The culture media were replaced by 1 mL of fresh culture media containing 10% FBS prior to the experiment. nMOF-1 and pooled siRNA/Cis@nMOF-1 were added to the cells at a siRNA dose of 0.4 µg (30 nM) per well, corresponding to the nMOF-1 dose of 10 µg per well. Following incubation for 72 h, the supernatant of the culture media was collected for the determination of TNF-α, IL-6, and IFN-γ.
by ELISA (R&D Systems, USA) following manufacturer’s instructions. Cells treated with saline served as controls.

5.5 References


6.1 Rationale of the nMOF design

Intracellular pH (pH$_i$) is crucial in regulating cellular behaviors such as vesicle trafficking, cellular metabolism and signaling, and cell proliferation and apoptosis.\textsuperscript{1,2} In eukaryotic cells, the functions of subcellular organelles are highly dependent on the pH values in these individual compartments.\textsuperscript{3} Endosomes and lysosomes that participate in the secretory and endocytic pathways have a relatively low pH ranging from 4.5-6.5. Real-time sensing and monitoring of pH changes inside live cells are thus important for understanding physiological and pathological processes and the rational design of intracellular drug delivery systems is of great interest. pH$_i$ can be measured with a variety of techniques, including proton-permeable microelectrodes, nuclear magnetic resonance (NMR), absorption spectroscopy, and fluorescence imaging.\textsuperscript{4-6} Fluorescence-based techniques are among the most powerful tools for pH sensing, owing to their high sensitivity and outstanding spatiotemporal resolution.\textsuperscript{7} In particular, ratiometric sensing by measuring fluorescent signals at two excitation or emission wavelengths of a pH-sensitive probe is not adversely influenced by fluctuation of local probe concentration, allowing accurate and reliable pH$_i$ measurements.\textsuperscript{8} Since Kopelman and co-workers designed PEBBLEs (probes encapsulated by biologically localized embedding) as the first generation of ratiometric fluorescence nanosensors,\textsuperscript{9} a number of polymeric nanoparticles, silica nanoparticles, quantum dots, latex nanobeads, and zeolite-based nanoparticles have been developed for pH$_i$ sensing.\textsuperscript{6,10-15} By taking advantage of the versatility of the nMOFs, we designed the first nMOF-based pH sensor for real-time pH$_i$ measurements in live cells.
Fluorescein and its derivatives (i.e. fluorescein isothiocyanate, FITC) are pH sensitive and exhibit pH-dependent ratiometric fluorescence changes, conferring its ability to sense the pH$_i$ in live cells.$^{16}$ However, the application of fluorescein in live cell imaging is severely limited by its rapid release from cells.$^{17}$ We expect to change the trafficking pathway of fluorescein moieties by covalent conjugation of FITC to the bridging ligands of nMOF-1, the nMOF we reported in Chapter 5, thereby generate a novel nMOF sensor for real-time pH$_i$ measurements in live cells (Figure 6-1). The FITC-conjugated nMOFs promise a few advantages for pH$_i$ sensing include: (1) the periodic and porous structures of nMOFs enable high FITC loadings without dye aggregation, thus preventing deleterious self-quenching; (2) the open channels of nMOFs allow rapid and free diffusion of hydronium ions to afford fast sensor response,$^{18-20}$ (3) the covalent conjugation of FITC to nMOFs prevents dye leaching, thus eliminating background interference stemming from the released dye during pH$_i$ sensing.

![Figure 6-1 Schematic presentation of FITC loading. Adapted with permission from J. Am. Chem. Soc., 2014, 136, 12253–12256. Copyright 2014 American Chemical Society.](image-url)
6.2 Results and Discussion

6.2.1 Preparation and Characterization of F-nMOF

*nMOF-1* was synthesized as described in Chapter 5. Transmission electron microscopy (TEM, Tecnai F30 and Tecnai Spirit, FEI, USA) micrographs showed the hexagonal plate-like morphology of *nMOF-1* and gave a diameter of ~100 nm and a thickness of ~30 nm (Figure 6-2 b,c). FITC was covalently conjugated to *nMOF-1* to afford a FITC-conjugated nMOF (F-nMOF) by forming a thiourea linkage between the isothiocyanate group on FITC and the amino group of the bridging ligand (Figure 6-1). F-nMOF retained the hexagonal plate-like morphology and powder X-ray diffraction (PXRD) pattern of *nMOF-1* as shown in Figure 6-2 a,d,e. Dynamic light scattering (DLS) measurements gave average diameters of 111.8 nm (PDI=0.140) and 123.2 nm (PDI=0.135) for *nMOF-1* and F-nMOF, respectively (Figure 6-3).

![Figure 6-2](image) Structures and morphologies of *nMOF-1* and F-nMOF. (a) Powder X-ray diffraction of *nMOF-1*, F-nMOF and F-nMOF incubated in HBSS for 12 h. The TEM images of *nMOF-1* (b,c), F-nMOF (d,e) and F-nMOF incubated in HBSS for 48h (f). Adapted with permission from *J. Am. Chem. Soc.*, 2014, 136, 12253–12256. Copyright 2014 American Chemical Society.
The comparison of $^1$H NMR spectra of FITC, the conjugated ligand FITC-L, F-nMOF and nMOF-1 confirmed the presence of both free H$_2$L and FITC-L in F-nMOF digestion (Figure 6-4), and mass spectrometry observed both the H$_2$L ligand (exact mass=333) and conjugated FITC-L (exact mass=722) signals (Figure 6-5).
Figure 6-4 $^1$H NMR spectra to confirm covalent attachment. The samples of FITC (a), FITC-L (b), F-nMOF (c) and nMOF-1 (d) are prepared or extracted in DMSO-d$_6$. 
Figure 6-4 (Continued) $^1$H NMR spectra to confirm covalent attachment. The samples of FITC (a), FITC-L (b), F-nMOF (c) and nMOF-1 (d) are prepared or extracted in DMSO-d$_6$. Adapted with permission from *J. Am. Chem. Soc.*, 2014, 136, 12253–12256. Copyright 2014 American Chemical Society.
Figure 6-5  Mass spectrum of F-nMOF digest. Inset shows the existence of both the free ligand (upper) and the conjugated ligand (bottom). Adapted with permission from J. Am. Chem. Soc., 2014, 136, 12253–12256. Copyright 2014 American Chemical Society.

Negligible dye leaching, good structural stability and high quantum efficiency are key factors of ideal fluorescence nanosensors. The covalent conjugation of FITC to nMOF-1 framework efficiently prevents the dye leaching, which is confirmed by UV-visible spectroscopy. Less than 4.5% of FITC fluorescence was observed in the supernatant after incubating F-nMOF in Hanks’s Balanced Salt Solution (HBSS) for 24 h (Figure 6-6). After incubation in HBSS for
up to 48 h. \textbf{F-nMOF} exhibited unaltered morphology and PXRD patterns (Figure 6-2 a, f, Figure 6-7), indicating its structural stability in the media used for pH sensing.

Low fluorescence efficiency is another common issue for dye-loaded nanosensors, which can be attributed to the insufficient dye loading or self-quenching due to dye aggregation. Typical fluorescence dye loadings in amorphous nanosensors range from 0.1-0.5\% in order to avoid aggregation-induced self-quenching.\textsuperscript{11,21,22} In contrast, the porous and regular structure of \textbf{nMOF-1} allows exceptionally high dye loadings without dye aggregation (see below).

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure6.png}
\caption{Studies of FITC leaching upon HBSS incubation. (a) The UV-vis absorption of supernatant after centrifugation removal of nMOFs at different time point. (b) The accumulative release percentage calculated from absorption at 480 nm. Adapted with permission from \textit{J. Am. Chem. Soc.}, \textbf{2014}, \textit{136}, 12253–12256. Copyright 2014 American Chemical Society.}
\end{figure}
Figure 6-7 TEM images of F-nMOF after incubation in HBSS for different time. Reprinted with permission from J. Am. Chem. Soc., 2014, 136, 12253–12256. Copyright 2014 American Chemical Society.

We evaluated the fluorescence efficiency of F-nMOF with a series of FITC loadings in order to obtain optimal F-nMOF for pH$_i$ sensing. The FITC loading increased with the FITC feed amount (1, 3, 5, 8, 12, 17, and 30 wt.%), and exhibited saturation behaviors when FITC feed
reached 12 wt.% (Figure 6-8 and 6-9). The fluorescence efficiency of F-nMOF at different FITC loadings was evaluated by comparing the absorbance of F-nMOF at 490 nm (Figure 6-10) and the fluorescence intensity of F-nMOF at 516 nm (with excitation at 490 nm), respectively. As shown in Figure 6-11, the absorbance of F-nMOF increased linearly as the FITC loading increased (after subtracting the light scattering of the blank nMOF-1). In contrast, the fluorescence linearly increased as the FITC loading increased up to a FITC loading of ~7 wt.% (corresponding to 8 wt.% of feed amount), and then saturated as the FITC loading further increased, suggesting appreciable self-quenching of FITC dyes at >7 wt.% loading. For subsequent pH sensing and imaging studies, we use F-nMOF with a FITC loading of 4 wt.% in order to avoid self-quenching of FITC dyes and potential complications from different pH dependence behaviors of dye aggregates.

Figure 6-8 FITC loading quantification. (a) The standard curve of FITC UV-vis absorption at 523 nm in the test media. (b) Absorbance spectra of the supernatant collected from each washing step after FITC loading at a series of FITC feed amount percent. Numbers shown in the figure legend represent the FITC feed wt.% The supernatant collected from FITC loading at a FITC feed of 17 wt.% and 30 wt.% was diluted with triethylamine/DMF (1:9, v/v) solution before determination. Adapted with permission from J. Am. Chem. Soc., 2014, 136, 12253–12256. Copyright 2014 American Chemical Society.
**Figure 6-9** Correlation between FITC feed wt.% and FITC loading wt.%. Reprinted with permission from *J. Am. Chem. Soc.*, **2014**, *136*, 12253–12256. Copyright 2014 American Chemical Society.

**Figure 6-10** Absorption spectra of F-nMOFs at a series of FITC loading amounts. (a) The original signal and (b) after subtracting the scattering from nMOF-1 (0%). Numbers shown in the figure legend represent the FITC feed wt.%. Adapted with permission from *J. Am. Chem. Soc.*, **2014**, *136*, 12253–12256. Copyright 2014 American Chemical Society.
Figure 6-11 Fluorescence efficiency of F-nMOFs with different FITC loadings. The absorbance was acquired at 490 nm and the fluorescence intensity was detected at excitation/emission wavelength of 490 nm/516 nm. Reprinted with permission from *J. Am. Chem. Soc.*, 2014, *136*, 12253–12256. Copyright 2014 American Chemical Society.

6.2.2 Response curve calibration

Ratiometric pH-sensitivity of F-nMOF was then determined and compared with free FITC to confirm that F-nMOF is an efficient pH sensor with rapid response. FITC acts as a pH sensor by providing pH-specific ratios of fluorescence intensities at 520 nm when excited at 488 nm and 435 nm, respectively. pH calibrations for both free FITC solution and F-nMOF suspension were carried out in acetate and PBS buffers with pH values ranging from 4.0 to 8.0 by fluorimetry. The 520 nm fluorescence intensity ratios by exciting at 488 nm and 435 nm (I\textsubscript{488/520}:I\textsubscript{435/520}) were
calculated and the correlation of fluorescence intensity ratio $r$ to pH was established by non-linear curve fitting (Figure 6-12 a,b), which we will discuss in detail later.

Figure 6-12 Calibration curves of $r$-pH responses. pH calibration curves of free FITC (a) and F-nMOF acquired by fluorimetry (b) and by CLSM (c). 488/435 in the Y-axis represents $r = I_{488/520}:I_{435/520}$. (d) CLSM images showing the overlay of green (488 nm excitation) and red (435 nm excitation) colors of F-nMOF particles in HBSS buffers with different pH values. Top, pH=4.0, 4.5 and 5.0; middle, pH=5.5, 6.0 and 6.5; bottom, pH=7.0, 7.5 and 8.0. Adapted with permission from J. Am. Chem. Soc., 2014, 136, 12253–12256. Copyright 2014 American Chemical Society.
Moreover, F-nMOF was mixed with HBSS buffers with pH values ranging from 4.0 to 8.0 and subjected to confocal laser scanning microscopy (CLSM) imaging. The images of F-nMOF were acquired using dual excitation wavelengths, 488 nm and 435 nm, and analyzed by Image J to quantify the fluorescence intensity of F-nMOF particles. A calibration curve was generated using the same fitting method as for the fluorimetry data (Figure 6-12 c,d and Figure 6-13).

**Figure 6-13** Images of F-nMOF dispersed in HBSS with a series of pH acquired by CLSM, applied with artificial colors by Image J.
Figure 6-13 (Continued) Images of F-nMOF dispersed in HBSS with a series of pH acquired by CLSM, applied with artificial colors by Image J. The excitation wavelengths are 488 nm (green) and 435 nm (red), respectively, and the same emission wavelength of 520 nm is applied. Bar represented 5 µm. Reprinted with permission from J. Am. Chem. Soc., 2014, 136, 12253–12256. Copyright 2014 American Chemical Society.

The dual-excitation fluorescence emission intensity ratio \( r \) to pH plot was similar to a titration curve, indicating that the pH response likely result from a deprotonation process. The pKa of fluorescein mono-anion is 6.7. The di-anion form of fluorescein has higher absorbance at 490 nm than its mono-anion form while the 435 nm absorption peak disappears.\(^{23,24}\) In order to better understand and analyze the correlation between \( r \) and pH, a fitting was performed as follows:

HA and A were used herein to refer to mono- and di-anionic forms of FITC, respectively. Since the other proton dissociation processes do not contribute to the ratio change of FITC
fluorescence, the other steps of proton dissociation were ignored. The concentration of each species is:

\[ [HA] = c_0 \frac{[H^+]}{[H^+] + K} \]

\[ [A] = c_0 \frac{K}{[H^+] + K} \]

Where \( c_0 \) is the total concentration of FITC, and \( K \) is the dissociation constant of the related deprotonation step.

The fluorescence intensity is linearly correlated to FITC specie concentrations:

\[ I_f = I_0 \phi_f e b c = k c \]

\[ I_{488\ nm} = k_{a1}[HA] + k_{b1}[A] \]

\[ I_{435\ nm} = k_{a2}[HA] + k_{b2}[A] \]

Where \( I_0, \phi_f, e, b, \) and \( c \) are incident light intensity, quantum yield, extinction coefficient, path length, and the concentration of the solution, respectively.

\( r \) can be calculated with the following equation:

\[ r = \frac{I_{488\ nm}}{I_{435\ nm}} = \frac{k_{a1}[H^+] + k_{b1}K}{k_{a2}[H^+] + k_{b2}K} = \frac{k_{a1} + k_{b1}K}{k_{a2} + k_{b2}K} \]

\[ r = \frac{k_{a1}e^{-2.303pH} + k_{b1}}{k_{a2}e^{-2.303pH} + k_{b2}} \]

Therefore, the \( r \) against proton activity \([H^+]\) fits a non-linear regression in a form of:
\[ y = \frac{P_1 x + P_2}{x + Q_1} \]

Where:

\[ P_1 = \frac{k_{a1}}{k_{a2}} \]
\[ P_2 = \frac{k_{b1}}{k_{a2}} K \]
\[ Q_1 = \frac{k_{b2}}{k_{a2}} K \]

Based on this hypothesis, we ran the regression on MatLab, which gave the following results:

(1) For free FITC solution by fluorimetry:

\[ r = \frac{0.98[H^+] + 7.42 \times 10^{-6}}{[H^+] + 4.74 \times 10^{-7}} \]

adjusted \( r^2 = 0.99 \)

(2) For F-nMOF by fluorimetry:

\[ r = \frac{1.05[H^+] + 8.17 \times 10^{-6}}{[H^+] + 6.14 \times 10^{-7}} \]

adjusted \( r^2 = 0.99 \)

(3) For F-nMOF by CLSM:

\[ r = \frac{1.11[H^+] + 8.61 \times 10^{-6}}{[H^+] + 6.24 \times 10^{-7}} \]

adjusted \( r^2 = 0.99 \)

Additionally, the errors of pH were calculated from the errors of \( r \) were based on these equations:

\[ [H^+] = Q_1 \left( \frac{H - L}{r - L} - 1 \right) \]
\[
\frac{dpH}{dr} = \frac{1}{2.303} \frac{(H - L)}{(r - L)(H - r)}
\]

where \(H\) and \(L\) are upper limit and lower limit of \(r\), respectively,

\[
H = \frac{P_2}{Q_1}
\]

\[
L = P_1
\]

As shown in Figure 6-12, the pH-dependent changes in the \(I_{488/520}:I_{435/520}\) ratios remain the same for free FITC and \(\text{F-nMOF}\), indicating that the FITC sensing function was completely preserved in \(\text{F-nMOF}\). The open channels of \(\text{F-nMOF}\) facilitate the rapid and free diffusion of hydronium ions, allowing rapid pH response of conjugated FITC.\(^\text{18}\) The pH calibration curves of \(\text{F-nMOF}\) acquired by fluorimetry and CLSM were similar, verifying the validity of the CLSM quantification method for subsequent live cell imaging studies. The pH response of \(\text{F-nMOF}\) exhibits high sensitivity and relatively small deviations at pH = 5.0-7.0, the typical pH range for cell culture media, cytosol, and endocytic compartments. The standard deviations of pH were below 0.2 pH unit in this pH range. Thus, \(\text{F-nMOF}\) represents an excellent nanosensor for sensing pH\(_i\), and is ideally suited for real-time monitoring of endocytosis of nMOF and endosome maturation.

### 6.2.3 Live cell pH sensing

pH measurements of live cells at fixed pH values were then performed to confirm the validity of the pH calibration curve \textit{in vitro}. Human non-small cell lung cancer H460 cells were incubated with \(\text{F-nMOF}\) in HBSS for 2 h and then incubated with fresh pH clamping buffers containing 100 \(\mu\text{M}\) nigericin and with fixed pH values ranging from 4.0 to 8.0.\(^\text{25}\) CLSM images
were obtained with dual excitation wavelengths and the $I_{488/520}/I_{435/520}$ ratios of F-nMOF particles inside the cells clamped at different pH values were analyzed by Image J (Figure 6-14). The pH vs. $r$ curve shown in Figure 6-15 fits well with the pH calibration curve presented in Figure 6-12c, which further validates the pH calibration curves established by both fluorimetry and CLSM.

**Figure 6-14** CLSM images of live cells clamped at various pH. Bar represented 5 µm.
Figure 6-14(Continued) CLSM images of live cells clamped at various pH. Bar represented 5 µm. Reprinted with permission from *J. Am. Chem. Soc.*, 2014, 136, 12253–12256. Copyright 2014 American Chemical Society.

The endocytosis of **F-nMOF** in H460 cells was investigated. Time-dependent cellular uptake of **F-nMOF** was quantified by inductively coupled plasma-mass spectrometry (ICP-MS). Efficient cellular uptake was observed for **F-nMOF** in the first 30 min of incubation (Figure 6-16a). No significant difference was noticed between the uptake amounts after incubating for 30 min and 120 min, indicating rapid internalization of **F-nMOF**.
Figure 6-15 pH calibration in live cells by clamping the cells at various pH values. 488/435 in the Y-axis represents $r = \frac{I_{488/520}}{I_{435/520}}$. Reprinted with permission from J. Am. Chem. Soc., 2014, 136, 12253–12256. Copyright 2014 American Chemical Society.

Intracellular distribution and stability of nMOF-1 were directly observed by TEM (Figure 6-16 b-d). Upon entering the cells, nMOF-1 located at the endosomes and maintained the structural integrity (hexagonal plate-like structure) inside the endosomes. The lattice fringes are clearly visible for endosome-trapped particles. The distance between lattice fringes was measured to be 2.25 nm (Figure 6-16d), in agreement with the $d_{100}$ value of 2.26 nm for the nMOF-1 structure. Fast Fourier Transform (FFT) analysis of the endosome-trapped nMOF-1 also gave an electron diffraction pattern that is consistent with that of pristine nMOF-1, confirming that nMOF-1 remain crystalline inside endosomes. These results collectively demonstrate that F-nMOF is a reliable pH$_i$ sensor owing to its efficient endocytosis and adequate stability inside cells.
Figure 6-16 Cellular uptake and intracellular distribution of F-nMOF in H460 cells. (a) Time-dependent cellular uptake of F-nMOF in H460 cells determined by ICP-MS.
Figure 6-16 (Continued) (b)-(f) High-resolution TEM image showing the distribution and structural integrity of nMOF-1 in the endosomes. Inset in (b) is a zoomed-in view showing the nMOF-1 inside one endosome. (d) Zoomed-in view showing the nMOF-1 marked by red circle in (c). Inset in (d) is the FFT image showing the electron diffraction pattern of (d). Bar represents 600 nm, 200 nm, 20 nm, 50 nm and 200 nm in (b)-(f), respectively. Adapted with permission from J. Am. Chem. Soc., 2014, 136, 12253–12256. Copyright 2014 American Chemical Society.

The luminal pH of endocytic organelles is acidic, and acidification constitutes an important part of endosome maturation.\textsuperscript{26} Endosome maturation can be completed within 30 minutes, with the pH dropping from \textasciitilde6.8 (early endosome) to \textasciitilde5.0 (late endosome).\textsuperscript{1,26} Because of the high sensitivity of F-nMOF in sensing pH ranging from 5.0 to 7.0 and its rapid and efficient endocytosis, we surmised that F-nMOF would be able to reveal the endosome acidification process and its own intracellular fate. Live cell imaging was thus performed to monitor the endocytosis of F-nMOF (Figure 6-17). Images were acquired every 20 s using dual excitation wavelengths (488 and 435 nm). The internalized F-nMOF particles were tracked and the 488/435 fluorescence intensity ratios were quantified by Image J. The pH of each individual endosome with F-nMOF entrapment was calculated using the pH calibration curve of F-nMOF obtained by CLSM (Figure 6-12c) and plot against time.
Figure 6-17 Time relapse pH changes in individual endosomes. (a)-(b) CLSM images showing overlays of DIC, 488 nm excitation (green), and 435 nm excitation (red). Each region of interest (ROI) was labeled with white circle and number. Small images showing under each CLSM image are zoomed-in views of overlays of green (488 nm excitation) and red (435 nm excitation) for each ROI. The small images represent ROI 1 to ROI 4 (a, video 1) or ROI 1 to ROI 3 (b, video 2) from left to right. Bar: 10 µm. (c)-(d) The pH evolution curve of each ROI was obtained by fitting the $I_{488/520}/I_{435/520}$ with the calibration curve. (c) and (d) were generated from (a) and (b), respectively. Adapted with permission from J. Am. Chem. Soc., 2014, 136, 12253–12256. Copyright 2014 American Chemical Society.

F-nMOF particles shown in region of interest (ROI) 1 and ROI 2 in Figure 6-17a and video 1 (referring to Supplemental File video 1 and Supporting Information, SI of J. Am. Chem. Soc.,
2014, 136, 12253–12256) were stuck on the cell membrane and were not internalized into the cells as evidenced by the orthogonal view obtained from the Z-stack series (Figure 6-18); the pH of these F-nMOF particles remained constant at ~6.8-7.0 over time (Figure 6-17c). The pH values of ROI 3 and ROI 4 in video 1 and ROI 3 in video 2 (referring to Supplemental File video 2 and SI of J. Am. Chem. Soc., 2014, 136, 12253–12256) dropped from ~6.6-6.8 to ~5.3-5.5 (Figure 6-17 c,d), suggesting that these F-nMOF particles were entrapped in endosomes and experienced endosome maturation. Interestingly, we also observed exocytosis of F-nMOF: ROI 1 in Figure 6-17b and video 2 did not show significant acidification in the first 300 s and the F-nMOF particles were recycled back to the cell membrane and underwent exocytosis in 300 s. Five individual F-nMOF particles were observed after exocytosis, likely from one single endosome. Additionally, the pH of ROI 1 in Figure 6-17b and video 2 was about 6.5 before exocytosis (Figure 6-17d), which was consistent with the pH for typical recycling endosomes (pH 6.5). ROI 2 in Figure 6-17b and video 2 also experienced exocytosis after about 500 s and its pH remained at ~6.5 (Figure 6-17d). These results suggest that sufficient endosome acidification is necessary for intracellular trafficking of nMOFs. In the absence of acidification process, nMOFs undergo exocytosis mediated by recycling endosomes.¹

We also performed pH$_i$ measurements on fixed cells that had been incubated with F-nMOF. The cells were incubated with F-nMOF for 5-20 min, fixed, and subjected to CLSM observation. The pH values of individual endosome in cells incubated with F-nMOF for different time periods were analyzed to provide histograms showing the numbers of endosomes of different pH values (Figure 6-19). The endosome maturation evolved over time with peak pH decreasing from 6.4 at 5 min to 5.6 at 20 min, which is consistent with previously reported endosome maturation processes.²⁶
Figure 6-18 Orthogonal views of cells incubated with F-nMOF showing that the particle of interest was stuck on the cell membrane over time. Images were obtained from video 1 and showed the overlay of green fluorescence (488 nm channel), red fluorescence (435 nm channel), and DIC. Reprinted with permission from J. Am. Chem. Soc., 2014, 136, 12253–12256. Copyright 2014 American Chemical Society.
Figure 6-19 CLSM images and histograms showing the numbers of endosomes of different pH values. H460 cells were incubated with F-nMOF for 5 min (top), 10 min (middle) and 20 min (bottom) and imaged with CLSM after fixation. The histogram shows the number of endosomes at different pH’s. Adapted with permission from J. Am. Chem. Soc., 2014, 136, 12253–12256. Copyright 2014 American Chemical Society.
6.3 Conclusion

In this chapter, we report the first example of nMOFs for real-time intracellular pH sensing in live cells. FITC conjugated nMOF-1 exhibited desired structural stability, fluorescence efficiency, pH response sensitivity, and efficient cellular uptake. Combining all these advantages of F-nMOF, this novel fluorescence nanosensor provides a reliable and accurate method for real-time intracellular pH sensing. Additionally, the present study also offers the first insight into the endocytosis and intracellular trafficking process of nMOFs.

6.4 Methods

nMOF-1 synthesis: A dimethylformamide (DMF) solution of 2’-amino-p-terphenyl-4,4”-dicarboxylic acid (H₂L, 2 mg/mL) was mixed with a DMF solution of ZrCl₄ (1.4 mg/mL), and the mixture was kept in an 80 °C oven for 5 days. The product was collected by centrifugation and washed with DMF, triethylamine/ethanol (1:20, v/v), and ethanol.

FITC conjugation: For a typical loading, an anhydrous DMF solution of FITC (50 µg/mL) was added to an nMOF-1 suspension (0.5 mg in 0.5 mL of anhydrous DMF). Different FITC feed amounts (from 1 wt.% to 30 wt.%) were used to evaluate the correlation between FITC loading and fluorescence efficiency. The mixture was stirred at room temperature in the dark for 24 hours and the orange F-nMOF product was collected by centrifugation and washed with DMF and ethanol.

Authentic FITC-conjugated ligand (FITC-L) was also synthesized for comparison. A mixture of H₂L (10.2 mg, 0.031 mmol) and FITC (11.8 mg, 0.030 mmol) was dissolved in 3 mL of
anhydrous dimethylsulfoxide (DMSO) in a 20-mL glass vial. The solution was stirred at room temperature in the dark for 6 hours. The solution was lyophilized to remove most of the solvent. The remaining solution (about 0.5 mL) was added to 100 mL of dichloromethane. Yellow precipitate was collected by centrifugation and was washed with dichloromethane. Yield: 62%.

$^1$H-NMR (DMSO-$d_6$): $\delta=$13.01 (br, 2H), 10.13 (s, 2H), 10.02 (s, 1H), 9.86 (s, 1H), 8.06 (d, 2H), 8.05-8.00 (m, 3H), 7.89 (d, 2H), 7.81 (dd, 2H), 7.63 (m, 3H), 7.57 (d, 1H), 7.12 (d, 1H), 6.66 (d, 2H), 6.57 (m, 4H).

$^1$H NMR sample digestion: For $^1$H NMR spectroscopy (Bruker AVANCE II+ 500; 11.7 Tesla NMR), F-nMOF or nMOF-1 was digested in a saturate solution of potassium phosphate in deuterium oxide. The organic species were extracted by DMSO-$d_6$. The $^1$H NMR spectra of FITC and FITC-L were also obtained in DMSO-$d_6$ for comparison.

Mass spectroscopy: F-nMOF was digested in a saturated potassium phosphate aqueous solution and the ligand was extracted with DMSO. The sample was delivered with 100% methanol on an LC-MS instrument (Agilent 1100 LC/MSD with ESI and APCI ion sources).

Dye leaching test: F-nMOF was incubated in HBSS at a concentration of 0.22 g/L. After 15 min, 30 min, 1 h, 2 h or 24 h of incubation the suspension was centrifuged at 13,000 rpm for 15 min to remove nMOFs and 500 µL of supernatant was collected for UV-vis measurement (and 500 µL HBSS was compensated each time). The supernatants were diluted by 5 fold with HBSS and subjected to UV-vis analysis. Accumulative FITC release was calculated by comparing the FITC amount in the supernatant with the total FITC loading.

FITC loading quantification: FITC was dissolved in a triethylamine/DMF (1:9, v/v) solution to obtain a series of FITC solutions with concentrations ranging from 1 to 5 mg/L. Absorption
spectra were recorded with a UV-vis spectrophotometer (UV-2401PC, Shimadzu, Japan). A standard curve was plotted from linear fitting of the absorbance at 523 nm as a function of FITC concentrations. The extinction coefficient was determined to be 0.0840 L·mg⁻¹·cm⁻¹.

The supernatant collected from each washing step after FITC loading was prepared into 3.3 mL of triethylamine/DMF (1:9, v/v) solution, and the FITC amount was quantified by UV-vis spectrophotometer. The FITC loading amount was calculated by subtracting the amount in the supernatant (unloaded) from the feed amount.

**Fluorescence efficiency in nMOFs with different FITC loading:** nMOF-1 and F-nMOF with different dye loadings were dispersed in phosphate buffered solution (PBS) at an nMOF concentration of 50 mg/L. The absorption spectra of F-nMOF were acquired and corrected by eliminating the scattering background from blank nMOF-1. Meanwhile, the fluorescence intensity of F-nMOF was determined at excitation wavelength of 490 nm and emission wavelength of 516 nm. The absorbance at 490 nm and fluorescence intensity of F-nMOF (excitation at 490 nm and emission at 516 nm) were plotted against FITC loading amount.

**Ratiometric pH calibration and measurements in buffers:** The pH response of F-nMOF was evaluated in buffered solution with pH ranging from 4.0 to 8.0 with a spectrofluorophotometer (RF-5301PC, Shimadzu, Japan) and by confocal laser scanning microscopy (CLSM, Leica SP5 II, Integrated Microscopy Core Facility at the University of Chicago).

For the calibration by fluorimetry, 20 µL of 1 mg/mL F-nMOF or 0.1 mg/mL FITC free solution was added to 2 mL of buffered solution (acetic buffered solution for pH 4.0-6.0 and phosphate buffered solution for pH 6.5-8.0), respectively. Fluorescence spectra were recorded using two excitation wavelengths, 435 nm and 488 nm. The fluorescence emission intensity ratio was
calculated at emission wavelength of 520 nm. A pH calibration curve was obtained by plotting the ratio of fluorescence intensity at 488 nm and 435 nm ($I_{488/520}:I_{435/520}$) as a function of pH.

For the calibration by CLSM, 1 µL of 1 mg/mL F-nMOF was mixed with 9 µL of HBSS Hank’s Balanced Salt Solution of which the pH was adjusted by 1 M NaOH or 1 M HCl to 4.0-8.0, and added to a glass-bottom petri dish (No. 1.5, uncoated glass, MatTek Corporation). The images were acquired using two different lasers (435 nm and 488 nm) and the same filter for 488 nm laser by CLSM. The fluorescence intensity of nMOF particles at dual excitation wavelengths was quantified directly from the images using Image J, and the fluorescence emission intensity ratio (488 nm versus 435 nm) was calculated accordingly. An in vitro pH calibration curve was obtained by plotting the ratio of fluorescence intensity at 488 nm and 435 nm ($I_{488/520}:I_{435/520}$) as a function of pH.

**pH clamping and measurement experiments:** H460 cells were seeded on a glass-bottom petri dish (No. 1.5, coated with poly-lysine, MatTek Corporation) at cell density of $5 \times 10^5$ cells and further cultured for 24 h. The cell culture medium was removed and replaced with fresh HBSS. The cells were further cultured with F-nMOF for 2 h. After the incubation, the HBSS was removed and replaced by clamping buffers (120 mM KCl, 5 mM NaCl, 1 mM MgCl$_2$, 1 mM CaCl$_2$, 20 mM HEPES) of pH ranging from 4.0 to 8.0, containing 100 µM nigericin.

Images were collected using Leica SP5 II microscope equipped with 100X, 1.4 oil objective, PMT fluorescence detector, transmitted light detector with DIC polarizer, and full wrap incubator box with warm air heating for live samples controlled by LAS_AF Leica confocal software. For pH measurements, cells were imaged in three channels to yield three images, (i) exciting at 488 nm and collecting at 520 nm (ii) exciting at 435 nm and collecting at 520 nm (iii)
DIC. Mean intensity of F-nMOF inside the cells was measured in 488 nm and 435 nm channels and a ratio of 488 nm to 435 nm intensities of F-nMOF was obtained. The pH was plot against $I_{488/520} / I_{435/520}$.

**Time-dependent cellular uptake:** H460 cells were seeded on a 6-well plate at $1 \times 10^6$ cells per well and cultured for 24 h. Thirty microliter of 2 mg/mL F-nMOF were added to each well. After a 10-min, 20-min, 30-min, and 120-min incubation, cells were collected by cell scraper, washed with PBS three times, and counted with hemocytometer. The cells were centrifuged at 3,000 rpm for 5 min and the cell pellet was digested with 500 µL of concentrated nitric acid. After 24 h, the digestion was diluted with water and subjected to inductively coupled plasma mass spectrometry (ICP-MS, Agilent 7700X) to determine the Zr concentration. Results were expressed as the amount of F-nMOF (pg) calculated from the Zr concentration associated with one cell.

**TEM observation of nMOF-1 cellular uptake:** The uptake and intracellular trafficking of nMOF-1 in H460 cells were directly observed by TEM. H460 cells were seeded on 10-cm petri dish at $2 \times 10^6$ cells and cultured for 24 h. Two hundred microliters of 1 mg/mL nMOF-1 were added to the cells. Following incubating for 2 h, the cells were fixed, sectioned at 40-70 nm thickness, and observed under TEM.

**Live cell image acquisition and analysis:** H460 cells were seeded on a glass-bottom petri dish (No. 1.5, coated with poly-lysine, MatTek Corporation) at cell density of $5 \times 10^5$ cells and further cultured for 24 h. The cell culture medium was removed and replaced with fresh HBSS before live cell imaging to avoid auto-fluorescence coming from the culture medium. The live cell imaging started right after adding 25 µL of 1 mg/mL F-nMOF to the cells. Images were
collected using Leica SP5 II microscope equipped with 100X, 1.4 oil objective, PMT fluorescence detector, transmitted light detector with DIC polarizer, and full wrap incubator box with warm air heating for live samples controlled by LAS_AF Leica confocal software. For pH measurements, cells were imaged in three channels to yield three images, (i) exciting at 488 nm and collecting at 520 nm (ii) exciting at 435 nm and collecting at 520 nm (iii) DIC. Cross talk and bleed-through were measured and found to be negligible for the present experimental setup. No auto-fluorescence was observed on blank cells. A time relapse experiment was carried out to monitor the endocytosis and exocytosis of F-nMOF in H460 cells at a time interval of 20 s and a total time ranging from 15 to 18 minutes. Z-stack scanning was applied to each frame. Mean intensity of F-nMOF was measured in 488 nm and 435 nm channels and a ratio of 488 nm to 435 nm intensities of F-nMOF was obtained. The pH evolution of F-nMOF experienced was calculated from the pH calibration curve obtained before.

**Intracellular pH sensing in fixed cells:** H460 cells were seeded on a glass-bottom petri dish (No. 1.5, coated with poly-lysine, MatTek Corporation) at cell density of $5 \times 10^5$ cells and further cultured for 24 h. The cell culture medium was removed and replaced with fresh HBSS. The cells were incubated with F-nMOF for 5 min, 10 min, and 20 min, and fixed with 4% paraformaldehyde. The cells were imaged using Leica SP5 II microscope equipped with 100X, 1.4 oil objective, PMT fluorescence detector, and transmitted light detector with DIC polarizer. For pH measurements, cells were imaged in three channels to yield three images, (i) exciting at 488 nm and collecting at 520 nm (ii) exciting at 435 nm and collecting at 520 nm (iii) DIC. Mean intensity of F-nMOF was measured in 488 nm and 435 nm channels and a ratio of 488 nm to 435 nm intensities of F-nMOF were obtained. pH was calculated from the pH calibration curve obtained before.
6.5 References


Supplemental Files

The following videos are available online. Both files can be found in Supporting Information of *J. Am. Chem. Soc.*, 2014, 136, 12253–12256.

**Video 1** The pH evolution of endosomes monitored by F-nMOF.

**Video 2** Direct observation of F-nMOF going through exocytosis.